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Eukaryotic translation elongation factor eEF1A exists in two closely related 
variant forms, eEF1A1 and eEF1A2, that are encoded by separate loci.  The former                 
is the second most abundant protein in the cell and is almost ubiquitously expressed but 
eEF1A2 expression is more limited and its presence was defined predominantly                    
in neurons and muscle cells. Both perform equally well in translation elongation                  
and are responsible for delivering aminoacylated tRNA to the A site of the ribosome               
in a GTP-dependent manner. 
Translation factor eEF1A2 was identified as an oncogene due to inappropriate 
expression being observed in the high proportion of ovarian, breast, lung, colon                  
and pancreatic tumours. Additionally, its forced expression in rodent fibroblasts resulted 
in soft agar colony formation along with tumours when overexpressing cells were 
injected into nude mice. The mechanism by which eEF1A2 contributes to oncogenesis 
remains unclear. Gene amplification is not solely responsible for eEF1A2 upregulation               
and neither activating mutations nor methylation status changes are seen in tumours. 
Interestingly, no connection of eEF1A1 with any malignancy has been made.                         
It is proposed that the oncogenic properties of eEF1A2 might be associated with its 
conventional role in translation or perhaps with non-canonical functions that differ from 
those of the eEF1A1 variant.   
The main objectives of this PhD project were to elucidate the differential 
functions of both variants of eEF1A in cancer and to investigate other possible 
mechanism of eEF1A2 upregulation. 
 In order to compare the contribution of overexpressed eEF1A variants to cellular 
transformation, stable cell lines were generated in NIH-3T3 mouse fibroblasts and tested 
in a panel of in vitro transformation assays. Mammalian expression plasmids used for 
transfection contained each eEF1A variant coding sequence with or without its own 




  Transient transfections with the same mammalian expression plasmids were 
performed to observe that incorporation of exogenous eEF1A1 and eEF1A2 resulted                
in a decrease of the endogenous eEF1A1 expression at the mRNA and protein level.                       
The dynamic interplay between exogenous and endogenous variants occurred within                 
the first 48 hours post transfection but Eef1a1 returned to the levels seen in controls                  
as soon as the expression of any of the exogenous eEF1A forms started to decline.                     
In contrast, in almost all tested stable cell lines, the levels of endogenous eEF1A1 
remained unchanged, at both the mRNA and protein level.  
 NIH-3T3 lines constitutively expressing eEF1A forms were subsequently 
subjected to various in vitro transformation assays. Stable cell lines of eEF1A1 coding 
sequence origin formed colonies and foci but with lower efficiency when compared to 
the eEF1A2 coding sequence variant. It was also shown that anchorage independent 
growth and foci formation were affected by incorporating either the eEF1A1 or eEF1A2 
5‟UTR in front of either eEF1A1 or eEF1A2 coding sequence. There was no apparent 
increase in migration and invasion of the cell lines stably expressing eEF1A.                        
No significant association between protein synthesis rate or increased overall eEF1A 
level and transformed phenotype in all tested stable cell lines was observed. 
 Expression of eEF1A1 or eEF1A2 was also determined immunohistologically             
in panels of different tumour arrays. Moderate to high expression of eEF1A2 protein 
was observed in 43% of colorectal cancers analysed. The level of eEF1A2 expression 
appeared to be inversely correlated (P = 0.024) with metastasis in lymph nodes in one of 
the tested colorectal tumour arrays. Moreover, no substantial upregulation of eEF1A2          
at the protein level was confirmed in hepatocellular carcinoma and malignant melanoma 









Chapter 1: Introduction 
 
1.1 Protein synthesis 
The central dogma of molecular biology determines the flow of biological 
information where the instructions from DNA are transcribed into mRNA - a template 
which will be used to produce a particular protein (Crick, 1970). Each cellular protein 
needs to be available in the correct structure, at the appropriate level and at the particular 
time and location to permit proper physiological functioning of the cells. Protein 
synthesis, known also as translation, requires a high amount of energy to proceed and 
many additional components are involved through the whole process. Three essential 
stages of protein synthesis exist: initiation, elongation and termination, which are 
mediated by particular stage-specific translation factors (Livingstone et al., 2010).  
 
Initiation 
During translation initiation, the start codon is base-paired with the anticodon of 
the initiating methionine-tRNA (Met-tRNAi) at the peptidyl-site (P-site) of the 80S 
ribosome. Early events of mammalian translation initiation require the formation of         
a „ternary complex‟ which consists of the GTP-coupled eukaryotic initiation factor 2 
(eIF2) and Met-tRNAi. Subsequently, the complex is placed on the 40S ribosomal 
subunit, already attached to eIF3, eIF1 and eIF1A, and the novel 43S pre-initiation 
complex is formed. Another factor, eIF4E, is recruited to the 5‟ end cap structure of the 
mRNA selected for translation and then bridged with eIF4G. A set of inhibitory proteins 
(4E-BP1, 4E-BP2 and 4E-BP3) competes with eIF4G to prevent its association                    
with eIF4E but this effect can be suppressed by phosphorylation of the inhibitory 
proteins. eIF4G is a scaffolding protein and possesses additional binding sites for the 
ATP-dependent RNA helicase eIF4A and eIF3. Three bridged initiation factors - eIF4A, 
eIF4G and eIF4E form a mulitimer known as eIF4F, which finally brings the 43S               





After the ribosome subunit is positioned on the mRNA, it starts to scan 
downstream of the cap, until the initiation codon in the optimum context is identified. 
The scanning process is assisted by eIF4A and its cofactor eIF4B, both of which 
promote RNA unwinding. Following AUG recognition, eIF5 mediates hydrolysis               
of eIF2-associated GTP, joining of a 60S ribosomal unit and release of the initiation 
factors in order to begin elongation of the polypeptides. eIF2B promotes                                 
GDP-GTP exchange and recycling of eIF2 for the next initiation cycle                               
(Jackson et al., 2010).  
If cap-dependent translation is compromised due to cellular stress conditions,                 
for instance during hypoxia, heat shock or nutrient withdrawal, translation is activated 
through internal ribosome entry sites (IRES) and ribosomes are positioned at or near                
the AUG codon, without scanning. This mechanism was first identified in picornaviruses 
but it was also found in a set of mammalian transcripts (Le Quesne et al., 2009).  
Elongation  
Throughout the elongation phase, amino acids are conjugated to the appropriate 
tRNA and the polypeptide chain is assembled according to the open reading frame 
sequence of the mRNA. One of the crucial players in this stage is eukaryotic translation 
elongation factor 1A (eEF1A), existing, at least in mammals, in two variants: eEF1A1 
and eEF1A2. 
The GTP-associated eEF1A delivers the correct aminoacyl-tRNA (aa-tRNA)               
to the aminoacyl-site (A-site) of the ribosome. Subsequently, the nascent polypeptide 
(bound to the tRNA at the P-site) is connected with the new amino acid at the A-site 
what results in elongation of the peptide chain. To complete the cycle, the deacylated 
tRNA and the peptidyl-tRNA are transferred to the ribosomal exit-site (E-site) and                 
P-site, respectively. Simultaneously, the mRNA is moved forward by exactly one codon 
with respect to the ribosome. These translocations are mediated by another elongation                  
factor-eEF2 which utilizes energy from GTP hydrolysis to catalyze the process.                        





of the elongation can begin (reviewed in Rodnina and Wintermeyer, 2009).  A schematic 
illustration of the elongation cycle is displayed in Figure 1.1. 
The eukaryotic translation elongation factor 1B (eEF1B) serves as a GTP-GDP 
exchange complex (consisting of eEF1Bα, eEF1Bδ and eEF1Bγ subunits)                                
for eEF1A and promotes its recycling for the new aa-tRNA binding. Both eEF1A forms 
appear to function equally well during in an in vitro translation elongation reaction but 
they show distinct GDP dissociation rates, seven-fold higher for eEF1A1 than for 
eEF1A2. eEF1A2 binds GDP more strongly than GTP and the opposite is true for 
eEF1A1 (Kahns et al., 1998). It would suggest that eEF1A2 is more dependent on                   
a GTP-exchange factor but Mansilla and co-workers reported that eEF1A2 showed 
absent or very weak affinity for the molecules of the eEF1B complex in the yeast              
two-hybrid system, in contrast to a strong eEF1A1:eEF1B partnership.                          
Perhaps an alternative guanine nucleotide exchange factor cooperates with eEF1A2                  
(Mansilla et al., 2002).   
Translationally controlled tumour protein (TCTP) was shown to interact with 
eEF1A and eEF1B in a yeast two-hybrid screen. TCTP preferentially stabilized the 
GDP-bound eEF1A form and impaired the guanine nucleotide exchange reaction 
governed by eEF1B (Cans et al., 2003). Since an antibody recognising both eEF1A 
variants was used in the Cans analysis, it remains unknown whether this interaction was 
specific for eEF1A1 or eEF1A2, or both forms.   
Termination 
Termination is mediated by the release factors eRF1 and eRF3.                               
The elongation stage of translation is continued until the „stop‟ nucleotide triplet enters 
the ribosomal A-site and eRF1 can be positioned instead of the aa-tRNA.                     
eRF1 and eRF3 assemble into a heterodimer complex to promote hydrolysis of the last 
peptidyl-tRNA bond in a GTP-dependent manner, hence facilitating release of the 
completed polypeptide and recycling of the ribosome subunits for the next round of 

























































































































































The translation elongation factor 1A is encoded by a multigene family that has 
been conserved among prokaryotes and eukaryotes. In many species there is more than 
one copy present per haploid genome, and some of these genes are expressed in a tissue 
specific or developmental stage manner. For example, in plants, 10-15 EEF1A genes 
were reported in maize (Carneiro et al., 1999) and 9 genes in cotton (Xu et al., 2007). 
There are two equivalents of the EEF1A gene (EF-Tu) in Escherichia coli (Jaskunas et 
al., 1975).  There are two EEF1A genes (TEF1 and TEF2) in the yeasts Saccharomyces 
cerevisiae and Candida albicans, whereas in Schizosaccharomyces pombe three 
homologs were discovered (Schirmaier and Philippsen, 1984, Sundstromet al.,1990, 
Mita et al., 1997).  In Drosophila melanogaster two EEF1A genes were found and they 
are expressed depending on the developmental phase (Hovemann et al., 1988). There are 
three EEF1A genes in Xenopus laevis (Dje et al., 1990) and five in Solea senegalensis 
(Infante et al., 2008) which are also expressed differently throughout the development of 
these organisms.  
The mammalian genome contains several EEF1A sequences but only EEF1A1 
and EEF1A2 are actively transcribed. The remaining genes are considered to be 
retropseudogenes, arising from EEF1A1 (Madsen et al., 1990, Lee et al., 1993b,                      
Lund et al., 1996). The EEF1A2 gene was first isolated in rat on the grounds of its 
antigenic similarity to statin and shares 78% homology with the human EEF1A1                     
(Ann et al., 1991). 
The genomic regions to which human EEF1A1 and EEF1A2 map are 6q14                
and 20q13.3, respectively (Lund et al., 1996). A low level of similarity was observed              
in the introns, promoter regions, 5‟UTRs and 3‟UTRs between EEF1A1 and EEF1A2, 
however there is a 75% similarity in the coding regions.  In addition, the structure of the 
two genes is conserved (Knudsen et al., 1993, Bischoff et al., 2000). EEF1A1 spans              





approximately 12 kb (including a 2 kb upstream promoter region), although it is 
similarly composed of 8 exons and 7 introns. The introns of EEF1A1 are substantially 
smaller than those of EEF1A2 (Bischoff et al., 2000). 
The promoter of EEF1A1 stimulated in vitro transcription at least 2 times more 
efficiently than the adenovirus major late promoter, indicating its high strength.                     
A typical TATA box has been found in the promoter region of EEF1A1 as well as a few 
Sp1 binding sites.  Sequences similar to the AP1 binding site were identified within               
the 5‟ flanking region and the first intron (Uetsuki et al., 1989). Several cis-regulatory 
elements, including E-boxes, binding sites for the EGR family of proteins and a MEF2 
binding site have been predicted based on a sequence analysis within promoter region of 
the EEF1A2. Additionally, there is an Inr element which mediates transcriptional 
activity. No TATA element was found within a 2kb 5‟flanking promoter region of 
EEF1A2 (Bischoff et al., 2000). 
The transcription of EEF1A1 starts from a cytosine residue which is followed by 
a stretch of 5 uninterrupted thymidines (Ts) (Uetsuki et al., 1989, Slobin and Rao, 1993). 
This structural motif is known as the 5‟-terminal oligopyrimidine tract (5‟TOP), hence 
eEF1A1 belongs to the family of the TOP mRNAs, which encode many proteins 
involved in the translational machinery, for example ribosomal proteins or most 
translation initiation and elongation factors (Meyuhas, 2000, Yoshihama et al., 2002, 
Iadevaia et al., 2008, Avni et al., 1997). The TOP sequence is a cis-acting element which 
is necessary for translational regulation of these mRNAs in conditions of growth 
restraint as they are distributed between active polysomes and inactive subpolysomal 
mRNPs (messenger ribonucleoprotein particles) (Levy et al., 1991, Avni et al., 1994, 
Hornstein et al., 2001). Variation in the number of Ts has been found in eEF1A1 mRNA 
and at least three Ts were required at its 5‟TOP for the high transcriptional activity of 
the EEF1A1 promoter (Shibui-Nihei et al., 2003). The TOP sequence was not found             









Translation elongation factor 1A is the second most abundant protein in the cell 
(Slobin, 1980, Condeelis, 1995). Mammalian eEF1A exists in two tissue-specific forms, 
eEF1A1 (formerly known as eEF1α) and eEF1A2. The latter has been confirmed                
in all mammals investigated to date, as well as in Xenopus and Gallus gallus                 
(Newbery et al., 2007, Boardman et al., 2002). Since there is no experimental evidence 
of the existence of an eEF1A2 orthologue, for instance in fruit fly or in other lower 
organisms, its presence might be limited to vertebrates.      
Human forms of eEF1A share 92% identity and 98% similarity with respect to 
their amino acid sequence (Tomlinson et al., 2005, Soares et al., 2009). The ClustalW 
(Thompson et al., 1994) protein line up is shown in Figure 1.2.  A similar level of 
correspondence was seen between eEF1A1 and eEF1A2 proteins among other 
mammalian species (Knudsen et al., 1993, Kahns et al., 1998). Alignment of the 
eEF1A2 amino acid sequence from different mammals shows a high degree of 
similarity.  For example, the rabbit and human proteins are identical and they differ                
by only one amino acid from their mouse and rat counterparts (Kahns et al., 1998,                    
Lee et al., 1994). The amino acids that distinguish eEF1A2 from the eEF1A1 variant are 
conserved between different species, indicating distinct functions or properties of both 
eEF1A forms that could have arisen through evolutionary selection (Lee et al., 1994, 
Soares et al., 2009). Two variants within the same animal were less identical than 
independent eEF1A forms compared among different mammalian species                     













eEF1A1_HUMAN      MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 60 
eEF1A2_HUMAN      MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 60 
                  ************************************************************ 
 
eEF1A1_HUMAN      DKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 120 
eEF1A2_HUMAN      DKLKAERERGITIDISLWKFETTKYYITIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 120 
                  **********************:***:********************************* 
 
eEF1A1_HUMAN      GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPPYSQKRYEEIVKEVSTYIKK 180 
eEF1A2_HUMAN      GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPAYSEKRYDEIVKEVSAYIKK 180 
                  ****************************************.**:***:*******:**** 
 
eEF1A1_HUMAN      IGYNPDTVAFVPISGWNGDNMLEPSANMPWFKGWKVTRKDGNASGTTLLEALDCILPPTR 240 
eEF1A2_HUMAN      IGYNPATVPFVPISGWHGDNMLEPSPNMPWFKGWKVERKEGNASGVSLLEALDTILPPTR 240 
                  ***** **.*******:********.********** **:*****.:****** ****** 
 
eEF1A1_HUMAN      PTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPVNVTTEVKSVEMHHEALS 300 
eEF1A2_HUMAN      PTDKPLRLPLQDVYKIGGIGTVPVGRVETGILRPGMVVTFAPVNITTEVKSVEMHHEALS 300 
                  ******************************:*:***********:*************** 
 
eEF1A1_HUMAN      EALPGDNVGFNVKNVSVKDVRRGNVAGDSKNDPPMEAAGFTAQVIILNHPGQISAGYAPV 360 
eEF1A2_HUMAN      EALPGDNVGFNVKNVSVKDIRRGNVCGDSKSDPPQEAAQFTSQVIILNHPGQISAGYSPV 360 
                  *******************:*****.****.*** *** **:***************:** 
 
eEF1A1_HUMAN      LDCHTAHIACKFAELKEKIDRRSGKKLEDGPKFLKSGDAAIVDMVPGKPMCVESFSDYPP 420 
eEF1A2_HUMAN      IDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVEMVPGKPMCVESFSQYPP 420 
                  :****************************.** *********:*************:*** 
 
eEF1A1_HUMAN      LGRFAVRDMRQTVAVGVIKAVDKKAAGAGKVTKSAQKAQKAK- 462 
eEF1A2_HUMAN      LGRFAVRDMRQTVAVGVIKNVEKKSGGAGKVTKSAQKAQKAGK 463 
                  ******************* *:**:.***************   
 
Figure 1.2   Amino acid sequence alignment between human eEF1A1 and eEF1A2.  Identical residues 
have black background whereas variant differences are shown in grey. One dot denotes semi-conservative 
amino acid residues and two dots mean conserved substitutions. Domain boundaries: green (domain I), 
orange (domain II), purple (domain III) (adapted and modified from Soares et al., 2009).  
 
1.2.2.1 Post-translational modifications and structural domains 
As eEF1A1 and eEF1A2 proteins share 92% identity, small differences in 
modifications of amino acids between the two eEF1A variants will be important to 
understand any differences in functioning and activity of the two forms. 
eEF1A1 from rabbit reticulocytes was chemically sequenced and seven                      
post-translational modifications were revealed. These included dimethylation of lysines 
at positions 55 and 165, trimethyllysine residues at 36, 79 and 318, and the incorporation 





The last modifications were also reported at the same residues for human 
eEF1A1 in the K562-48 erythroleukemia cell line (Rosenberry et al., 1989) and in 
eEF1A2 from rabbit skeletal muscle (Kahns et al., 1998). In contrast to eEF1A1, lysines 
at positions 55 and 165 were not dimethylated but trimethylated in rabbit eEF1A2 
(Kahns et al., 1998). 
Eckhardt et al. used mass spectrometry and site-directed mutagenesis to confirm 
phosphorylation of human eEF1A1 at Thr432 by PASKIN (PAS Domain 
serine/threonine) kinase (Eckhardt et al., 2007). Analysis of phosphopeptides from 
human embryonic kidney 293T cells demonstrated phosphorylation of eEF1A1 at Tyr29 
and Ser163 (Molina et al., 2007). Phosphorylated tyrosine was also detected for both 
eEF1A forms by Panasyuk et al., but specific localisation of the modification within             
the amino acid sequence was not determined. eEF1A2 was shown to be characterized by               
a greater phosphorylation level than eEF1A1 (Panasyuk et al., 2008). Lamberti and 
colleagues showed INFα-mediated phosphorylation of the eEF1A protein at serine and 
threonine residues by C-Raf in H1355 cells. Serines 18, 157, 316, 383 and threonines 
242, 432 were extrapolated as the most probable phosphorylation sites for C-Raf                      
in the 3D model of human eEF1A, hypothesizing that this increases cell survival activity 
and cellular stability of translation factor (Lamberti et al., 2007). These residues are 
conserved between the two variants. A vast repertoire of modifications by 
phosphorylation at serine, threonine and tyrosine amino acids was shown for eEF1A.  
However, it should be stressed that the majority of these studies identified peptides that 
fit within completely conserved regions of both variants, making it impossible to resolve 
whether changes are specific to eEF1A1 or eEF1A2.  
A high resolution crystal structure of Saccharomyces cerevisiae eEF1A revealed 
various functionally important sequences spread across three structural domains of the 
protein (Andersen et al., 2000, Andersen et al., 2001). Three consensus GTP-binding 
motifs were found in domain I (Dever et al., 1987), whereas domain II is implicated in 





with eEF1Bα during the exchange of GDP for GTP (Andersen et al., 2000).                             
It was shown that domain II and domain III carry residues important for the interaction 
of eEF1A with the actin cytoskeleton in S.cerevisiae, rat or Dictyostelium                            
(Gross and Kinzy, 2005, Gross and Kinzy, 2007, Liu et al., 2002). Various GFP-fusions 
of carrot eEF1A were introduced into fava bean leaf epidermal cells and it was 
determined that domain III was involved in the unconditional binding of eEF1A with 
microtubules (Moore and Cyr, 2000). Three-dimensional models of human eEF1A1 and 
eEF1A2 variants were bioinformatically assessed on the platform of the yeast 
counterpart, showing high conservativeness of the residues linked to the translation-
related functions of eEF1A (Soares et al., 2009).  
 
1.2.2.2 Expression pattern 
 
The two variants of the mammalian translation elongation factor 1A exhibit 
distinct expression patterns. While eEF1A1 is almost ubiquitously expressed,                 
eEF1A2 abundance is definitely more limited. Its expression was confirmed in the brain, 
heart and skeletal muscle of mice, rats, rabbits and humans (Chambers et al., 1998,                       
Lee et al., 1992, Kahns et al., 1998, Knudsen et al., 1993).  However, the above analyses 
were confirmed exclusively by Northern blotting.  Lee and co-workers shed some light 
on the presence of eEF1A2 in the rat brain by in situ hybridization studies and they 
observed this variant in neurons of the cerebral cortex, motor neurons of the medulla     
and in cerebellar Purkinje cells (Lee et al., 1993a).  
Analysis of the expression of eEF1A variants in different tissues was later 
expanded by studies at the protein level as different groups started to generate specific 
antibodies. These were in overall agreement with the specific expression patterns               
seen  at the mRNA levels. Therefore, the eEF1A2 protein is strictly expressed in heart, 
skeletal muscle and brain whereas the eEF1A1 variant is highly abundant                   
(except in adult muscle), as confirmed in mice, rats and humans (Khalyfa et al., 2001). 





cords. Whereas eEF1A2 is solely confined to neurons, eEF1A1 is mostly seen in white 
matter and glial cells (Khalyfa et al., 2001, Pan et al., 2004). However eEF1A1 was also 
seen trapped in the nucleus of spinal cord motor neurons (Newbery et al., 2007).  
Apart from the established expression of eEF1A2 in muscle and brain tissues, 
there is evidence of its abundance in other cell specific locations. Detection of eEF1A2 
was confirmed by immunohistochemistry in sporadic pancreatic islets (predominantly 
glucagon-producing), neuroendocrine cells in stomach and in up to two enteroendocrine 
cells within a single colon crypt. Expression of the eEF1A variant in the novel cell types 
was conserved in human and mouse, indicating a possible functional relevance of the 
presence of eEF1A2 at these locations (Newbery et al., 2007).  
It appears that expression of the eEF1A1 and eEF1A2 in heart, skeletal muscle 
and brain is tightly regulated in development.  The former variant is present in mice and 
rats muscles throughout embryonic stages but is gradually downregulated within the first 
two postnatal weeks. Thereafter, eEF1A1 is completely abolished and replaced by 
eEF1A2 which becomes the major translation elongation factor 1A in muscles 
(Chambers et al., 1998, Khalyfa et al., 2001, Lee et al., 1993b, Lee et al., 1995).  
In the brain of mouse embryos (E16), eEF1A1 was reported to be located in the 
perikaryon of the developing neurons (Pan et al., 2004). Although eEF1A1 is postnatally 
expressed in glial cells and eEF1A2 presence is limited to neurons, the status of the 
developmental transition between eEF1A forms at the level of whole brain tissue 
remains less clear (Khalyfa et al., 2001, Pan et al., 2004).   
The direct mechanism and the reason for the developmental switch between two 
eEF1A forms remains an open question.  It has been implied that the transition of 
eEF1A1 into eEF1A2 is associated with terminal differentiation of the neurons, 
myocytes and cardiomyocytes (Lee et al., 1995).  However there are other cell types,                
for instance keratinocytes, which are also terminally differentiated but do not express 
eEF1A2 (Newbery et al., 2007). Since the two eEF1A variants have equivalent 
functioning at the translation elongation stage (Kahns et al., 1998),                                          





or avoid non-canonical properties assigned to the former variant.  On the other hand,              
it may be the lack of eEF1A1 rather than presence of eEF1A2 which is the key issue                               
(Newbery et al., 2007). 
 
1.3 The wasted mouse  
 
Information about the effects of compromised expression of the eEF1A2 variant 
was obtained from studies in the wasted mouse. Wasted (wst) is a spontaneous 
autosomal recessive mutation that occurred in the HRS/J mice stock at the Jackson 
Laboratory in 1972. Mice homozygous for this mutation grow normally until around 
three weeks after birth but later, they develop body weight loss, tremors, gait 
abnormalities as well as progressive atrophy of the spleen and thymus, and die by 
postnatal day 28 (Shultz et al., 1982).  
The genetic lesion in wasted mice is a 15.6 kb deletion that removes all promoter 
elements and the first noncoding exon of the Eef1a2 gene, leading to its complete 
inactivation (Chambers et al., 1998). Expression of the eEF1A1 in wild-type mouse 
muscle gradually declines until almost undetectable levels by around 21 days when it is 
subsequently replaced by eEF1A2.  In wasted animals both eEF1A variants are absent      
in muscles, since after eEF1A1 is shut down, there is no eEF1A2 to compensate                    
in translation elongation (Chambers et al., 1998, Khalyfa et al., 2001). Therefore,                     
the abnormal muscular phenotype coincides perfectly with the loss of the eEF1A2 
activity in muscle and the dramatic loss of the muscle bulk appears to be a major cause 
of the body weight decline (Chambers et al., 1998, Newbery et al., 2005).  
The site of the major pathological changes in wasted mice is in the spinal cord, 
which displays vacuolar degeneration of motor neurons (Newbery et al., 2005, Lutsep 
and Rodriguez, 1989). In the spinal cords of wst/wst mutants eEF1A1 was present                
in white matter and glial cells (as in wild-type counterparts), but eEF1A2 was not 
detectable in the cytoplasm of motor neurons, therefore one would predict no translation 





also reported for wasted mice (Shultz et al.,1982). This corresponds with the observation 
that eEF1A2, but not eEF1A1, is expressed in the Purkinje cells of wild-type animals 
(Newbery et al., 2007). 
It has been clarified that the neuromuscular abnormalities in wasted mice 
coincides with a developmental switch between eEF1A forms at 21 days after birth              
and that the loss of the eEF1A2 function is fully responsible for the wasted phenotype. 
Constructs carrying a human PAC or a mouse BAC with a functionally active eEF1A2 
were sufficient to rescue wasted phenotype in transgenic lines, and no other genes 
appear to be affected by the presence of the deletion in the wasted animals                    
(Newbery et al., 2007).  
 
1.4 The non-canonical functions of eEF1A 
 
Translation elongation factor 1A1 has been called a moonlighting protein.             
In addition to its well established role in translation, it has been also implicated              
in a wide repertoire of non-canonical functions (reviewed in Ejiri, 2002, Mateyak and 
Kinzy, 2010). This implicates eEF1A1 in the coordination of multiple biological 
processes which correlates with the high abundance of this protein within cells.                      
On the other hand, biochemical studies of eEF1A2 are incomplete and even though               
the two variants exhibit high similarity at the amino acid level, it has not yet been 
established whether these unconventional roles are shared between eEF1A1 and eEF1A2 
or whether the two variants have different properties. Knowledge about the functional 
differences in performing noncanonical roles could be beneficial for explaining                   
the developmental switch between eEF1A forms, as well as the potential association of 









1.4.1 Protein degradation 
 
Evidence from several studies demonstrates that eEF1A1 might be a common 
factor in coordinating two opposite pathways: protein synthesis and protein degradation. 
However, the precise mechanism of this quality control remains elusive. 
Eukaryotic translation elongation factor 1A in S.cerevisiae was proposed                    
to participate in the binding of nascent and misfolded proteins that were ubiquitinated 
after translational damage, thus facilitating their delivery onto the proteasome                
(Chuang et al., 2005). 
Gonen and co-workers reported that eEF1A1 promoted degradation of certain 
N
α
-acetylated proteins in vitro, namely the core nucleosomal histone H2A, actin and                   
α-crystallin in the presence of the 26S protease complex. It is suggested that eEF1A1 
might function as an enzyme or as a chaperone which changes the conformation of 
ubiquitin-conjugated proteins and makes them more susceptible to degradation by the 
26S proteasome (Gonen et al., 1994).  
Recent findings from Andersen and colleagues have shown that eEF1A1                 
is targeted in vivo in HEK293 cells by thioredoxin-like protein I (TxnlI), the novel redox 
component of the proteasome‟s 19S regulatory complex. The authors suggest that under 
oxidative stress, TxnlI prevents eEF1A1 from oxidative inactivation in order to ensure 
efficient degradation of the damaged proteins (Andersen et al., 2009).      
 
 
1.4.2 Cytoskeleton interactions and remodelling 
 
A wealth of data supports the concept of a physical link between cytoskeletal and 
translational components, and its benefit for global and local protein synthesis        
(reviewed by Kim and Coulombe, 2010). Substantial evidence from many laboratories 
supports a functional relationship between eukaryotic translation elongation factor 1A 





Originally, a 50kDa protein designated as ABP-50 was isolated from 
Dictyostelium discoideum and was found to display actin binding and bundling 
properties (Demma et al., 1990). ABP-50 was soon confirmed as the functional eEF1A 
of Dictyostelium amoebae (Yang et al., 1990). Resting cells in this organism exhibit               
a diffuse distribution of eEF1A in the cytosol, whereas upon the addition of cAMP 
eEF1A was localized in the filopodia. About 10% of total eEF1A was associated with 
the cytoskeleton in nonstimulated cells (Dharmawardhane et al., 1991). 
Immunoprecipitated eEF1A was bound to nonfilamentous actin or G-actin,                  
but this interaction was inhibited by GTP. In contrast, bundling of F-actin by eEF1A        
was unaffected by guanine nucleotides (Dharmawardhane et al., 1991), but was 
dependent on pH changes (Edmonds et al., 1995). Liu et al. demonstrated that binding of 
F-actin or aa-tRNA to the eEF1A of D. discoideum was mutually exclusive and the 
interaction between eEF1A and aa-tRNA was not dictated by pH ranges                      
(Liu et al., 1996). Additionally, in actin bundles associated with eEF1A, a unique type of 
filament crosslinking was seen (Owen et al., 1992, Munshi et al., 2001).  Here, filaments 
were rotated by 90 degrees in relation to each other and remaining actin bundling 
proteins were excluded from these special square packed actin arrangements                         
(Owen et al., 1992). 
Association of eEF1A with the actin cytoskeleton is not solely restricted to the 
slime mold but has been also established across species, from yeast to mammals. 
Interaction between eEF1A and actin was confirmed in vivo in Schizosaccharomyces 
pombe.  When eEF1A was overexpressed, abnormal localization of F-actin, disturbed 
branching and growth polarity were observed (Suda et al., 1999). Growth defects, 
abnormal morphology and similarly altered actin distribution were reported for 
Saccharomyces cerevisiae overexpressing eEF1A. Disruption of the actin cytoskeleton 
by upregulation of eEF1A did not affect protein synthesis (Munshi et al., 2001).               
eEF1A mutants of S. cerevisiae with impaired ability to bind and bundle actin shared         
a phenotype matching the one with the eEF1A overexpression; however no substantial 





mutants, suggesting the two roles of eEF1A are distinct (Gross and Kinzy, 2005).                    
On the other hand, the same group showed that different classes of mutation displayed 
more severe actin phenotypes which were correlated with slow growth and a block in 
translation initiation (Gross and Kinzy, 2007). 
Bassell and co-workers postulated that in human fibroblasts eEF1A colocalized 
with polysomes and poly(A) mRNA at actin filament intersections (Bassell et al., 1994). 
Ultimately, eEF1A has been also implicated in indirect simulation of the actin 
cytoskeleton arrangements due to its involvement in phosphatidylinositol 3- and 4-
kinases signalling (Yang et al., 1993, Yang and Boss, 1994, Amiri et al., 2006, 
Jeganathan and Lee, 2007, Jeganathan et al., 2008). This aspect will be described more 
extensively in another section of this chapter. 
 Since eEF1A and actin are two of the most abundant proteins in eukaryotic 
cells, the possibility of their cooperation is not surprising, especially since in contrast to 
yeast, an intact cellular actin filament network is required for efficient mammalian 
protein synthesis (Stapulionis et al., 1997). 
 Several studies have also suggested an association between eEF1A and 
microtubule dynamics. Durso and Cyr isolated a 50kDa polypeptide that bound                  
and bundled microtubules of carrot cells in vitro which was identified as eEF1A. 
Binding and bundling between eEF1A and microtubules in Daucus carota                        
was coordinated in a Ca
2+
/calmodulin-dependent manner. According to the authors, 
eEF1A was implicated in the modulation of the assembly, dynamics and stability of the 
microtubules (Durso and Cyr, 1994, Moore et al., 1998). Moore and Cyr also reported 
the in vivo association of eEF1A and microtubules in the epidermal cells of fava bean 
leaves (Moore and Cyr, 2000). The key regulatory component of the centrosome                 
and the mitotic apparatus of the sea urchin eggs was structurally and functionally related 
to eEF1A (Kuriyama et al., 1990, Ohta et al., 1990). Overexpression of eEF1A in fission 
yeast Schizosaccharomyces pombe led to a disturbance in the normal organization of the 
microtubule cytoskeleton and a curled phenotype around the ends of the cells                     





Xenopus laevis egg extracts modulated the severing of taxol-stabilized microtubules              
in vitro. Moreover, human recombinant eEF1A also displayed microtubule binding and 
fragmentation activity in vitro and when microinjected into rat 3Y1 fibroblasts                
(Shiina et al., 1994). 
The ability of eEF1A to influence the assembly and stability of the cytoskeleton 
might influence cellular motility and also it would place this elongation factor                       
as a common denominator in the coordination of transport, anchorage and efficient 
translation of most cytoplasmic mRNAs (Condeelis, 1995). Alternatively, this role might 
not be associated with its canonical functioning in translation. A clear and in-depth 





Several lines of evidence suggest that eEF1A1 might be involved in apoptosis.  
In BALB/c fibroblasts subjected to serum deprivation, cell death and protein synthesis 
rate were reduced when the cells had stably downregulated expression of the eEF1A1 
protein. In contrast, fibroblasts with constant overexpression of eEF1A1 exhibited 
increased apoptosis upon serum restraint in culture although the rate of protein synthesis 
remained unchanged, suggesting these two processes are independent                            
(Duttaroy et al., 1998).  
Substantial upregulation of eEF1A1 in cardiac myocytes was also implicated               
in conditions of oxidative stress induced apoptosis. On the other hand, transient 
transfections with antisense eEF1A1 cDNA were sufficient to rescue this embryonic rat 
heart cell line from H2O2-mediated cell death. Chen and colleagues suggested that 
increased abundance of eEF1A1 is necessary to execute apoptosis during oxidative 
stress and the high availability of the actively translatable eEF1A1 mRNA is dependent 





In a further set of experiments, an erythroleukemic cell line carrying                    
the temperature-sensitive p53 mutant was susceptible to apoptosis at 32
o
C, but not                    
at 37
o
C. This model was used to screen for genes associated with cell death.                         
EEF1A1 was identified as the predominant candidate and the gene was found to contain 
three conserved p53-response elements within its sequence.  The authors propose that 
cell death was mediated by the microtubule-severing abilities of the p53-upregulated 
eEF1A1 (Kato et al., 1997). 
Kobayashi et al. showed that Chinese hamster ovary cells (CHO) induced                          
to drive impaired chromosomal condensation and tetraploidy were eliminated by                     
a caspase-independent apoptosis, which was associated with the downregulation of 
eEF1A1 (Kobayashi and Yonehara, 2008). Accumulation of the translationally inactive 
eEF1A1 mRNA was confirmed in processing bodies and the 5‟TOP sequence was 
suggested as the driving force behind this transition. Interestingly, induction of short 
hairpin RNA specific for eEF1A1 led to similar caspase-independent cell death but the 
restored expression of eEF1A1 significantly inhibited apoptosis in tetraploid cells.                 
In the model proposed by the authors, downregulation of eEF1A1 contributes to the 
elimination of tetraploidy and inhibition of tumourgenesis by provoking apoptosis.                 
The effect of eEF1A2 overexpression in this system was less clear as the corresponding 
data were not shown directly. However, Kobayashi and co-workers reported that in spite 
of addition of exogenous eEF1A2 (the endogenous counterpart was not present in CHO 
cells), withdrawal of endogenous eEF1A1 was still observed on schedule but inhibition 
of the cell death response was observed instead (Kobayashi and Yonehara, 2008).                  
This would fit with the notion of the prosurvival character of the eEF1A2 and thus could 
explain the involvement of eEF1A2 in oncogenesis.  
For instance, Ruest and colleagues suggested opposing functions of eEF1A 
forms during caspase 3-dependent apoptosis. Upon differentiation of C2C12 and L6 
myoblast cells, eEF1A1 decreased but eEF1A2 increased. In myotubes subjected to 
serum deprivation-induced apoptosis, the effect was completely reciprocal to that seen 





eEF1A1 cDNA transfected cultures were rescued from cell death whereas upregulation 
of eEF1A1 did not have a prosurvival effect (Ruest et al., 2002). 
Additionally, mouse eEF1A2 was used as bait in a yeast two-hybrid screen of 
mouse brain cDNA library and peroxiredoxin-1 (Prdx1) was identified as the interactor 
with the highest number of hits. Despite high homology between the two eEF1A forms, 
eEF1A1 from cultured cell extracts and mouse tissues did not co-precipitate                        
in a complex with Prdx1. NIH-3T3 cells stably co-expressing eEF1A2 and Prdx1 were 
subjected to H2O2 treatment which was sufficient to protect cultures from oxidative 
stress–induced apoptosis. Single transfectants were characterised by partial resistance to 
cell death. Moreover, the complex of eEF1A2 and Prdx1 blocked apoptosis signalling 
through a rise in Akt abundance and a concomitant decrease in the levels of caspase 3 
and 8 activation (Chang and Wang, 2007).  
 
1.4.4 Nuclear transport 
 
The potential involvement of eEF1A in nuclear transport (of eEF1A itself                   
or when it is mediating transport of other proteins) is very inconclusive and it remains              
a speculative matter as to whether this ability is truly a noncanonical function or                        
if it is linked to the conventional role of eEF1A, for instance in the tRNA channelling 
process during protein synthesis (Mateyak and Kinzy, 2010). 
Two independent groups observed that eEF1A was actively exported from the 
nucleus upon its aa-tRNA dependent recruitment to the exportin-5 (Exp5)/RanGTP 
complex.  Exactly how eEF1A could be trapped in the nucleus is not yet understood.  
Under normal conditions, no obvious eEF1A shuttle system was confirmed by these 
studies, indeed eEF1A was completely excluded from the cell nucleus                               
(Bohnsack et al., 2002, Calado et al., 2002). The nuclear presence of aa-tRNA could be 
the prerequisite for eEF1A export. Such export seems rather to be a consequence of the 
interaction between aa-tRNA and Exp5 as they can bind without the assistance of 





a correction mechanism if eEF1A is trapped in nucleus (for instance after cell division) 
(Calado et al., 2002). Nonetheless, some studies suggest that eEF1A can access the 
nucleus as shown in msn5∆ mutants of S.cerevisiae (msn5 is a yeast counterpart of 
Exp5) or in HeLa cells depleted of Exp5 (Murthi et al., 2010, Lund et al., 2004). 
More recently, eEF1A was reported by Khacho and colleagues to be a novel 
component of the transcription dependent nuclear export mechanism (TD-NEM)                   
in mammalian cells (Khacho et al., 2008). eEF1A specifically interacted with the                  
TD-NEM sequence found in certain proteins, for instance in PABP (Poly (A) binding 
protein) or in the von Hippel-Lindau (VHL) tumour suppressor. Nuclear export activity 
of eEF1A was clearly uncoupled from its canonical role in translation and was also 
independent of the Exp5 pathway. As eEF1A was not observed in the nuclear 
compartment, it was proposed that eEF1A executed its role in the nuclear export 
mechanism from the cytoplasmic side by receiving proteins after they pass through              
the nuclear pore complexes (Khacho et al., 2008). A similar assumption was made               
in yeast where cytoplasmic eEF1A was shown to facilitate transport of the aa-tRNA 
from the nucleus and nuclear accumulation of mature tRNAs was observed upon 
downregulation or mutations of eEF1A (Grosshans et al., 2000).  
 
1.4.5 Heat shock 
 
In vertebrates, the heat shock transcription factor 1 (HSF-1) binds to heat shock 
elements (HSE) on the HSP promoters upon environmental or physiological stress 
stimuli to induce expression of the specific heat shock proteins (as reviewed in 
Shamowsky and Nudler, 2008).  
Translation elongation factor 1A from whole cell lysates of HeLa and BHK-21 
cells was retained on Sepharose-immobilized HSF-1. Full HSF1 activation requires two 
elements, trimerization and the gain of specific DNA-binding activity, both of which 
were induced by the eluted eEF1A-containing fraction as shown by an electromobility 





activate recombinant mouse HSF-1 in vitro, exclusively in tandem with a novel                 
non-coding RNA, approximately 600 nucleotides long, named by the authors heat shock 
RNA-1 (HSR-1). Shamovsky and co-workers suggested that upon heat shock-induced 
collapse of the cytoskeleton and the general shut down of proteins synthesis, substantial 
amounts of eEF1A are released and concomitantly become more available for HSF-1 
activation (Shamovsky et al., 2006). Unfortunately, apart from the in vitro reconstitution 
experiment where it was clearly stated that eEF1A was purified from rat liver                   
(which is known to express only eEF1A1), the description of techniques used in the 
referenced studies does not allow a conclusion to be formed about whether heat-shock 
response is specific to eEF1A1 or eEF1A2, or both.  
Batulan and colleagues showed that cultured motor neurons, motor neurons of 
spinal cords from SOD-1 transgenic mice and ALS patients failed to express Hsp70 after 
different heat shock conditions stimulation.  This suggests that these cells exhibit a high 
threshold for induction of the temperature-induced stress response. The authors 
implicated the compromised ability of motor neurons to activate HSF-1 as the origin of 
their failure to mount a heat shock response (Batulan et al., 2003). Additionally, motor 
neurons express eEF1A2 in cytoplasm but not eEF1A1 (some expression of which was 
seen in nucleus) (Newbery et al., 2007) and if the latter is involved in HSF-1 activation, 
then this would fit with the notion of motor neurons having an impaired heat shock 
response.  Consequently, possible differential behaviour of both eEF1A variants in terms 
of the stress response could relate back to diseases, for example to ALS where motor 
neurons are predominantly vulnerable, or to cancer.  
In many tumours HSP are expressed in increased amounts which correlates with 
patients being more resistant to therapeutic treatment and poor survival prognosis 
(Ciocca and Calderwood, 2005). Overexpression of Hsp70 was implicated in the 
inhibition of programmed cell death and the enhanced activity of oncogenes such as 
MYC or RAS. Cancer cells exhibiting higher expression of HSF-1 and Hsp70 were 






1.5 Translation and cancer connection 
 
Deregulation or misexpression of several translational machinery components is 
commonly seen in many cancers where translational control is seriously compromised. 
As the intracellular availability of these components is increased, preferential expression 
of specific cell proliferation- or survival-related proteins is consequently upregulated 
(Ruggero and Pandolfi, 2003, Le Quesne et al., 2009, Silvera et al., 2010).                           
Perhaps the best characterized translation factor that has been linked to tumour 
development is the cap-binding protein eIF4E. This protein was shown to transform 
NIH-3T3 and Rat2 fibroblasts when overexpressed and the resulting cells were highly 
tumourigenic in nude mice (Lazaris-Karatzas et al., 1990). This initiation factor 
transcript was overexpressed in many malignant cell lines (Miyagi et al., 1995)                    
and elevated protein levels were demonstrated for solid tumours, including colorectal, 
breast, bladder, lung and head and neck, to name but a few (Rosenwald et al., 1999,                         
Li et al., 1997, Crew et al., 2000, Rosenwald et al., 2001, Nathan et al., 1999).                         
It was postulated that overexpressed eIF4E executes transformation by increasing                 
the translation of a subset of particular mRNAs which contain a highly structured 
5‟UTR. These particular mRNAs encode proteins involved in cell cycle progression, 
angiogenesis, growth or survival such as ODC (ornithine decarboxylase), VEGF 
(vascular endothelial growth factor), FGF2 (fibroblast growth factor 2), cyclin D1,                
c-Myc (reviewed in Mamane et al., 2004). 
 
1.5.1 eEF1A1 and cancer 
 
Regardless of the high degree of structural and functional relatedness of both 
eEF1A variants, eEF1A1 has not been directly implicated in a transformed phenotype. 
Although EEF1A1 maps to the 6q14 region which has been amplified in some childhood 
brain tumours (Shlomit et al., 2000), it is more frequently a loss of this region                        





It has therefore been suggested that 6q14 might contain a tumour suppressor gene 
(Thornton et al., 2003) and that perhaps the U50 snoRNA gene could be one of the 
candidates (Dong et al., 2008). 
 However, Tatsuka and co-workers reported a mouse fibroblast cell line variant 
BALB/c A31-I-13, constitutively expressing eEF1A1 that was highly susceptible to 
chemically or physically induced neoplastic transformation. In order to explain this 
oncogenic effect, it was proposed that the overexpression of eEF1A1 forces the cells to 
be competitive for growth rather than hypersensitive to carcinogens or ultraviolet light. 
Alternatively, it could lead to rearrangements of actin filaments or enhanced translation 
of growth related proteins (Tatsuka et al., 1992). In addition, overexpression of eEF1A1 
was observed in the MTLn3 metastatic line compared to the weakly metastatic MTC 
cells in rat mammary adenocarcinoma (Edmonds et al., 1996). The main concern is that 
the vast majority of studies published so far have been explored with antibodies or DNA 
probes that do not distinguish between the two eEF1A forms.  Indeed, in some cases, 
mass spectrometry analysis picked up peptides whose sequence is conserved between 
eEF1A1 and eEF1A2. 
Inappropriate expression of eEF1A1 at the RNA level was seen in different 
tumours and cancer cell lines, namely primary glioblastoma, oral tongue squamous cell 
carcinoma, prostate cancer, pancreatic adenocarcinoma, hepatocellular carcinoma or 
colon cancer (Scrideli et al., 2008, Zhou et al., 2006, Mohler et al., 2002, Grant et al., 
1992, Grassi et al., 2007, Alon et al., 1999). A few cancer related interactors of eEF1A1 
were also indentified, for example osteopontin (OPN) which is overexpressed in many 
human tumours and is the main phosphoprotein secreted during advanced metastasis 
(Zhang et al., 2009). Authors investigated the possibility that eEF1A1 was an actin 
dependent regulator of the OPN mRNA stability and expression. A higher abundance of 
OPN was seen in invasive HepG2 cells upon low levels of F-actin and lack of eEF1A1 
binding to OPN 5‟UTR. Association of OPN mRNA with F-actin via binding of 
eEF1A1 led to decreased expression of OPN and a less invasive phenotype of the 





Y-encoded (TSPY) as a novel interactor of eEF1A1 in yeast two-hybrid screen of a 
mouse foetal gonadal cDNA library (Kido and Lau, 2008). TSPY is frequently 
overexpressed in gonadoblastoma and testicular germ cell tumours. Either eEF1A1 or 
eEF1A2 co-localized in cytoplasm with TSPY in COS7 co-transfected cells and interact 
with TSPY in GST-pull down assay. TSPY was co-expressed with eEF1A in both 
human normal testicular germ cells and germ cells tumours (but an antibody                      
cross-reacting with both eEF1A variants was used). The authors suggest that by 
interacting with eEF1A, TSPY could modulate protein synthesis and upregulate the 
genes involved in cellular proliferation and tumour development (Kido and Lau, 2008). 
The EEF1A1 gene was differentially expressed in several cancer cell lines 
subjected to treatment with pharmacological compounds suggesting that it might be             
a potential therapeutic target. Overexpression of EEF1A1 by at least a 2-fold change was 
seen in MIA PaCa-2 (pancreatic cancer), K562 (erythroblastic leukaemia) and Saos-2 
(osteosarcoma) cell lines resistant to methotrexate (MTX) in comparison to the sensitive 
line counterparts (Selga et al., 2009). Harris and colleagues reported a list of proteins 
modulated in NB4 acute promyelocytic leukaemia line that was exposed to treatment 
with all-trans-retinoic acid (ATRA) and downregulation of eEF1A1 protein but 
unchanged mRNA levels were observed (Harris et al., 2004). Overexpression of 
eEF1A1 at the mRNA level was reported in UMSCC 10b/Pt-S15 head and neck 
carcinoma cell line which acquired resistance to cisplatin (Johnsson et al., 2000). 
Differential modulation of eEF1A1 expression observed in cell lines subjected to MTX, 
cisplatin or ATRA treatment might be attributed to the proapoptotic abilities displayed 
by eEF1A1. 
 
1.5.2 eEF1A2 as an oncogene 
 
While the tumourigenicity status of the eEF1A1 is less clear, eEF1A2 has been 
clearly implicated as an oncogene (Anand et al., 2002).  A wealth of data supports this 





oncogenes are characterised by the hyperactivation or expression at abnormally high 
levels in primary human cancers, and by capacity to induce a transformed phenotype in 
rodent cell lines cultured in vitro (usually NIH-3T3 or Rat1) (Lee, 2003).  
Amplification of the 20q13 genomic region (EEF1A2 maps to 20q13.3)                          
is a frequent chromosomal alteration and number of putative oncogenes has been 
identified within this region. Increased copy number at this locus was documented in 
breast, ovarian,  colorectal and lung cancers by CGH or FISH (Kallioniemi et al., 1994, 
Tanner et al., 1994, Suehiro et al., 2000, Aust et al., 2004, Zhu et al., 2007).  Indeed, 
these tumours were associated with a worse survival prognosis and faster cancer 
progression (Isola et al., 1995, Tanner et al., 2000, Aust et al., 2004). 
It seems that high eEF1A2 expression at the RNA and protein level is a common 
property in a large proportion of transformed cell lines, regardless of their tumour origin 
(Joseph et al., 2004, Tomlinson et al., 2005, Tomlinson et al., 2007, Cao et al., 2009). 
Joseph and colleagues performed studies of the eEF1A2 cDNA hybridization                     
on a cancer profiling array which contained 241 paired samples of several tumours and 
normal tissues. It was revealed that the EEF1A2 transcript was overexpressed by at least 
two-fold in 35% of colon, 24% of lung, 22% of rectum, 20% of kidney and 21% of 
ovary cancer cases when compared to the corresponding controls (Joseph et al., 2004). 
Anand et al. demonstrated that 25% of primary ovarian tumours exhibited 
EEF1A2 amplification and high eEF1A2 expression at the RNA level was seen in 
around 30% of ovarian tumours and ovarian cancer cell lines. No detectable EEF1A2 
transcript was reported in normal ovarian epithelium. Moreover, forced expression of 
eEF1A2 in NIH-3T3 and Rat1 fibroblasts resulted in colony formation in soft agar, 
accelerated growth rate and foci formation, respectively. NIH-3T3 and ES-2 clear cell 
carcinoma lines generated to express eEF1A2 were reported to form tumours when the 
cells were injected into nude mice (Anand et al., 2002). In addition, microarray analysis 
of gene expression from 113 ovarian epithelial tumours showed EEF1A2 to be 
upregulated in clear cell carcinoma by an average 4-fold over other major histological 





tumours tested overexpressed EEF1A2 at the mRNA level. Expression of eEF1A2 was 
associated with the clear cell tumour subtype and eEF1A2 upregulation at both,                      
RNA and protein level was present in up to 75% of ovarian clear cell carcinomas 
(Tomlinson et al., 2007). Furthermore, Pinke and colleagues reported that the eEF1A2 
protein was highly expressed in 32% of the 500 primary ovarian tumours tested                  
in a tissue microarray but respectively 50% and 30% of these were of serous and 
endometrioid type. Ectopic expression of eEF1A2 in SK-OV-3 clear cell carcinoma line 
led to enhanced proliferation in vitro and allowed tumour-like spheroids to develop in 
hanging drop culture (Pinke et al., 2008).  
Kulkarni et al. determined that high protein and mRNA expression of eEF1A2 
occurs in up to 60% of primary breast tumours. They suggest that high eEF1A2 
expression may coincide with an increased probability of 20-year survival, therefore this 
could serve as a prognostic outcome marker of breast cancer (Kulkarni et al., 2007).                 
In studies of Tomlinson et al., eEF1A2 was shown to be barely detected at the mRNA 
level in normal human breast tissue or benign breast tumours whereas it was expressed 
up to 30-fold higher in malignant breast tumours. About 63% of breast tumours that 
were subjected to immunohistochemistry analysis displayed a significant overexpression 
of eEF1A2 protein (Tomlinson et al., 2005).   
Strong upregulation of eEF1A2 at the protein level was also found in 83%                  
of pancreatic cancer tissues whereas there was little expression in normal pancreas or 
chronic pancreatitis tissues. Moreover, the SW1990 pancreatic adenocarcinoma cell line 
with ectopic expression of eEF1A2 showed accelerated growth and proliferation, 
increased invasion and migration in vitro and development of tumours when the line was 
xenografted in nude mice (Cao et al., 2009). 
In a gene profiling study of four newly established lung adenocarcinoma cell 
lines (HKULC1-4), EEF1A2 was shown to be significantly overexpressed when 
compared to normal bronchial epithelial cells (Lam et al., 2006). Moreover, quantitative 
RT-PCR analysis performed on normal lung tissue and 27 primary lung 





in tumours (Zhu et al., 2007). Using simultaneous CGH, transcript microarray and mass 
spectrometry analysis of six lung adenocarcinoma cell lines, Li et al. identified four 
genes (PRDX1, EEF1A2, CALR and KCIP-1) in which increased protein expression was 
in agreement with elevated DNA copy number and mRNA transcripts. In addition, 
specific inhibition of eEF1A2 in four of these cell lines reduced their proliferation rate 
and led to increased apoptosis. When immunohistochemical analyses of eEF1A2 
expression were performed on a tissue microarray with samples from pathologic stage I 
non-small-cell lung cancer patients, its presence was confirmed in 28% cases                          
(but note that antibody that detects both eEF1A forms was used).  Expression of eEF1A2 
was associated with a shorter survival time (Li et al., 2006). As PRDX1 amplification 
and expression are both elevated in this study alongside EEF1A2 and also,                               
the corresponding proteins were found to act synergistically against the peroxide-
induced death of NIH-3T3 cells through Akt modulation (Chang and Wang, 2007),                  
it is possible they block apoptosis in a similar manner in lung cancer. It is noteworthy 
that overexpression of eEF1A2 was seen in a large proportion of primary lung tumours 
(Julia Boyd, unpublished observations). 
Increased expression of Eef1a2 transcript was also reported among unique 
primary B cell lineage neoplasms of mice-plasmacytomas (PCT) (Li et al., 2010). 
Moreover, elevated levels of EEF1A2 were found in human multiple myeloma (MM, 
human plasma cell neoplasm) but very high levels of the eEF1A2 protein were seen only 
in 15% of primary MM samples. They were tested alongside normal bone marrow 
plasma cells and non-transformed precursors to MM, known as the monoclonal 
gammopathy of undetermined significance (MGUS). It was shown that expression of the 
EEF1A2 transcript gradually increased during the progression of normal plasma cells                 
to MGUS and then to MM. Elevated levels of eEF1A2 were also a hallmark of a subset 
of the mouse PCT and human MM origin cell lines. In addition, silencing of the Eef1a2 
transcript and protein in PCT cell lines was associated with reduced growth, probably 
due to a delayed cell cycle entry from G1/G0 to S and these cells were sensitive to 





1.5.3 Oncogenicity mechanism of eEF1A2 
 
The mechanism by which eEF1A2 contributes to oncogenesis remains elusive.  
For other genes, overexpression seems to be result of gene amplification but this cannot 
be considered as a general cause behind tumourigenicity of the eEF1A2.                         
In Anand et al. studies of primary ovarian tumours overexpressing eEF1A2, one of three 
samples displayed elevated EEF1A2 expression but had no increase in gene copy 
number (Anand et al., 2002).  In the Tomlinson study there was no correlation between 
gene expression and copy number at the EEF1A2 locus, suggesting the existence of an 
alternative mechanism that mediated upregulation (Tomlinson et al., 2007).                           
Also, increased amplification of the EEF1A2 gene was seen in ovarian tumours that did 
not express eEF1A2. In fact, sequencing of the gene from low copy number tumours has 
shown no activating mutations or mutations leading to eEF1A2 upregulation.                              
In addition, no correlation between expression and methylation status of the gene was 
observed (Tomlinson et al., 2007). Similarly, in the few cases of mouse plasmacytomas, 
overexpression of Eef1a2 was not due to increased copy number or mutation of the 
Eef1a2 coding sequence (Li et al., 2010). 
It is yet not clear why eEF1A2 drives oncogenesis in tissues where eEF1A1                
is so highly abundant. It was shown in eEF1A2-overexpressing ovarian and pancreatic 
tumours that levels of the EEF1A1 transcript remained unaffected (Anand et al., 2002, 
Cao et al., 2009) but there is no information available about protein expression status                   
in these samples. In general, at least two possible explanations have been suggested to 
solve the role of eEF1A2 in tumourgenesis.  
Firstly, the mechanism of oncogenicity might be associated with the canonical 
function of eEF1A2 in translational elongation. Thornton suggested that eEF1A2 might 
lead to a straightforward increase in overall protein synthesis, resulting in elevated 
proliferation (Thornton et al., 2003). It is not clear whether tumours with upregulated 
eEF1A2 would have a greater protein synthesis capacity since eEF1A is already in 





and it is rather initiation that is a limiting step of translation (Hershey, 1991).                           
In fact, increased elongation rate in S. cerevisiae was linked to an elevated level of 
translational errors (Song et al., 1989, Carr-Schmid et al., 1999). Alternatively, 
upregulated eEF1A2 could specifically promote the expression of proteins associated 
with growth activation or apoptosis inhibition (like c-Myc or Bcl-2) thus following the 
oncogenicity-driving mechanism of eIF4E (Thornton et al., 2003). 
Secondly, regardless of the 92% identity at the amino acid level between eEF1A 
variants (Soares et al., 2009), it has been suggested that both forms might perform only 
subtly or completely distinct noncanonical roles, therefore eEF1A2 could enhance 
oncogenesis independently of the translation network (Anand et al., 2002,                          
Kulkarni et al., 2007). For instance, this notion would fit with the opposite role of 
eEF1A variants in apoptosis where eEF1A2 was anti-apoptotic and the opposite was true 
for eEF1A1 (Ruest et al., 2002, Chang and Wang, 2007).     
Alternatively, the cytoskeletal modifying properties of eEF1A could be the next 
possibility to explore. Amiri et al. reported that eEF1A2 expression increased                       
the formation of spike shaped structures called filopodia in rodent and human cells                   
(Amiri et al., 2006). These cell membrane protrusions consist of parallel actin bundles 
and are critical for cell migration or invasion (Chodniewicz and Klemke, 2004, 
Yamaguchi et al., 2005). This increase in eEF1A2 expression caused elevated motility 
and invasion of the BT-549 breast cancer cell line in vitro (Amiri et al., 2006). 
Moreover, they found that the capacity of eEF1A2 to promote filopodia formation is 
phosphatidylinositol-3 kinase (PI3K) and Akt kinase dependent, although no direct 
physical interaction between them and eEF1A2 was confirmed (Amiri et al., 2006, 
Jeganathan et al., 2008). On the other hand, eEF1A1 was confirmed as a binding partner 
for Akt2 (Lau et al., 2006) and eEF1A was identified in the phosphorylated Akt kinase 
interactome of breast cancer cells (Pecorari et al., 2009).  Several lines of evidence led to 
the conclusion that PI3K/Akt signalling  is linked to tumourigenesis due to its role in cell 
proliferation stimulation, actin filaments remodelling abilities and apoptosis suppression                        





Amiri et al. suggest that the ability of eEF1A2 to regulate actin rearrangement and                 
to activate Akt may occur through phosphoinositide-dependent signalling                           
(Amiri et al., 2006).  
Furthermore, eEF1A2 was also shown to directly bind to PI4KIIIβ in rodent               
and human cells and to increase its lipid kinase activity in vitro.  An increase in 
intracellular phosphatidylinositol 4-phosphate (PI4P) abundance was also reported upon 
overexpression of eEF1A2 in Rat2 and BT-549 cells (Jeganathan and Lee, 2007).               
PI4P is a regulatory precursor for PI(3,4)P2, PI(4,5)P2 and PI(3,4,5)P3 which are well 
known products of PI3K and PI4K-driven phosphorylation and also the second 
messengers that regulate actin cytoskeleton organization, proliferation and apoptosis 
(Pendaries et al., 2003, Bunney and Katan, 2010, Martelli et al., 2006). Jeganathan and 
co-workers hypothesize that high levels of eEF1A2 in tumours might lead to activation 
of PI3K or PI4KIIIβ, followed by the accumulation of the cellular pool of 
phosphoinositides and stimulation of filopodia formation, sufficient to execute the 
neoplastic phenotype of the cells (Jeganathan and Lee, 2007, Jeganathan et al., 2008).     
There is also some evidence that eEF1A2 might be dependent on microRNA 
(miRNA) expression alterations. Over the last decade, these 20-24 nucleotide long 
noncoding RNAs have emerged as significant regulators of many biological processes, 
including cellular proliferation, apoptosis or differentiation timing.  miRNAs target sites 
in the 3‟UTR and posttranscriptionally regulate gene expression by either 
repressing/activating translation or promoting mRNA degradation (Chekulaeva and 
Filipowicz, 2009). Malfunction of the expression pattern of miRNAs is associated with 
most malignancies and, depending whether they are down- or upregulated, miRNAs can 
act as tumour suppressors or as oncogenes (Esquela-Kerscher and Slack, 2006).               
Dahiya and colleagues identified eEF1A2 as a plausible candidate for let-7f regulation 
because when this miRNA was overexpressed in BG-1 ovarian cancer cell line, there 







1.6 Hepatocellular carcinoma  
 
A recent epidemiological study has shown that liver cancer was the sixth 
common malignancy around the world but ranked as third as a cause of death.                     
An estimated 748 000 new cases  and approximately 695 000 deaths appeared in 2008 
(Ferlay et al., 2010b). Estimates of liver cancer incidence and mortality in 2008 for 
Europe were 60 200 and 60 100, respectively (Ferlay et al., 2010a). Approximately               
24 120 new cases of liver cancer are expected to occur in the USA during 2010, 
accompanied by an estimated 18 910 deaths. More than 80 % of the primary liver cancer 
cases in adults are qualified as hepatocellular carcinoma (HCC) (American Cancer 
Society, 2010). Incidence and mortality rates are more common among men than women 
(Ferlay et al., 2010b). The occurrence of HCC varies distinguishably between 
geographical areas due to differences in risk factors. Approximately 80% of new HCC 
incidents are identified in developing countries, especially in sub-Saharan Africa,                 
and East and Southeast Asia. There is a lower incidence in areas of Northern and 
Western Europe as well as North America, however the numbers of HCC new cases in 
Europe and the USA are increasing, partially due to elevated levels of hepatitis C virus 
(HCV) infections (Wong and Ng, 2008). 
The most prominent risk factors linked to the development of HCC are chronic 
hepatitis B virus (HBV) and HCV infections, alcohol abuse or consumption of aflatoxin 
B1-contaminated food. Other etiological causes are also implicated in HCC, including 
tobacco smoking, obesity and some diseases like diabetes, hereditary haemochromatosis 
or non-alcoholic fatty liver disorder (NAFLD) (Farazi and DePinho, 2006). 
 Hepatocarcinogenesis is considered as a multistep and long process (Figure 1.3). 
Liver injury is followed by inflammation, accompanied by continuous rounds of 
destruction and proliferation of hepatocytes, resulting in chronic liver disease.                   
Such cycles of necrosis and regeneration increase the risk of spontaneous mutations            
due to an insufficient time to repair altered DNA and ultimately, accumulation of these 
changes leads to uncontrolled growth of hepatocytes and activation of stellate cells.                  





liver fibrosis – a prerequisite step before cirrhosis. In cirrhosis, abnormal nodules 
gradually progress to dysplastic nodules and finally to HCC (Michielsen et al., 2005, 
Farazi and DePinho, 2006). 
 
 
Progressive changes during hepatocellular malignancy develop not only                    
as a result of cellular transitions, but also due to genetic alterations, chromosomal 
aberrations or changes in signalling pathways. The Wnt/β-catenin network is frequently 
deregulated in HCC which developed due to HBV/HCV infections and alcohol abuse 
mediated cirrhosis. In such cases, mutations in β-catenin prevent its phosphorylation, 
ubiqitination and proteasome degradation, regardless of the activation status of the Wnt 
pathway. Here, β-catenin accumulates in the nucleus and induces transcription of cell 
differentiation- and proliferation-related genes like MYC or CJUN (Aravalli et al., 2008, 
Whittaker et al., 2010). In many HCC cases, CGH studies have shown DNA copy 
number losses at 1p, 4q, 6q, 8p, 13q and 17p and gains on 1q, 6p, 8q, 17q or 20q 
chromosomal arms (Farazi and DePinho, 2006). 
A large proportion of HCC cases usually develops on a background of chronic 
hepatitis or cirrhosis but there are also incidents of  aflatoxin-induced liver malignancy 
(Thorgeirsson and Grisham, 2002). Aflatoxin B1 (AFB1) is a secondary metabolite of                       
Aspergillus flavus and its ingestion elevates the risk of HCC development. 
Approximately 28.2 % of HCC cases worldwide are cases associated with toxin 
Figure 1.3 Diagram of hepatocellular carcinoma progression. Model was adapted and modified 





consumption. The risk of AFB1-mediated HCC increases upon concomitant exposure to 
HBV infection, especially in regions of rural Africa and Far East (Liu and Wu, 2010, 
Farazi and DePinho, 2006). AFB1 induces a specific mutation in the p53 tumour 
suppressor gene (one nucleotide substitution in codon 249).  This particular mutation is 
characteristic for early events in HCC, and it is seen also in malignancy-free areas of 
liver chronically exposed to toxin. Mutations of TP53 in non-AFB1-induced cases are 
associated with late progression of hepatocarcinogenesis and were identified                            
in dysplastic nodules (Liu and Wu, 2010, Zender et al., 2010). 
 The most potent causes of liver cirrhosis worldwide are the chronic intake of 
high dosages of alcohol and viral HBV/HCV infections. Frequent consumption of 
ethanol is thought to drive liver damage by the induction of inflammation or by 
oxidative stress. In the former situation, circulating metabolic toxins activate the release 
of chemokines and cytokines (TNFα, IL1β, IL6, prostaglandin E2) by Küpffer cells                  
and this promotes higher sensitivity of hepatocytes to the cytotoxic effect of TNFα.                      
This exposes them to chronic necrosis-regeneration cycles, induction of stellate cells         
and finally cirrhosis. Oxidative stress contributes to HCC not only by lipid      
peroxidation-induced damage of hepatocytes, culminating in liver fibrosis, but also by 
compromising the IFNγ-mediated activation of STAT1 and protection of hepatocytes 
(signal transducer and activator of transcription 1) (Farazi and DePinho, 2006). 
 The risk of HCC incidence is elevated up to 15- and 17-fold in chronic HBV 
and HCV-infected patients, respectively. About 20-30% of chronic carriers will develop 
hepatic cirrhosis in a 20-30 year period (Tsai and Chung, 2010). HBV and HCV are 
indirectly linked to HCC initiation by propagation of liver inflammation and frequent 
necrosis-regeneration cycles, or directly by viral-host protein interactions and integration 
into the hepatocyte genome (Michielsen et al., 2005).  
HCV, as an RNA virus, does not integrate into the host genome. Proteins of the 
viral core induce the overexpression of TGFβ which in turns leads to elevated fibrosis 
and the risk of cirrhosis (Farazi and DePinho, 2006). Incorporation of HBV DNA into 





associated with microdeletions. Such integration occurs at sites linked to cell signalling 
regulation, proliferation or viability. Telomerase reverse transcriptase (TERT),                
plateled-derived growth factor receptor (PDGFR), mitogen activated protein kinase 1 
(MAPK1), 60S ribosomal protein genes or cyclin A2 are common genetic targets of 
HBV integration. Additionally, HBV incorporates its own gene sequence - HBx 
(hepatitis B protein x) whose product interacts with p53 or propagates TP53 
transcriptional repression. As a result, viral infection leads to a decrease in apoptosis, 
compromised cell cycle regulation and faulty DNA damage repair. HBx is also 
responsible for the transactivation of several signalling networks, including PI3K, 
JAK/STAT, Wnt or JNK (Tsai and Chung, 2010).  
 
1.7 Malignant melanoma 
 
Abnormal proliferation of epidermal melanocytes gives rise to melanocytic 
naevi, malignant lesions and finally to cutaneous malignant melanoma (CMM). 
Melanocytes reside within the basal layer of the epithelial surfaces and arise from                     
a population of migratory embryonic cells called neural crest cells. Melanocytes 
specialise in production, storage and transfer of melanin pigments to the surrounding 
epithelium (Uong and Zon, 2010). Most melanomas present on the skin but tumours can 
also occur in other tissues, including the inner ear, uveal tract of the eye or oral and sinus 
mucosa (Houghton and Polsky, 2002). CMM occurrence continues to increase 
worldwide, however the highest numbers are reported for Australia, New Zealand, North 
America and Northern Europe (Parkin et al., 2005). According to the most recent 
GLOBOCAN estimates, approximately 197 000 new cases were diagnosed with CMM 
and an estimated 46 000 deaths occurred due to this malignancy in 2008 (Ferlay et al., 
2010b). In 2008, incidents and mortality for Europe were 84 000 and 20 100, 
respectively (Ferlay et al., 2010a). In the USA, approximately 68 000 people are 
expected to be diagnosed and about 8700 will die from malignant melanoma of the skin 





cancers, it is associated with the highest mortality among all skin-related malignancies 
(Cummins et al., 2006a).  It occurs more frequently in females than males and women 
have better survival prognosis (Parkin et al., 2005).  
Development of CMM is predominantly associated with prolonged exposure to 
the sun and other sources of ultraviolet radiation. Also, people with high sun sensitivity, 
a history of sunburns and extensive skin damage, compromised immune system and 
family history of CMM are in a higher risk group. Specific ethnic background 
determines predisposition to CMM, frequently among populations with light 
pigmentation of eyes, hair and skin, for instance in patients of the Central or Northern 
European ancestry. Approximately 30% of CMM develop from acquired or congenital 
melanocytic naevi and the risk increases with the number of observed skin lesions                     
or alterations in their appearance (Cummins et al., 2006a).  
The „ABCDE‟ clinical system states for asymmetry, borders (and surface) 
irregularities, colour, diameter (>6mm), evolving and facilitates screen for abnormal 
moles. Subsequent evaluation of the biopsy from suspicious lesions is necessary for the 
correct diagnosis and eventual treatment. Detection of melanoma as early as possible             
is crucial for cure and survival (Goldstein and Goldstein, 2001).  There are four major 
groups of CMM: superficial spreading melanoma (the most common type with 
prolonged horizontal growth phase), lentigo maligna melanoma (a less aggressive type 
which occurs on highly sun-damaged areas of skin), nodular melanoma (the second most 
common and the most aggressive type with extremely short radial growth) and acral 
lentiginous melanoma (characteristic in populations with dark skin pigmentation) 
(Cummins et al., 2006a, Goldstein and Goldstein, 2001). 
The generally accepted model of the melanoma progression (Figure 1.4) states 
that abnormal proliferation of melanocytic clones could promote the assembly of benign 
or dysplastic naevus (atypical mole). Overcoming cell senescence would subsequently 
lead to an in situ melanoma which is defined by radial growth. The radial growth phase 
is characterised by horizontal spreading of transformed melanocytes within                   





dermis. If left untreated, this can promote the vertical growth phase, defined by deeper 
invasion through the dermis and subcutaneous tissue. Reaching metastasis in distant 
sites is a culminating point where, for example, suppression of apoptosis is highly 
required (Houghton and Polsky, 2002, Zabierowski and Herlyn, 2010).  
 
 
   
The cumulative sequence of genetic and molecular changes is suggested to 
complement the pathologic mechanism underlying melanocytic transformation. 
Alterations in the mitogen-activated protein kinase signalling maintain increased 
proliferation across the linear progression phase of melanoma. Mutagenic activation of 
the MAPK network is seen in up to 90% of melanomas, mostly due to mutations                   
in NRAS or BRAF, which occur in a mutually exclusive manner. Activating NRAS 
mutations are common in about 26% of sporadic melanoma cases. Somatic BRAF 
missense mutations account for 60-70% of all melanoma cases and in about 90% of 
these, a single substitution of valine for glutamic acid at position 600 is the most 
common. The V600E mutation keeps BRAF constitutively activated, which in turn 
promotes continuous MEK/ERK signalling in cells without assistance of extracellular 
stimuli. The BRAF and NRAS mutations are as common in benign naevi as in melanoma, 
suggesting that they promote melanocytic proliferation and growth arrest but are not 
sufficient to fully activate malignant transformation, see review (Palmieri et al., 2009, 
Meyle and Guldberg 2009, Fecher et al., 2007).  
The overcoming of the cellular senescence is the next step to facilitate neoplastic 
transition. The CDKN2A (cyclin-dependent kinase inhibitor 2A) gene encodes two 




which function as tumour 
Figure 1.4  Schematic model of linear melanoma progression. RGP-radial growth phase,  VGP-





suppressors in two separate pathways. Deletions, mutations or hypermethylation of the 
CDKN2A promoter are responsible for the gene inactivation in the vast majority of the 
melanoma cases. Hence, loss of the CDKN2A function leads to serious alterations in the 
Rb and p53 networking. The p16
INK4a 
blocks CDK4 (cyclin-dependent kinase 4) 
complex-mediated phosphorylation of the retinoblastoma protein. As a result, activated 
Rb binds and represses the E2F transcription factor, and cell cycle transition from phase 
G1 to S is held. Alternatively, p14
ARF
 complements the p16
INK4a 
–mediated senescence 
barrier by interacting with the murine double minute 2 protein (MDM2),                           
hence stabilizing p53. MDM is an ubiquitin ligase which targets p53 for proteasome 
degradation. CDKN2A is also recognised as a melanoma susceptibility gene                       
and mutations of the gene are frequently reported in patients with a strong family history 
of melanoma (~10% of familial cases). The pentrance of the CDKN2A mutations 
depends on UV exposure and geographical location. CDK4 is implicated as a second 
melanoma susceptibility gene. Germline mutations of CDK4 (R24C, R24H) are very 
rare and are carried only by a small number of melanoma-predisposed families across 
the world. These substitutions are most commonly seen among somatic mutations of 
CDK4 and they affect binding of CDK4 protein to p16
INK4 
(Palmieri et al., 2009,                 
Meyle and Guldberg 2009, Fecher et al., 2007).  
 When pre-melanoma cells overcome the senescence barrier, suppression of 
apoptosis is the next level in facilitating the vertical growth and metastasis phases. 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a negative 
regulator of the PI3K/Akt signalling pathway. PTEN promotes dephosphorylation of 
PIP3 through the lipase phosphatase activity. Loss of this tumour suppressor gene was 
reported in 5-20% of uncultured melanomas and in 30-50% of melanoma cell lines. 
Somatic mutations of PTEN were found in 10-20% of primary melanomas and 40-60% 
of melanoma cell lines. Inactivating mutations of PTEN and activating mutations                  
in NRAS were reported be rare within the same tumour, thus it is likely they function 
mutually exclusively. The inactivation of PTEN by deletions or mutations leads to 





melanoma cases and 548 benign neavi samples, PI3K expression was shown to be 
higher in CMM and metastatic cases than in naevis, indicating an association of PI3K 
with late tumour progression. Activating mutations in the p110 alpha subunit of PI3K 
occurred in 1% of primary melanomas and 3% of melanoma metastases,                                
but amplifications of PI3K subunits have not been confirmed by array CGH so far. IHC 
studies showed overexpression of phospho-Akt in about 54% of naevi and in 71% of 
primary and metastatic melanomas. Increased expression of phospho-Akt was associated 
with tumour progression and lower survival rate. Akt3 is the predominantly 
overexpressed Akt variant found in CMM. The complete overview of genetic alterations 
and pathways linked to melanoma can be found in reviews above. 
Interestingly, about 26-50% of CMM was reported to originate from naevi, 
indicating that melanoma can arise from skin of normal appearance, regardless of the 
linear model of progression and corresponding genetic alterations. An alternative 
hypothesis states that transformed melanocytic stem cells or melanocyte progenitors are 
precursors of melanoma. Interaction of precursors with the tumour microenvironment 
might promote their transition directly into normal, benign or transformed and metastatic 
melanocytic cells, without occurrence of intermediates (Zabierowski and Herlyn, 2010). 
 
1.8 Colorectal cancer 
 
According to the 2008 worldwide cancer statistics, tumours of the colon and 
rectum were ranked third in terms of incidence (1 233 000 new cases) and were the 
fourth most common cancer-related mortality in 2008 (608 000 deaths).                                  
The highest incidence rates were observed in regions of Australia/New Zealand                   
and Western Europe. Colorectal cancer occurs more frequently in men than                      
in women (Ferlay et al., 2010b). In 2008, estimates for Europe predicted 435 000 new 
cases and 212 000 deaths (Ferlay et al., 2010a). The American Cancer Society expects 
approximately 142 000 new cases and 51 000 deaths associated with colorectal cancer in 





The risk of colorectal cancer (CRC) development increases with age and more 
than 90% of cases are diagnosed in patients of at least 50 years old. Increased risk                 
is associated with obesity, type 2 diabetes, a family history of CRC or polyps, inherited 
genetic mutations, physical inactivity, alcohol abuse, smoking and a diet high in red 
meat. A large proportion of CRC cases (~95%) are classified as adenocarcinomas 
(American Cancer Society, 2010).  In the vast majority of cases primary CRC                           
is sporadic but inherited factors accounts for about 15% of cases (Kinzler and 
Vogelstein, 1996). Germline mutations are the genetic basis for either familial 
adenomatous polyposis coli (APC) syndrome or hereditary non-polyposis colorectal 
cancer (HNPCC) (Markowitz et al., 2002). 
Colorectal cancers evolve over several years through a series of chronological 
events known as the „adenoma-carcinoma‟ sequence (Figure 1.5). It starts from the 
transformation of epithelial cells lining the lumen of the colon or rectum, followed by 
the formation of aberrant crypt foci, then larger adenomatous lesions and finally,                     
the progression to invasive cancer. Importantly, this sequence of phenotypic alterations 
throughout tumour development is complemented by a repertoire of genetic changes 
(Markowitz et al., 2002).  
 
 
At least two genetic characteristics have been identified: chromosomal instability 
(CIN) and microsatellite instability (MSI), which can be also supplemented by CpG 
island methylation phenotype (CIMP). Colorectal tumours might display a combination 
of these features, however CIN and MSI correlate inversely (Pino and Chung, 2010). 
CIN is reported in about 75% of CRC sporadic cases and refers to losses/gains    
of the whole or just fragments of the chromosome. CIN can be associated with defects  
Figure 1.5  Colorectal cancer progression. Diagram of adenoma-carcinoma series was taken and 





in the spindle checkpoint genes like hMAD (mitotic arrest-deficient) or hBUB (budding 
uninhibited by benzimidoazoles) and subsequent mis-segregation of chromosomes. 
Apart from karyotypic aberrations, accumulation of mutations in tumour suppressor 
genes and oncogenes is characteristic for CIN and crucial for pathology of CRC                
(Pino and Chung, 2010). APC is a tumour suppressor of Wnt signalling-mediated 
transcription as it catalyzes the ubiquitin-dependent degradation of β-catenin.                
Germline inactivating mutations in APC are responsible for APC syndrome and carriers 
have almost a 100% risk of developing CRC by 40 years of age.  Importantly, somatic 
mutations and deletions occur in about 70 % of non-familiar CRCs. On this occasion, 
APC mutations are frequently carried in aberrant crypt foci and adenomas which 
indicate that functional loss of the gene is associated with early events of CRC 
development. In addition, hypermethylation of the APC promoter was reported in 18% 
of adenomas and primary CRCs (Pino and Chung, 2010, Markowitz et al., 2002).                 
The second key genetic event in CRC is mutational inactivation of TP53 and loss of its 
function was seen in up to 26% of early adenomas, 50% of late adenomas and 75%               
of CRCs, suggesting that such dysfunction is coupled to adenoma-invasive carcinoma 
transition (Pino and Chung, 2010).  
Many colorectal tumours with MSI have unaffected APC expression.                      
Instead, they exhibit mutations in β-catenin, which prevents its interaction with APC and 
subsequent degradation of β-catenin by proteasome (Boland and Goel, 2010).                    
It is commonly accepted that aberrations in DNA mismatch repair genes are associated 
with the MSI phenomenon. Inability to repair errors within repetitive elements of the 
DNA sequence drives changes in the size of microsatellites stretches. MSI-mediated 
CRCs is observed in the majority of patients with HNPCC syndrome where mutations  
in the MMR (mismatch repair genes MLH1, MSH2, MSH6 and PMS2) are germline 
transmitted or their second alleles are somatically inactivated (Balmana et al., 2010, 
Boland and Goel, 2010, Markowitz et al., 2002). Moreover, somatic inactivation of 





Sporadic CRCs associated with MSI are frequently characterised by biallelic silencing of 
the MLH1 promoter or absence of MLH1 and PMS2 proteins (Boland and Goel, 2010). 
 
1.9 Field cancerization 
 
Based on the studies of oral cancers, Slaughter introduced a new concept called 
„field cancerization‟ (Slaughter et al., 1953). The term was proposed to explain                   
the development of multiple primary tumours and occurrence of the second primary 
tumour sites following surgery of the initial carcinoma. Field cancerization has been 
described in a large proportion of tumour studies of the head and neck, lung, skin, breast, 
ovary, colon or bladder. It underlines the importance of an expanding preneoplastic field 
in epithelial carcinogenesis. Epithelial cells frequently undergo renewal and are 
commonly exposed to environmental factors or carcinogens. Consequently, they are 
predisposed to aberrant proliferation and initiation of genetically altered cancer fields, 
hyperplasia and finally tumours. The concept of field cancerization fits with the linear 
model of cancer progression where an accumulation of genetic alterations accompany 
transition from a normal cell to neoplasm.  
The theory of field cancerization proposes that in the initial phase, a stem cell 
acquires genetic changes and forms a patch of daughter cells sharing a common 
genotype. The new genetic events facilitate conversion of patches into cells with             
a growth advantage which in turn develops into an expanding field. As the field grows, 
additional genetic hits propagate the formation of various subclones within the lesion. 
Following clonal divergence and selection, a subclone will eventually evolve into 
invasive cancer. Regardless of a cancer-negative outcome from biopsy evaluation,                 
there is still a risk for growth of another malignancy if the field remains after surgical 
tumour resection. Field effect in skin neoplasms is associated with TP53 mutations 
whereas a gradient of CEA expression (carcinoembryonic antigen) or epigenetic 
silencing of MGMT (O
6





effect in colorectal cancer. The concept of field cancerization is reviewed elsewhere 
(Braakhuis et al., 2003, Dakubo et al., 2007). 
 
 
1.10 Project aims 
 
The majority of studies on the involvement of the eEF1A in cancer have focused 
upon eEF1A2, but very little is known specifically about eEF1A1 and its eventual role         
in tumourigenicity. One of the main aims of this PhD project was to investigate whether 
eEF1A1 is capable of driving neoplastic transformation in a similar manner to eEF1A2 
using rodent fibroblasts stably expressing eEF1A variants followed by a variety of 
different in vitro oncogenicity assays. The relationship between increased expression of 
two eEF1A forms and global protein synthesis rate was also determined in the stable cell 
lines in order to investigate possible mechanisms of oncogenicity. The final aim was to 
establish the distribution and expression pattern of eEF1A1 and eEF1A2 in liver,                 
skin and colorectal cancers using commercial tumour arrays. The data obtained could be 
used to screen for possible associations with clinicopathological features and provide 
some insight into the role of eEF1A in these malignancies and its significance for 








2.1.1 Buffers and solutions 
 
A list of buffers and solutions that were used throughout this study, along with                     
their corresponding recipes is presented in Table 2.1. 
 
 
Table 2.1 Review of solutions and buffers required for performing experiments within the project.  
 
NAME COMPOSITION 
10 x Laemmli running buffer 
250 mM Tris-HCl pH 8.3 
1.9 M glycine 
10% (v/v) SDS 
2 x Laemmli Sample Buffer 
50 µl β-mercaptoethanol 
950 µl Laemmli Sample Buffer (Bio-Rad) 
3,3’-diaminobenzidine (DAB)   solution 
(Vector Laboratories) 
5 ml dH2O  
2 drops of buffer Stock Solution 
4 drops of DAB Stock Solution 
2 drops of the Hydrogen Peroxide Solution 
Transfer buffer 
25 mM Tris 
192 mM glycine 
dH2O up to 1 liter 
Blocking buffer for Western blots 
5% (w/v) Marvel dried skimmed milk 
0.2 % (v/v) Tween 20,  PBS 
Citric acid solution for antigen retrieval in 
immunohistochemistry 
0.1 M citric acid pH 6.0 
dH2O up to 1 liter 
Clarke’s fixative Glacial acetic acid and methanol at the 1:3 ratio 
Crystal violet solution 
0.4 g of crystal violet  
100 ml methanol  




Freezing medium for liquid nitrogen 
stocks 
10% (v/v) newborn calf serum  
90% (v/v) DMSO 
Labeling/Cell Detachment Mixture 
(Calbiochem) 
3.25 µl Calcein-AM solution per 1 ml Cell Detachment 
Buffer 
Lithium carbonate solution 
67.7 mM lithium carbonate 
dH2O up to 1 litre 
Orange G loading buffer 
30% (v/v) glycerol 
100 mg Orange G 
dH2O up to 50ml 
Peroxidase blocking solution 
2 ml of 30% (v/v) hydrogen peroxide solution  
2.5 ml of 10 % sodium azide 
dH2O up to 400 ml 
Phosphate Buffered Saline (PBS) 
1 PBS tablet (Sigma) 
100 ml dH2O 
Autoclaved, stored at 4
o
C 
Radioimmuno- precipitation assay (RIPA) 
buffer 
50 mM Tris-HCl pH 7.5 
150 mM sodium chloride 
1% (v/v) NP-40 
0.5 % (w/v) sodium deoxycholate 
0.1% (v/v) SDS 
1 tablet of  Protease Inhibitor Cocktail (Roche) 
dH2O up to 10 ml 
Stored at -20
o
C after tablets were added 
Membranes stripping buffer 
10% (v/v) SDS 
0.5 M Tris-HCl pH 6.8 
0.8 % (v/v) β-mercaptoethanol 
dH2O up to 100 ml 
TBE (Tris-Borate-EDTA) 90 mM Tris-Borate, 2 mM EDTA pH 8.0 
TE buffer 











2.1.2 Antibodies  
 
In order to carry out this project, a wide range of different antibodies was used in various 
applications. A review of the antibodies used along with their working solutions for each 
type of assay can be found in Table 2.2. 
 
 
Table 2.2 List of antibodies together with conditions for performing Western Blotting (WB) and 
immunohistochemistry (IHC). 
 
NAME/TARGET COMPANY SOURCE 
APPLICATION AND 
DILUTION 
Anti-goat biotynylated Dako          Rabbit     IHC 1:500 
Anti-goat HRP Dako          Rabbit     WB  1:1000-4000            
Anti-mouse HRP Dako          Rabbit     WB  1:1000 





         Sheep     WB  1:400 
    IHC  1:10 
EF1A1-3 Custom  
(Helen Newbery) 
         Sheep     WB  1:400 
    IHC  1:40 
EF1A2-1 Custom 
(Helen Newbery) 
         Sheep     WB  1:200 
    IHC  1:25 
EF1A2-3 Custom 
(Helen Newbery) 
         Rabbit     IHC  1:10 
GAPDH Chemicon (Millipore)          Mouse     WB  1:30000 
V5 Invitrogen          Mouse     WB  1:5000 
1. Dr Helen Newbery is a Postdoctoral researcher working in Prof Cathy Abbott‟s group. 
A detailed procedure of obtaining of the anti-eEF1A1 and anti-eEF1A2 peptide antibodies is 




 A list of the primers used throughout this project is shown in Table 2.3.  
Primers were designed with the Primer3 programme (Rozen and Skaletsky, 2000)                            
or retrieved from RTPrimerDB (Lefever et al., 2009) and ordered from Invitrogen or 
Sigma. Upon arrival, all the primers were dissolved in dH2O to a final concentration of 
100 µM and stored at -20
o
C until later use. Before amplification reactions, fresh working 






Table 2.3   Primer sequences used for different PCR applications. 
 
NAME TARGET SPECIES SEQUENCE  5’ TO  3’ 
mTBP F TATA-binding protein Mouse CCCCACAACTCTTCCATTCT 
mTBP R TATA-binding protein Mouse GCAGGAGTGATAGGGGTCAT 
mB2MG F β-2-microglobulin Mouse CATGGCTCGCTCGGTGACC 
mB2MG R β-2-microglobulin Mouse AATGTGAGGCGGGTGGAACTG 
m18S F 18S ribosomal RNA Mouse CGGACAGGATTGACAGATTG 
m18S R 18S ribosomal RNA Mouse CAAATCGCTCCACCAACTAA 
mA1/3U F2 Eef1a1 Mouse CGTGACATGAGGCAGACAGT 
mA1/3U R2 Eef1a1 Mouse GTGGCAGGTGTTAGGGGTAA 
hA1/V5 F1 EEF1A1 Human AAGTCTGCCCAGAAAGCTCA 
hA1/V5 R EEF1A1 Human AGACCGAGGAGAGGGTTAGG 
mhE2/3 1A1 F eEF1A1 Mouse 
Human 
GCCCCAGGACACAGAGACTT 
mhE2/3 1A1 R eEF1A1 Mouse 
Human 
CCAGCTTCAAATTCACCAAC 
Q m1A2 F       Eef1a2 Mouse GCTCCAGGACACCGAGACTT 
Q m1A2 R      Eef1a2 Mouse GAGTGCGTGTTCCCGGGTT 
Q h 1A2 R EEF1A2 Human AAGTCGCGGTGGCCGGGGGC 
F3A2 (Qh1A2F) EEF1A2 Human GCGGAGGTATTGACAAAAGG 
Q  h1A2/V5 F EEF1A2 Human TAGGCGTCATCAAGAACGTG 
QEF1A F2B    eEF1A Human 
Mouse 
CACATTGCCTGCAAGTTTGC 
QEF1A R2 eEF1A Human 
Mouse 
GAGAAGCTCACAACACACATGGG 
R1V5 V5 tag - AGACCGAGGAGAGGGTTAGG 
A1 attB1 EEF1A1 Human GGGGACAAGTTTGTACAAAAAAGCA
GGCTTCACCATGGGAAAGGAAAAGA
CTCATATC 






GAPDH F GAPDH Human 
Mouse 
CATCACCATCTTCCAGGAGC 
GAPDH R GAPDH Human 
Mouse 
ATGACCTTGCCCACAGCCTT 
M13 F plasmids M13 GTAAAACGACGGCCAG 
































Plasmids that were used for cloning purposes are reviewed in Table 2.4. 
 
 
Table 2.4 Plasmids used for cloning and expression applications 
 
NAME INSERT/NOTE VECTOR ANTIBIOTIC SOURCE 
pDONR221                   - pDONR221 kanamycin Invitrogen 
pDEST40 
C-terminal V5/His tag pDEST40 ampicillin, 
geneticin 
Invitrogen 



















5‟UTR sequence from 
EEF1A1 in front of the 
EEF1A1 complete 
coding sequence  
pDEST40 geneticin Julia Boyd
1 
2.1-V5 
5‟UTR sequence from 
EEF1A2 in front of the 
EEF1A1 complete 
coding sequence  
pDEST40 geneticin Julia Boyd 
2.2-V5 
5‟UTR sequence from 
EEF1A2 in front of the 
EEF1A2 complete 
coding sequence  
pDEST40 geneticin Julia Boyd 
1.2-V5 
5‟UTR sequence from 
EEF1A1 in front of the 
EEF1A2 complete 
coding sequence  
pDEST40 geneticin Julia Boyd 
A1-V5 
EEF1A1 complete 
coding sequence  
pDEST40 geneticin Justyna 
Janikiewicz 








2.1.5 Cell lines 
 
The cell lines used in this study are listed in Table 2.5. 
 
Table 2.5  Panel of cell lines used in different tissue culture applications 
 
CELL LINE NAME SPECIES CELL TYPE MAINTENANCE MEDIUM SOURCE 
NIH-3T3 Mouse 






Rat 2 Rat 















































Stable cell line  
expressing 5‟UTR 


















Stable cell line  
expressing 5‟UTR 












Stable cell line  
expressing 5‟UTR 
of EEF1A1 and 
EEF1A2 coding 
sequence 








Control stable cell 
line expressing 
empty vector 









Control stable cell 
line expressing 








Control stable cell 
line expressing  
H-Ras oncogene 
DMEM+10% FBS Lynne Marshall
1 
HT-1080 Human Fibrosarcoma DMEM+10% FBS Abigail Wilson
2 
1.   Lynne Marshall; Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, 
Glasgow G61 1BD, UK 
 
2. Abigail Wilson; University of Edinburgh, Molecular Medicine Centre, Western General Hospital, 









2.1.6 Tumour microarrays (TMAs) 
 
A selection of commercially available TMAs used to investigate the expression of 
eEF1A forms is displayed in Table 2.6. 
 
Table 2.6 Commercial TMAs used in immunohistochemical assays 
 
COMPANY TYPE OF TISSUE NUMBER OF CORES/SLIDE 
BioChain Colon cancer 64 
Folio BioScience Liver cancer + normal liver tissue 41 + 37 
Folio BioScience Melanoma + normal skin 32 in duplicate + 8 
Biomax  Melanoma + normal skin 40 + 8 
Zymed Colon  cancer 20+20 cancer adjacent 
mucosa+20 remote mucosa from 
a normal colon epithelium 
Accumax Normal tissues: liver, lung, 
stomach, colon, brain, heart, 
kidney, breast, Fallopian tube, 





















2.2.1 Cell culture 
 
2.2.1.1 Maintenance of the cell cultures 
 
 For experiments and maintaining cultures, all the cell lines were grown                    
in DMEM (Gibco) supplemented with 10% (v/v) of an appropriate serum (Gibco)                
and a suitable antibiotic unless stated otherwise in the text of this thesis. Usually,                  
two types of serum were used, either New Born Calf Serum (NBCS) or Fetal Bovine 
Serum (FBS). Growing cells were kept at 37
o
C in a 5% CO2 incubator until they reached 
90% confluence. After that, used media were aspirated; cells were washed once with 
prewarmed DBPS (Gibco) and incubated in 5 ml of trypsin (Gibco) for 5 minutes.   
Next, an equal volume of warm DMEM was added to the detached cells and                        
the suspension was subjected to centrifugation at 1200 rpm for 5 minutes.                       
The supernatant was discarded and the cell pellet was resuspended in 5 ml of fresh 
DMEM. Cells were split either 1 in 5 or 1 in 10 depending on the further assay or cell 
volumes required. Cells were grown in Cell Start T25, T75 or T175 flasks               
(Greiner Bio-One) in 10 ml, 25 ml or 50 ml of culture media, respectively. In a standard 
maintenance, cells were split every 3-5 days and kept growing until they reached 
passage number 20 when they were utilized. 
 
2.2.1.2 Cell counting 
 
 Monolayers of growing cells were washed with DPBS and trypsinized. 
Subsequently, amounts of DMEM equal to amounts of trypsin were added to the flask 
and cells were collected in falcons for centrifugation (1200 rpm, 5 min). Next, cells were 
suspended in 5 ml of DMEM and 100 µl of the cell suspension were transferred to                  
9.9 ml of isoton (Beckman Coulter). Finally, cells were subjected to automatic counting 




2.2.1.3 Cryopreservation of the cell lines 
 
 In order to obtain liquid nitrogen stocks of the cultured cell lines, cells were 
maintained in T75 flasks and subjected to trypsinization as stated in 2.2.1.1. Next,                
cell pellets were suspended in 10 ml of 90% NBCS/10% DMSO mixture and transferred 
into 1ml screw cap CryoTube vials (Nunc). The tubes were wrapped in a paper towel, 
put into a polystyrene box and placed in the -70
o
C freezer for 24 hours. Next day,                      
the vials were moved to the liquid nitrogen tank for a longer storage. 
 
2.2.1.4 Transfection by nucleofection 
 
 The Lonza Nucleofector system was used to incorporate DNA into the cells.               
Cells were grown at 37
o
C in a 5% CO2 incubator in DMEM supplemented with                  
10% of appropriate serum (Gibco) until 80-90% confluence was reached.                                   
Next day, cells were trypsinized and counted as described before (2.2.1.2).  
 Subsequently, 1x10
6 
cells were centrifuged at 900 rpm for 5 minutes and the 
pellet was suspended in one hundred microlitres of the appropriate Nucleofector 
Solution (as listed in Table 2.7). Next, the Nucleofector Solution/cell pellet mixture was 
added to approximately 5μl of plasmid DNA (1-5 μg) and then moved to the cuvette 
provided by Lonza. The cuvette was placed inside the Nucleofector machine and cells 
were electroporated using the appropriate programme.  
 After transfection, 500µl of prewarmed DMEM was added to the cuvette                 
and cells were immediately transferred into a well of the 6 well-plate that already 
contained 1.5 ml of DMEM. Following transfection, cells were put back                          
into the humidified 37
o
C/5% CO2 incubator until further usage. 
 Storing the cell suspension longer than 15 minutes in Nucleofector Solution              
was avoided due to possible reduction of cell viability and gene transfer efficiency.                 
Cells with the addition of DNA and Nucleofector Solution but not subjected                              






Table 2.7 List of the cell lines transfected by nucleofection and corresponding solutions required for 
efficient DNA delivery 
 
CELL LINE TYPE NUCLEOFECTOR SOLUTION NUCLEOFECTOR PROGRAMME 
                    NIH-3T3 R U-030 
                    HeLa R I-013 


























2.2.2 Methods for protein analysis 
 
2.2.2.1 Protein extraction 
 
 To obtain whole cell lysates, cells were grown until reaching 80-90% 
confluence. Culture dishes were placed on ice. Next, cell culture maintaining medium 
was removed, cells were washed twice with ice-cold DPBS and depending on the cell 
volumes, 200-500 µl of the radioimmune precipitation buffer (supplemented with 
Complete Protease Inhibitor Cocktail, Roche) was added to the dish. Subsequently,                 
cells were scraped from a dish surface and the cell suspension was transferred to the pre-
cooled micro-centrifuge tubes. Tubes were then placed on a rotating wheel for                      
30 minutes at 4
o
C for cell membranes disruption. After that, prospective extracts were 
centrifuged at 13000 rpm for 30 minutes. The pellet was discarded and the supernatant 
(proper cell lysate) was taken to -20
o
C for storage until needed in further experiments. 
 
2.2.2.2 Quantification of the protein concentration in cell lysates 
 
 Total protein concentration in cell lysates obtained as in 2.2.2.1 was determined 
by the Lowry method, using the Bio-Rad DC quantification system and compared with 
BSA standard curve.  
 To establish standard curve, a series of BSA dilutions in lysis buffer (range 
from 0-4 mg/ml) was prepared in triplicate. A mixture of 20 µl of reagent S per each 
milliliter of reagent A was combined in advance to produce reagent A1. Next, 10 µl of  
each standard dilution was added to dry tubes, followed by 50 µl of reagent A1 and 400 
µl of reagent B and mixed immediately. Tubes were left aside for fifteen minutes at 
room temperature and absorbance was read at 750 nm. In order to produce the standard 





 To quantify protein concentration in the whole cell lysates, exactly the same 
procedure was followed with all reagents. The value of absorbance from the cell extract              
was then plotted on the standard curve and its protein concentration was obtained. 
 
2.2.2.3 Immunoblot analysis 
 
2.2.2.3.1  Preparing samples 
 
 Fifty microlitres of β-mercaptoethanol were mixed with 950µl of loading buffer 
(Bio-Rad) in advance. Usually, ten to fifteen micrograms of a total protein extract               
of known concentration (Section 2.2.2.2) was combined with loading buffer to obtain           
20 µl final volume.  In order to disrupt the protein complexes and denature proteins, 
samples were kept in a heat block for 5 minutes at 98
o
C before being subjected to 
electrophoretic separation on a gel. 
 Control samples of wild type and wasted mouse tissues (brain, muscle, liver)               
were kindly provided by Yuan Cao, fellow PhD student.  
 
2.2.2.3.2  SDS-PAGE electrophoresis 
 
 This assay was performed to separate proteins by molecular weight. Separating 
gel (10%) was prepared as follows (enough for 3 gels): 
 
30% acrylamide    5.2 ml 
1.5 M Tris-HCl pH 8.8   4.0 ml 
dH2O     6.68 ml 
20% SDS    80 µl 
25% AMPS    40 µl 





The gel mixture was poured between two glass plates (Bio-Rad) up to 1 cm from 
the top edge and the remaining gap was filled with 100 µl of water. Next, gels were put 
aside at room temperature for at least 30 minutes to set. After that, water was aspirated 
off and replaced with 4.3 % stacking gel solution prepared as below (enough for 4 gels): 
 
30% acrylamide    1.45 ml 
0.5M Tris-HCl pH 6.8   2.5 ml 
dH2O     5.95 ml 
20% SDS    50 µl 
25% AMPS    50 µl 
TEMED     5 µl 
 
 Subsequently, depending on the needs of the experiment, a comb of 10 or 15 
slots was put on the top and the gels were put aside at room temperature for 25 minutes 
to set. After the gels were ready, the gel apparatus was assembled (Mini Protean 3,               
Bio-Rad) and filled with about 500 ml of 1x Laemmli running buffer.  
 
 The combs were removed and samples prepared as stated in Section 2.2.2.3.1 
were loaded onto individual wells. The first well was always filled with 5-7 µl of the 
protein size marker (Full-Range Rainbow, Amersham, GE Healthcare). Next, separation 
was performed at 100V through stacking gel (15 minutes) and at 120V through 
separating gel until the blue dye front reached the bottom edges of the glass plates. 
 
2.2.2.3.3  Western blot transfer 
 
 When the electrophoretic separation was finished, glass plates were 
disassembled and gels were placed in a tray with a transfer buffer. Six Whitman filter 
papers (7cm x 9 cm each) as well as two sponges per gel were prepared in advance and 




(Amersham, GE Healthcare) of 6 cm by 8 cm was cut and transferred to a dish 
containing methanol.   
 Next, a blot package was assembled on a plastic blotter as follows: first sponge, 
3 sheets of the Whitman filter paper, gel, the membrane, 3 sheets of the Whitman filter 
paper, second sponge. The whole package was closed and placed into a transfer 
apparatus, filled with a transfer buffer; the apparatus also contained a magnetic stirrer                           
and a pre-frozen ice pack. Transfer was then carried out at 100V/400A in a cold room                    
for 70 minutes. Subsequently, the blotting package was disassembled, the membrane                    
recovered and blocked either overnight or 1 hour at 4
o
C in 5% (w/v) powdered milk/ 
0.2% (v/v) Tween 20 in PBS. 
 
2.2.2.3.4  Immunostaining  
 
 After blocking, the membrane was probed with a primary antibody, diluted                       
to an appropriate concentration in 5% (w/v) powdered milk/ 0.2% (v/v) Tween 20 in 
PBS as listed in Table 2.2. The membrane was incubated for a minimum of 1 hour with 
gentle agitation before washing (5 minutes x 4) with cold PBS.  
 Next, the membrane was probed with a species-specific anti-immunoglobulin 
conjugated to horseradish peroxidase (DAKO) diluted in blocking buffer (Table 2.1),               
at room temperature for 1 hour. After washing in cold PBS (5 minutes x 4), 
immunoreactive bands on the membrane were visualized by the ECL Western blotting 
detection system (Amersham, GE Healthcare) according to the manufacturer‟s 
instructions. 
 
2.2.2.3.5  Densitometric analysis 
 
 Selected pictures of the Western blot results were scanned into a computer                 
and quantification of the signal intensity of the immunoreactive bands was measured 





2.2.2.3.6  Re-probing the membranes 
 
 If membrane re-probing with a different antibody was necessary, it was washed              
in a cold PBS (10 minutes x 2) to get rid of the remaining ECL and transferred to                   
a closed dish with stripping buffer (Table 2.1), prewarmed at 50
o
C. This process was 
performed at 50
o
C for up to 50 minutes with gentle agitation. Next, stripping solution 
was disposed of; the membrane was rinsed with cold PBS (10 minutes x 4) and blocked 
in 5% milk-PBS-0.2 % Tween20 solution before re-probing with a new antibody as 
described in Section 2.2.2.3.4.  
 
2.2.2.4  Immunohistochemistry 
 
 To compare expression of both eEF1A variants at the cellular level in colon,             
skin and liver cancer, immunohistochemistry was performed on commercially available 
tumour microarrays (TMA). The slides used for this assay were paraffin-embedded                  
and sometimes formalin-fixed as summarized in Table 2.6. 
 
 Sections were first deparaffinised twice with xylene for 5 minutes each time. 
Next, slides were rehydrated in a series of solutions for 5 minutes as follows:                
absolute ethanol x 2, 70% ethanol x 2 and washed in distilled water.                                     
In case of formalin-fixed slides, an additional step of incubation in picric acid                        
was performed for 15 minutes, followed by washing in distilled water.                     
Subsequently, slides were subjected to antigen retrieval by microwaving sections                     
in citric acid at pH 6, cooling, and then washing in running tap water and loaded                      
onto Shandon ®  Sequenzas (Thermo Scientific).  
 
  For immunohistochemistry with primary antibodies raised in rabbit, slides were 
washed with PBS for 5 minutes, treated with peroxidase blocking solution (Table 2.1) 
for 5 minutes and washed again with PBS for 5 minutes. Next, sections were incubated 




primary antibody at an appropriate concentration (in PBS) were applied for 30 minutes 
(or overnight). Sections were washed in PBS and three drops of Dako REAL EnVision 
Detection System solution (Dako Cytomation) were added onto each slide. Slides were 
incubated for 30 minutes at room temperature and then washed with PBS for 5 minutes.  
 
 Alternatively (when primary antibodies were raised in sheep), after the antigen 
retrieval step, sections were treated with 3% hydrogen peroxide for 10 minutes                    
on a rocker in order to remove endogenous hydrogen peroxidase activity                             
and then washed in a running water for 5 minutes. Next, slides were incubated                       
for 10 minutes in 100 µl of blocking serum. Serum was diluted 1 in 5 in PBS                     
and came from the same animal species as the secondary antibody was raised in.                  
Then sections were incubated with an appropriate concentration of the primary antibody 
for 30 minutes (or overnight), followed by washing with PBS and then incubation with 
100 µl of biotynylated secondary antibody (Dako Cytomation).  After washing slides 
with PBS for 5 minutes, three drops of Vectastatin R.T.U. Elite® ABC Reagent                             
(Vector Laboratories) were added per slide and treated at a room temperature for another 
30 minutes. Sections were then again washed in PBS for 5 minutes. 
 
 Next, no matter which of the above methods was performed, slides were 
unloaded from Sequenzas, put on a tray and treated with diaminobenzidine solution 
(Table 2.1) for 2 minutes that was applied to cover the whole section. The slides were 
washed with water, counterstained in haematoxylin and lithium carbonate solution. 
Sections were later dehydrated in series of the solutions (70% ethanol, absolute ethanol 
x 2), cleared in xylene twice and mounted in pertex.  
 
 The slides were viewed by light microscopy on Olympus BX51 and pictures 
were captured using DP software (Olympus) or on Olympus BX60 with capturing 





 All antibody dilutions were prepared in PBS and the required concentrations             
are listed in Table 2.2. Slides treated with no primary antibody but just with biotinylated 
secondary antibody or Dako REAL EnVision Detection System solution were used              
as negative controls. 
 
 Immunohistological scoring was performed by two independent researchers.               
For each core on the TMA, the score based on the staining strength was established as 3 
when staining was strong, as 2 when staining was moderate, as 1 when staining was low 
and 0 when staining was negative. The percentage of a tumour tissue (excluding stroma) 
was then evaluated for each score type. Results were obtained by multiplying the 
percentage of a tumour tissue in each of the staining categories by the score they were 






















2.2.3 Molecular biology 
 
2.2.3.1 RNA extraction 
 
 Cell pellets were collected from cultured cells straight after centrifugation 
(Section 2.2.1.1) and either kept on ice for immediate use or stored at -70
o
C until 
needed. Total RNA from cell line pellets was extracted with the help of the RNeasy 
Mini Kit (Qiagen) as recommended by the manufacturer. During extraction, RNA was 
treated for 15 minutes with DNase I (Qiagen) to exclude any DNA contamination.  
 RNA concentration (ng/µl) in samples was assessed using a NanoDrop® 1000 
device (Fisher Scientific) and the absorbance was measured at 230 nm (the blank               
was the buffer that RNA was dissolved in). 
 
 
2.2.3.2 Synthesis of cDNA 
 
 In order to synthesize cDNA, First Strand cDNA Synthesis Kit for RT-PCR 
(Roche) and 1 µg of RNA were used.  The reaction mixture was prepared as follows: 
 
10 x Reaction Buffer    2.0 µl 
25 nM Magnesium chloride  4.0 µl 
Deoxynucleotide Mix   2.0 µl 
Random primers    2.0 µl 
RNase Inhibitor    1.0 µl 
MV Reverse Transcriptase  0.8 µl 
RNA sample    depending on concentration 








Next, the following set of incubation steps was performed: 
 
Step 1  25
o
C  10 minutes 
Step 2  42
o
C  60 minutes 
Step 3  99
o
C    5 minutes 
Step 4    4
o
C    5 minutes 
 
Samples that contained reaction mixture but no RNA, or one that included RNA              
but no AMV reverse transcriptase were used as negative controls and were subjected to 
the same procedure as other samples. When reactions were finished, samples were 
stored at -20
o
C until later use. 
 
2.2.3.3 Polymerase chain reaction and associated methods 
 
 Depending on experimental requirements and assay purposes, different PCR 
systems were set. 
 
2. 2. 3. 3. 1  PCR with Phusion polymerase 
 
 Most of the cloning reactions were performed with proof-reading Phusion              
High-Fidelity DNA Polymerase (Finnzymes) in order to obtain a high accuracy                       
of the resulting templates for further analysis. All steps of setting up the reactions                           
were performed on ice. A reaction mixture was prepared as listed below: 
 
dH2O      up to 20 µl 
2 x Phusion™ Master Mix                10 µl 
Primer 1 (0.25 µM)                               1.0 µl 
Primer 2 (0.25 µM)                 1.0 µl 
Template cDNA or plasmid                1.0 µl 




The reactions were then processed on a thermal cycler with the following conditions: 
 
Step 1  x 1  98
o
C 2 minutes Initial denaturation 
Step 2  x 25-28  98
o
C 10 seconds Denaturation 
     X
o
C 30 seconds Annealing 
    72
o
C        X  Extension 
Step 3  x 1  72
o
C 1 minute Final extension 
Step 4  x 1    4
o
C 5 minutes 
 
 The temperature of annealing depended on the primers‟ melting temperature                  
(Tm). Usually the range was between 55-63
o
C and for primers > 20 nucleotides 
annealing was performed at a Tm +3
o
C of the lower Tm primer. For primers ≤ 20 
nucleotides, an annealing temperature equal to the Tm of the lower Tm primer was used. 
As for extension time, this depended on the amplicon length and complexity.                          
As a basic rule for this polymerase, it was determined that a time of 15 seconds was 
efficient for extension of a 1 kb DNA fragment. Resulting products were kept at -20
o
C 
until further use or loaded onto agarose gels to confirm presence of the specific bands of 
a desired size. 
 
2. 2. 3. 3. 2  PCR with Taq Polymerase 
 
 In a routine PCR amplification, each reaction was prepared as follows: 
 
10x PCR buffer    2.5 µl 
10 mM dNTPs mixture (0.2 mM each) 1.0 µl 
50 mM MgCl2     1.5 µl 
Primer 1 (0.25 µM)   1.0 µl 
Primer 2 (0.25 µM)   1.0 µl 
Template DNA     1.0 µl 
Taq DNA polymerase   0.4 µl 




Every component of the mixture was purchased from Invitrogen. Subsequently,                  
the tubes were processed on a thermal cycler with the programme established as listed 
below: 
 
Step 1  x 1  94
o
C       3 minutes   
Step 2  x 30  94
o
C       45 seconds 
    55-60
o
C    30 seconds  
    72
o
C      90 seconds   
Step 3  x 1  72
o
C  10 minutes  
Step 4  x 1   4
o
C  5 minutes 
 
2. 2. 3. 3. 3 Real-time PCR 
 
 The accumulation of PCR product was detected by a fluorescent SYBR Green 
dye (Finnzymes). Primers were designed to amplify a template region of 100-180 bp and 
to be free of any secondary structures or complementarity presence (primer-dimer 
formation). Primers were also designed to possess a GC content of 50-60%                 
and a melting temperature between 50 and 65
o
C. Whenever possible, PCR primers were 
created at splice junctions to avoid producing a product from genomic DNA. 
 
 
Reaction mixture was made up as follows: 
 
2 x DyNAmo Flash Master mix  10 µl 
Primer 1                                            final concentration of 0.1; 0.125; 0.25 or 0.5µM 
Primer 2                                            final concentration of 0.1; 0.125; 0.25 or 0.5µM 
cDNA                   2.0 µl 
dH2O                                             up to 20 µl 
 
No template sample (containing water and reaction mix), no Reverse Transcriptase 




Next, reactions were transferred to MyiQ Thermal Cycler (Bio-Rad) and the programme 
was run as follows: 
 
Step 1  x 1  95
o
C  6 minutes 
Step 2  x 40  95
o
C  10 seconds 
    60
o
C  20 seconds 
    72
o
C  20 seconds – data collection 
Step 3  x 1  95
o
C  1 minute 
Step 4  x 1  60
o
C  1 minute 
Step 5  x 80  60
o
C  10 seconds – data collection 
                                                        (Setpoint temperature was increased by 0.5
o
C                
per each cycle for melt curve data collection and 
analysis) 
 
 A standard curve was conducted as a series of control cDNA dilutions (1:10; 
1:100; 1:1000; 1:10000 and 1:100000) for each pair of primers. In order to construct               
a standard curve, the logarithms of the particular RNA amounts were plotted along               
the x-axis and their respective Ct values for each dilution were plotted along the y-axis. 
Reaction efficiencies between 90-110% and R
2 
> 0.99 were considered as acceptable for 
further analysis. The results of the reaction for each amplicon of interest were 
normalised against three reference genes: 18S rRNA, TBP and β-2-microglobulin.                       
Real-time PCR results analyses were determined by a standard curve method to evaluate 
relative mRNA levels. All reactions were conducted in three technical repeats,                        
in triplicate unless stated otherwise. The melting curve was performed at the end of each 
reaction to confirm specificity of the PCR products where a single sharp peak indicated 








2. 2. 3. 3. 4  Sequencing 
 
2. 2. 3. 3. 4. 1  Pre-sequencing PCR 
 
 When PCR product rather than plasmid DNA was used as a template for further 
sequencing, it was subjected to a reaction with ExoSAP-IT (USB).  Two microlitres              
of ExoSAP-IT were added per 5 µl of PCR product and incubation conditions                     
were established at 37
o
C for 15 minutes, followed by 15 minutes at 80
o
C.                       
Next, BigDye (Applied Biosystems) pre-sequencing PCR was performed as follows: 
 
Reaction mixture 
5x BigDye sequencing buffer   1.5 µl 
2.5 x BigDye mastermix    1.0 µl 
Primer (only one, forward or reverse)  1.5 µl  
Template (PCR product, plasmid DNA)  3.0 µl 
dH2O      3.0 µl  
 
Conditions of reaction in thermal cycler 
 
Step 1  x 1  96
o
C  1 minute  
Step 2  x 24  96
o
C  30 seconds 
    50
o
C  15 seconds   
    64
o
C  4 minutes   
Step 3  x1  hold at 4
o
C  until  needed 
 
2. 2. 3. 3. 4. 2  Cleaning of pre-sequencing reaction products 
 
 When the reaction was finished, 2.5 µl of 125 mM EDTA was added strictly to 
the bottom of the each well, followed by 30 µl of absolute ethanol. Next, the plate was 
sealed and inverted 4 times to mix and then left for 15 minutes at a room temperature.                 




on a paper towel and then briefly spun down at 1000 rpm in order to remove most                     
of the ethanol. After that, 30 µl of 70% ethanol was added to each well and centrifuged                
at 3000 rpm at 8
o
C for additional 15 minutes. Plates were again inverted over the paper 
towel and centrifuged for the few seconds at 1000 rpm to remove the remains of the 
ethanol. Wells were left to air dry at room temperature before storing at -20
o
C.                  
The sequencing reactions were performed by Agnes Gallagher in the MRC HGU Unit.  
 
2. 2. 3. 3. 5  Colony screening by PCR 
 
 In order to confirm the presence of a cloned insert in bacterial colonies, a set of 
PCR tubes was pre-filled with 5 µl of dH2O. A single colony was touched with a fresh 
toothpick, which was then dipped into individual PCR tube. Usually, at least 15-20 
colonies were randomly chosen for screening each time. Next, each PCR tube with 
individual clone was filled with 15 µl of PCR master mix and the amplification reaction 
was established as stated in Section 2.2.3.3.2.             
 Following screening, independent Falcon tubes filled with 5 ml of LB Broth                  
(with suitable antibiotics) were inoculated with positively PCR-verified clones and left 
overnight at 37
o
C incubator with the constant shaking. Mini-preps were prepared next 
day from 4.5 ml of broth cultures using QIAprep Spin Miniprep kit (Qiagen)                  
as recommended by the manufacturer.  The remaining 0.5 ml of the each culture was 
mixed with 0.5 ml of glycerol and stored at -70
o
C as stock.  
 If necessary, the presence of the correct insert was additionally confirmed                         
by sequencing mini-prep DNA as described in Section 2.2.3.3.4. 
 
2. 2. 3. 3. 6  PCR product purification 
 
 Amplification reaction products were subjected to a direct purification process                   
on the QIAquick columns with the help of the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer‟s recommendations. Purified DNA was analyzed                      




2. 2. 3. 3. 7  Agarose gels 
 
 In order to confirm the presence of specific DNA bands and their correct size 
after PCR or to isolate a particular DNA fragment, agarose gels were prepared                      
in advance. The concentration of agarose in 0.5 x TBE buffer (Table 2.1) varied from 
0.9%-2% (w/v), depending on the expected size of the bands. Usually, when large DNA 
fragments were analyzed (3-10 kb), 0.9%-1.5% gels were prepared. In case of the small 
bands (0.2-1 kb), 2 % agarose gels were conducted. Agarose was weighted, mixed with 
0.5 x TBE buffer and microwaved for at least 2 minutes to let agarose dissolve.                   
Next, the solution was cooled and 5 µl of SYBR Safe (Invitrogen) were added per                
100 ml of the mixture.  It was then poured into a plastic tray with combs and left to set                     
at room temperature. Subsequently, Orange G loading buffer (Table 2.1) was added               
to the samples to constitute 10% of the total sample volume and reactions were loaded 
onto a gel. Separated bands were compared to the 1kb or 50 bp molecular ladders 
(Invitrogen) loaded into the first well. The agarose gel was then run at 100V in a tank 
pre-filled with 0.5 x TBE running buffer until the frontal orange line was approximately 
0.5 cm from the gel‟s edge. Bands on the gel were visualized under ultraviolet light 
using the UVIdoc Gel Documentation System (UVItec). 
 
2. 2. 3. 3. 8  Purification of DNA from agarose gel 
 
 In order to extract and purify DNA after enzymatic reactions, samples were run                  
on an agarose gel and then bands of the required size were excised. Subsequently, 
agarose fragments were dissolved and DNA was recovered with QIAquick Gel 












2.2.3.4 Cloning techniques and associated methods 
 
2. 2. 3. 4. 1  Generating of the C-terminally V5-tagged human eEF1A1 construct 
 
 To produce full-length eEF1A1 with the C-terminal V5 tag, cDNA was cloned 
into the pDEST40 vector using the Gateway Cloning System (Invitrogen).                               
Full-length cDNA of human eEF1A1 was recovered by PCR (Section 2.2.3.3.1)                    
from a corresponding Image clone (Table 2.4). Both primers were designed to include 
attB sites to facilitate recombination, followed by the Kozak sequence in forward primer 
and with reverse primer not containing a stop codon. The sequences of primers used, 
along with their names, are listed in Table 2.3. After amplification of the cDNA, PCR 
products were run on a 1% agarose gel (Section 2.2.3.3.7) to confirm expected size and 
purified with QIAquick PCR purification kit (Qiagen) as described in Section 2.2.3.3.8. 
 
2. 2. 3. 4. 1. 1  BP recombination reaction 
 
 Purified PCR product was combined with pDONR221 donor vector and the BP 
reaction was conducted according to the manufacturer‟s instructions. In general,                 
BP Clonase II enzyme mix would catalyze recombination between attB sites of the PCR 
product and attP-containing donor vector to produce an entry clone.  One microlitre of 
each BP reaction was used to transform competent cells as described below. Clones 
were isolated from the plate and screened as listed in Section 2.2.3.3.5 to confirm the 
presence of the insert. 
 
2. 2. 3. 4. 1. 2 Transformation of bacteria 
 
 One microlitre of recombination BP reaction mix was gently combined                    
with TOP10 competent cells and left on ice for 30 minutes. After incubation, cells were 
heat-shocked for 20 seconds in a 42
o
C waterbath and then cooled on ice for 2 minutes. 
After adding 250µl of S.O.C. medium (Invitrogen) to the cells, they were next incubated 
for 2 hours at 37
o




with constant shaking at 180 rpm. Approximately 50 µl of bacteria were spread on the 
LB plate containing ampicillin (100μg/ml) and a dish was then left overnight at 37
o
C 
incubator (Plus II, Gallencamp). The pUC19 DNA plasmid (Invitrogen) was used in the 
transformation protocol as above as a positive control. 
 
2. 2. 3. 4. 1. 3  LR recombination reaction 
 
 Once the presence of a positive clone of eEF1A1 in pDONR221 was 
confirmed, LR Clonase II Enzyme mix was used according to the Invitrogen instructions 
in order to create an expression clone in pDEST40 destination vector. In a LR reaction, 
plasmid DNA from the mini-prep of the positive clone was combined with DNA of the 
vector and then used to transform competent bacterial cells as described above.                                    
Next, well developed colonies were isolated and screened as described in Section 
2.2.3.3.5. 
 
2. 2. 3. 4. 2  Plasmid preparation 
 
 In order to purify plasmid for applications like cloning, PCR or sequencing, 
mini-preps were prepared as described in Section 2.2.3.3.5. 
 If high yields of ultrapure DNA were needed (for example for mammalian cell 
transfections), 200 ml LB cultures of bacteria were centrifuged at 6000 rpm for fifteen 
minutes at 4
o
C and the cell pellet was subjected to plasmid purification                        
with the HiSpeed® Plasmid Maxi Kit (Qiagen) according to the manufacturer‟s 
instructions.  
Eluted DNA was dissolved in TE buffer provided with each kit and retrieved 
samples were analyzed by agarose gel electrophoresis (Section 2.2.3.3.7).                            
DNA concentration (ng/µl) in samples was assessed using the NanoDrop® 1000 device 







2.2.4 Cell culture assays 
 
2.2.4.1 Generation of stable cell lines  
 
2. 2. 4. 1. 1  Killing curve 
 
 In order to generate a stable cell line that will express the protein of interest 
from a mammalian expression construct, the minimum concentration of selection 
antibiotic required to kill untransfected host cell line (NIH-3T3) was determined.                 
Cells were plated at 5 x10
5 
cells per Ø 10 cm dish in 9 repeats and were grown for 24 





 (G418) was added to each plate.  Concentrations used in this 
assay were as follows: 0, 100, 200, 300, 400, 500, 600, 800 and 1000 µg/ml.                       
Next, the selective medium was replenished every 3-4 days and the percentage of 
surviving cells was observed on each occasion. A concentration of 450µg/ml for 
Zeocin
TM
 or 600µg/ml for G418 was established as the minimal one that kills majority 
of the cells within 2 weeks of culturing. 
 
2. 2. 4. 1. 2  Selection of the stable transfectants 
 
 Cells were harvested and counted as described in section 2.2.1.2. One million 
cells were subjected to nucleofection with the gene of interest (Section 2.2.1.4).                 
Two Falcon tubes containing 50 ml of pre-warmed DMEM+10%NBCS were prepared 
and a nucleofection reaction of total 600 µl was divided into those Falcons, 300 µl each.                 
Next, 10 ml of the cell suspension were transferred to Ø 10 cm dish such that each                   
of the ten plates contained 1x10
5 
cells in total. Cells were left to grow for 24 hours                     
and the following day, medium was replaced with fresh DMEM+10% NBCS containing 
the determined concentration of a selective antibiotic. Cells were fed with selective 





2. 2. 4. 1. 3  Isolation of the drug resistant clones 
 
 After clearly visible colonies developed, dishes were washed with DPBS               
and ten random, well separated clones on each plate were marked in a circle.                   
Next, cloning discs (Sigma) were soaked in trypsin (Gibco) and each disc was put on the 
top of the marked colony. These were then left for 5 minutes at a room temperature in 
order to stick the cells to the discs. Discs containing colonies were transferred to the 
individual wells of the 96-well plate filled with selective medium in advance. Cells were 
grown in selective DMEM to near confluence before being shifted to the larger format 
dishes. The abundance of insert in every colony was confirmed by conventional Reverse 
Transcription PCR (Sections 2.2.3.2 and 2.2.3.3.1) as well as by Western blotting 
(Section 2.2.2.3). 
 
2.2.4.2 In vitro tumourigenesis assays 
 
2. 2. 4. 2. 1  Focus formation assay 
 
 Selected NIH-3T3 stable cell lines were harvested and counted as described 




cells were plated per Ø 10 cm dish and 10 ml of 
DMEM + 10% NBCS with the correct antibiotic concentration was added.                                   
Cells were fed every 3-4 days and kept growing for 3 weeks after reaching                         
100% confluence. After 3 weeks media were aspirated off, cells were washed                   
with DPBS and incubated for 10 minutes with 4 ml of Clarke‟s fixative (Table 2.1). 
Next, the solution was removed and 4 ml of 0.4% (w/v) crystal violet solution                        
was poured on the top of the cells for additional 10 minutes. Subsequently, dishes were 
washed several times with dH2O and dried. Photographs of the stained cell surfaces and 
foci were documented on the Olympus BX60 microscope using the corresponding                      





2. 2. 4. 2. 2  Colony formation assay 
 
 Assays of colony formation in soft agar were performed to assess                              
the anchorage-independent growth ability of cells. Autoclaved select agar (1.2%; Sigma) 
was mixed with an equal volume of DMEM + 20% NBCS and poured into individual 
wells of a six-well plate resulting in a 0.6% base agar layer. Cells at a concentration of 
1x10
5 
per well were suspended in 0.3% agar containing DMEM + 20% NBCS                           
+ the appropriate concentration of antibiotic (Zeocin
TM 
or G418) and the mixture                  
was immediately overlaid on the base layer of agar. Plates were left to grow for at least         
3 weeks in the 37
o
C/5% CO2 incubator and then subjected to counting of colonies. 
Colonies were documented on Axiovert200 (Zeiss) microscope with the QCapture 
software. 
 
2. 2. 4. 2. 3  Cell migration assay 
 
 In order to study cell motility in response to a chemical attractant,                           
the InnoCyte™ Cell Migration assay (Calbiochem) was performed following                      
the manufacturer‟s recommendations.  
 Briefly, cells were harvested and counted as described in Section 2.2.1.2.                           
A cell suspension of 3 x 10
5
cells/ml was prepared in serum-free DMEM and 150 µl               
of DMEM + 10% NBCS were added to each well of the lower chamber. After the cell 
culture insert was assembled, 150 µl of the cell suspension was transferred to designated 




 The following day, 200 µl of the Labelling/Cell Detachment solution were 
transferred to the corresponding wells into an additional 96-well tray, provided by the 
manufacturer. The media were discarded from the upper compartment; the chamber was 
assembled with the additional tray and then incubated for 30 minutes in the 37
o
C/5% 




 Next, the upper part of the migration chamber was tilted several times                      
in order to facilitate dislodgement of the cells. The tray containing detached cells was 
covered with a lid and subjected to further incubation for 45 minutes.  
 After incubation, 150 µl from each well containing dislodged and labelled cells 
were transferred to corresponding wells of the black 96-well plate (Thermo Scientific) 
and the fluorescence values were retrieved at 485 nm excitation and 520 nm emission by 
fluorescent microplate reader (BioTek Synergy HT).  
 
2. 2. 4. 2. 4  Cell invasion assay 
 
 In order to investigate the invasive capacity of the cells, InnoCyte™                    
Laminin-based 96-well cell invasion assay (Calbiochem) was conducted according               
to the manufacturer‟s instructions.  
 Briefly, 100 µl of serum-free DMEM was added to each compartment                        
of the pre-warmed upper chamber in order to re-hydrate the laminin protein layer.                   
After 30 minutes of incubation, media were aspirated off, the upper chamber was lifted              
and 150 µl of DMEM + 10% NBCS were added to each well of the lower chamber. 
When the chambers were assembled again, 150 µl of the cell suspension                                 
(3 x 10
5 
cells/ml) were added to appropriate wells of the cell culture insert and the whole 
compartment was incubated overnight in the 37
o
C/5% CO2 incubator.  
 The following day, 200 µl of the Labelling/Cell Detachment Mixture were 
transferred to the additional tray provided by the manufacturer, combined with upper 
chamber of the cell culture insert and incubated for 30 minutes in the 37
o
C/5% CO2 
incubator. Next, the upper chamber was tilted several times in order to facilitate 
dislodgement of the cells; the tray with cells was covered with a lid and subjected to 
further incubation for thirty minutes.  
 After incubation, 150 µl from each well containing detached and labelled cells 
were transferred to corresponding wells of a black 96-well plate (Thermo Scientific)             
and the fluorescence measurements were taken at 485 nm excitation and 520 nm 




2.2.4.3 Proliferation assay with AlamarBlue® 
 
 AlamarBlue® (AbD Serotec) staining responds to the chemical reduction of 
medium by growing cells due to its oxidation-reduction indicator. Either fluorimetric 
excitation or emission contributes to the cell proliferation readout (Voytik-Harbin et al., 
1998).  
 The assay was performed in a 96-well plate format during three independent 
experiments, within 5 small wells on the plate per cell line on every occasion. Readings 
were collected for 8 days.  
 Briefly, cells in the logarithmic phase of the growth were harvested and counted 
as described before (Section 2.2.1.2). The cell count was adjusted to obtain 2 x 10
3 
cells 
in 150 µl of DMEM + 10% NBCS per well. Cells were then plated and on particular 
days exposed for 5 hours to the test agent in an amount equal to 10% of the volume                
in the well. Cell proliferation was measured using a fluorescent microplate reader 
(BioTek Synergy HT) with excitation at 530 nm and emission at 590 nm.  
 
2.2.4.4 Protein synthesis assay 
 
 To measure the rate of protein synthesis (Welsh and Proud, 1992), cells of 
interest were counted (Section 2.2.1.2) and plated at 2x10
3 
cells per well of a 24-well 
plate. Cells were left to grow overnight in a humidified 37
o
C/5% CO2 incubator.                 
The following day, medium was discarded and replaced with 0.5 ml of the fresh                
DMEM without methionine and cysteine (Sigma). After 20 minutes of incubation,              
media was aspirated off and replaced with 0.5 ml of fresh DMEM (methionine and 




S labelling mix (Perkin Elmer) in each well.                         




S-Cys were added per 1 ml of medium. After 1 hour, 
the radioactive medium was discarded; cells were washed once with ice-cold DPBS             
and lysed in 0.5 ml of 0.2 % (v/v) SDS. Next, ice-cold trichloroacetic acid (TCA)                
was added to 20% (v/v), cells were scraped carefully and precipitated proteins were 




with 1 ml of 10% (w/v) ice-cold TCA and then four times with 1 ml of 95% (v/v) 
ethanol. Subsequently, filters were air dried and subjected to liquid scintillation counting 
in 3 ml of Ecoscint 0 (National Diagnostics) using a LS6500 Multi-Purpose Scintillation 





































Chapter 3: Characterization of eEF1A variants interactions 





 Eukaryotic translation elongation factor 1A plays a crucial role in protein 
synthesis as it catalyzes the first step of the elongation cycle. In its active GTP-bound 
state, eEF1A delivers aminoacylated tRNA to the A site of the ribosome. Two highly 
similar eEF1A variants, eEF1A1 and eEF1A2, act equally well in that process, however 
the latter one has more affinity for GDP than for GTP. Additionally, they also have been 
implicated in non-canonical functions like apoptosis and cytoskeletal remodelling. 
While the eEF1A1 form is almost ubiquitously expressed, the presence of the eEF1A2 
variant is more limited. It is found in certain types of cells like neurons and muscle cells 
where eEF1A1 is down-regulated. Expression of both variants is observed only                      
in tumours and cultured cell lines. Cell lines that only express eEF1A2 but not eEF1A1,               
do not exist to our knowledge. 
 
 In order to determine the effects of overexpression of eEF1A1 or eEF1A2                    
in cells, different constructs were designed for transfections. These include constructs 
with the full coding sequence of each variant or constructs with the coding sequence 
preceded by the 5‟UTR from its own or the other variant.  A structural hallmark                      
of the eEF1A1 5‟UTR is the 5‟ terminal oligopyrimidine tract (5‟TOP sequence)                
which acts as a cis-regulatory element and which is not seen in the eEF1A2 5‟UTR,              
therefore it was crucial to determine whether the lack of eEF1A2 translational repression 
via this mechanism has any link to cancer.  Studies were performed on transiently and 
stably transfected NIH-3T3 mouse fibroblasts that do not express eEF1A2. Expression 
of exogenous constructs and their effects on endogenous forms of eEF1A were 






3.2     Results 
 
3.2.1 Generation and validation of expression constructs with eEF1A variants 
 
In order to address the contribution of different eEF1A variants to cellular 
transformation, a panel of constructs was engineered in mammalian expression vectors 
(pcDNA3.1 or pDEST40). Constructs were designed to contain the full coding sequence              
of each human eEF1A variant preceded with its own or the reciprocal 5‟UTR. 
Alternatively, plasmids that exclusively expressed the coding sequence of human 
eEF1A1 or eEF1A2 were also generated. Expression was driven by the CMV promoter                    
of the vector and additionally, each construct was tagged with a COOH-terminal V5 
epitope downstream of the cloned sequence. A schematic map of the constructs is shown   
in Figure 3.1.   
 
Constructs of 1.1, 2.1, 2.2 and 1.2 were generated and sequenced                          
by Dr Julia Boyd, a former member of Professor Cathy Abbott research group.                                  
Variants of A1, 1.1, 2.1, 2.2 and 1.2 were cloned into the pDEST40 vector.                     
The A2 construct was purchased from Invitrogen as pcDNA3.1-EEF1A2 GeneStorm 
ready-to-express clone.  
 
 To determine whether the constructs could be expressed (before stable cell line 
generation experiments were conducted), NIH-3T3 mouse fibroblast cells                        
were transfected independently by nucleofection either with the experimental construct 
or with an empty vector control (pcDNA3.1 or pDEST40). Samples for Reverse 
Transcription PCR along with Western blot detection were prepared from cells collected 







                                Construct design                Name 
                
 
Figure 3.1 Diagram of eEF1A variant constructs. Specific regions of each expression construct 
are colour coded in blue for EEF1A1 origin or in red for EEF1A2 origin. Plasmids                            
were designated A1 (EEF1A1 coding sequence construct), 1.1 (EEF1A1 coding sequence preceded 
by its own 5‟UTR), 2.1 (EEF1A1 coding sequence preceded by EEF1A2 5‟UTR),                                        
A2 (EEF1A2 coding sequence construct), 2.2 (EEF1A2 coding sequence preceded                                      




Reverse Transcription PCR was carried out using primers specifically designed 
to amplify regions within the coding sequence of EEF1A1 or EEF1A2 and the V5 tag.                    
As shown in Figure 3.2, PCR results were the correct molecular size for A1 (125 base 
pairs), A2 (150 base pairs), 1.1/2.1 (800 base pairs) and 2.2/1.2 (410 base pairs).                 
The empty vector transfected cells and untransfected NIH-3T3 cells, acting as negative 
controls, showed no amplification. Samples which were Reverse Transcriptase negative 
(RT-) or did not contain any cDNA were run to confirm lack of genomic DNA                  
or reaction reagents contamination, respectively.  
  5’UTR EEF1A2+ EEF1A2  = 2.2 
ATG 














EEF1A2   EEF1A2 coding sequence  = A2 
EEF1A1 
EEF1A1 
  5’UTR EEF1A1+ EEF1A2  = 1.2 
5’UTR 






Figure 3.2 RT-PCR analysis of eEF1A variants expression in NIH-3T3 fibroblasts.                    
Mouse fibroblasts were transfected with A1, 1.1, 2.1, A2, 2.2, 1.2 and empty vectors (pcDNA3.1, 
pDEST40). Total RNA was extracted from cell pellets 24 hours after nucleofection in order to synthesize 
cDNA. Negative controls:  RT- (no Reverse Transcriptase added for cDNA synthesis), no cDNA (no RNA 
added for cDNA synthesis) and neg PCR (negative PCR; only mastermix used in reaction).                      
GAPDH was used as an internal control.   
 
Immunoblot analysis of transfectants from different eEF1A1 plasmids                     
was performed using anti-V5 tag or anti-eEF1A1 antibodies (Figure 3.3, panel A). 
Expression obtained with eEF1A2 construct variants was analysed by probing 
membranes with anti-V5 or anti-eEF1A2 antibodies as presented in Figure 3.3, panel B.                 
Ectopic expression of proteins from mammalian plasmids was verified successfully                
for all constructs on membranes subjected to probing with anti-V5 antibody.                         
As expected, a single major band was detected for tagged proteins of 52kDa molecular 
weight, whereas no bands were observed for parental cells or cells transfected with 
empty vector. This preliminary result suggests that incorporation of the 5‟UTR                  
from eEF1A2 in front of the eEF1A1 coding sequence results in increased expression 





sequence only.  In contrast, eEF1A2 with its own 5‟UTR was expressed more effectively  




Figure 3.3 Overexpression of A1, 1.1, 2.1, A2, 2.2 and 1.2 variants in NIH-3T3 mouse fibroblasts. 
The lysates from the NIH-3T3 transfectants were subjected to Western blot. Detection of expression                  
for eEF1A1 origin constructs is shown in the panel A, while the presence of eEF1A2 variants is exhibited                 
in the panel B. Samples from untransfected parental cells along with NIH-3T3 cells transfected                    
with empty vector were used as negative controls for V5 tagged constructs. Tissue extracts                            
from wild-type mouse (27 day old) were used as indicators for positive expression of eEF1A1 (liver +/+) 
or eEF1A2 protein (muscle+/+, brain +/+).  In contrast, tissue extracts from 25 day old wasted mouse 
(muscle w/w, brain w/w) and wild-type liver (liver +/+) were used as a negative control for eEF1A2 
expression. GAPDH was used as a loading control.  
 
Predicted protein products were also obtained with the anti-eEF1A1 and anti-
eEF1A2 antibodies. These antibodies work equally well for proteins of human and 
mouse origin (Newbery et al., 2007). Whereas eEF1A1 levels were similar, eEF1A2                             
levels significantly increased when compared to almost undetectable endogenous 





Extracts from selected mouse tissues were used to demonstrate antibodies specificity,             
as described in Figure 3.3.  
 
 
3.2.2 Generation of stable cell lines in NIH-3T3 mouse fibroblasts 
 
Once it was demonstrated that the expression constructs produced the  predicted 
protein products, NIH-3T3 mouse fibroblast cells were transfected by nucleofection  
with either one of expression plasmids (A1, A2, 1.1, 2.1, 2.2, 1.2) or the empty control 
vector (pcDNA3.1, pDEST40). Cells transfected with A2 and pcDNA3.1 vector                
were subjected to selection with Zeocin™ while cells transfected with the remaining 
plasmids were selected with G418® (geneticin). 
 Individual clones that appeared to be resistant to antibiotic selection                     
were randomly isolated for each construct and grown further in order to obtain sufficient 
material for subsequent analysis. Cell lysates were then prepared and a total of 306 
colonies were screened for positive expression of exogenous proteins by Western 
blotting against the V5-tag antibody. Only clones that exhibited a single band of 52kDa      
were considered as positive (data not shown). A comparison of the yield of stable cell 
lines for different eEF1A plasmids is presented in Table 3.1. While a few clones                
were positive for A1 (6/34, 18%), 1.1 (4/56, 7%) or 2.1 (10/48, 21%) expression,                
the majority of clones for A2 (38/52, 73%), 2.2 (47/56, 84%) or 1.2 (28/60, 47%) 
demonstrated expression. 
 
Table 3.1 Summary of stable cell lines generation efficiency in NIH-3T3 mouse fibroblasts 
Type of stable cell line Number of clones 
analyzed 
Number of eEF1A-V5 
variant positive clones 
eEF1A1                             (A1) 34 6 
eEF1A2                             (A2) 52 38 
5’UTR eEF1A1+eEF1A1     (1.1) 56 4 
5’UTR eEF1A2+eEF1A1     (2.1) 48 10 
5’UTR eEF1A2+eEF1A2     (2.2) 56 47 







For further analysis, a few clones that exhibited V5-specific bands were chosen 
and re-screened by RT-PCR and Western blot for confirmation before further 
experiments.  
The results of screening for several representative clones of the three eEF1A1 
origin constructs (A1, 1.1 or 2.1) are shown in Figure 3.4. As expected, proteins                     
of 52kDa were detected for A1 clones number 3.2 and 8.6 but to a lesser extent in clones 
number 10.2, 8.3, 6.4 and 4.6 (panel A). No expression was noticeable for clone 
designated as 1.3. A protein lysate sample collected from NIH-3T3 cells 24 hours post 
transfection with the A1 construct was used as a positive control. No detection was 
observed for NIH-3T3 or pcDNA3.1 vector transfected cell lines. 
The majority of A1 clones exhibit mRNA of the expected molecular size                
(850 bp) while clones number 3.3, 3.4, 4.5 or 7.2 were negative for predicted transcripts 
(panel A). An artefact in gel running suggests uneven amounts of GAPDH PCR 
products for clones 1.1-3.4. It is noteworthy that even when mRNA levels are high, for 
example in clone 1.3, 6.4 or 8.3, the protein levels for these clones remain from very low 
to undetectable.  
Analysis of representative 1.1 clones is shown in Figure 3.4, panel B.                        
A fifty two kilodalton protein was detected in all four clones (panel B), with the lowest 
expression level for clone number 1.1-54. The presence of exogenous transcripts                
was also confirmed at the mRNA level by detecting a 740 bp product.  
Results from the investigation of representative 2.1 clones are presented                       
in Figure 3.4, panel C. Four (2.1-9, 2.1-15, 2.1-18 and 2.1-27) out of five                        
clones were positive for 52kDa exogenous protein expression while clone 2.1-21                
was negative (but note that GAPDH results suggest uneven loading). The same four 
clones gave a 740 bp fragment at the mRNA level. RT-PCR products for clone                  












     
Figure 3.4 Verification of stable cell lines generated with eEF1A1 expression plasmids in NIH-3T3 
mouse fibroblasts. Pictures reflect several representative clones for each construct. Detection                         
of A1 (panel A), 1.1 (panel B) and 2.1 (panel C) plasmids was assessed by immunoblotting with anti-V5 
tag antibody and Reverse Transcriptase PCR. Parental NIH-3T3 cells and vector transfected cells                  
were used as negative controls in Western blots. Negative controls in RT-PCR were: minus Reverse 
Transcriptase (RT-), no template samples (no cDNA), PCR mastermix sample (Neg PCR) and parental 
cells. GAPDH was used as an internal control. The first digit in the names of the A1 construct clones 
represent the plate from which clone was isolated while the second digit reflects clone number on that 










The results of several representative clones for three eEF1A2 origin constructs 
(A2, 2.2 or 1.2) are shown in Figure 3.5. As shown in panel A, proteins of the predicted 
52kDa molecular weight were detected at modest levels for all representative                       
A2 clones.  It is obvious that less protein lysate was loaded for clones designated as 4.3, 
4.6, 5.2, 6.8 and 7.1.  
Ten clones that were tested for the presence of the A2 transcript by RT-PCR 
showed a 940 bp PCR product. The unequal intensity of GAPDH-derived bands 
suggests the possibility of higher V5-transcript amounts for clones 6.1, 6.8 and 7.2. 
Additionally, low GAPDH mRNA levels were detected for parental cells. The difference 
in size of the mRNA bands for clones number 6.8 and 7.2 is a gel running artefact. 
Detection of exogenous 52kDa V5-tagged protein was confirmed for 1.2 clones 
designated as 2, 9, 27, 39, 42 and 56 while clones 11 and 16 were negative as shown in 
Figure 3.5, panel B. GAPDH protein loading was not equal. RT-PCR amplification 
mirrored the protein detection. RT-PCR reactions of for clone 1.2-11 and minus reverse 
transcriptase were run on the next gel so this picture is separate from the picture of the 
remaining clones. 
Analysis of eleven 2.2 construct clones (Figure 3.5, panel C) confirmed 
expression of the expected exogenous protein (52kDa) for clones number 2, 6, 9, 18, 33, 
46, 52 and 55 while clones 4 and 25 were negative (but note uneven GAPDH protein 
loading). The results from protein analysis are reflected by the presence of 940 bp long                     






















Figure 3.5 Verification of stable cell line generation with expression plasmids of eEF1A2 origin              
in NIH-3T3 mouse fibroblasts. Pictures reflect several representative clones for each construct. 
Detection of A2 (panel A), 2.2 (panel B) and 1.2 (panel C) plasmids was assessed by immunoblotting                
with anti-V5 tag antibody and Reverse Transcriptase PCR. NIH-3T3 cells were used as negative controls 
for Western blots. Negative controls for RT-PCR were: minus Reverse Transcriptase (RT-),                         
PCR mastermix sample (Neg PCR) and parental NIH-3T3 cells. GAPDH was used as an internal control.  
The first digit in the names of A2 construct clones represents the plate from which the clone was isolated 
while the second digit reflects the clone number on that plate. Numbers standing after 2.2 or 1.2 clone 









3.2.3 Evaluation of eEF1A variants at the mRNA and protein level in selected 
stable cell lines 
 
3.2.3.1 Levels of total eEF1A1 protein remain unchanged in representative NIH-3T3 
stable cell lines 
  
After establishing which colonies were positive, representative stable cell lines    
of each construct had to be chosen for experimental assays. A list of cell lines that were 
used in experiments is given in Table 3.2.  
 
                   Table 3.2  Names of different eEF1A stable cell lines selected for experiments. 
           The lack of a third clone for 1.1 stable cell lines is marked with minus. 
 
Stable cell line 
type 
Clone number 
A1 3.2 8.6 10.2 
A2 7.2 9.6 10.2 
1.1 9 23 - 
2.1 1 15 18 
2.2 1 33 52 




When possible, three clones representing mild, moderate and robust protein 
expression of each construct were selected. The cell lines were double-checked                       
by RT-PCR (Figure 3.6, panel A) along with Western blot (Figure 3.6, panel B and 
Figure 3.7) to monitor if the expression of the transgenes remained at the same level 
with increasing passage numbers. Finally, the selected clones were re-cultured                         
in order to obtain more biological material for subsequent experiments and to collect 















                      
        
      
    Figure 3.6 Analysis of mRNA and protein levels in different eEF1A transgene stable cell lines.               
Panel A depicts confirmation of exogenous transcripts presence in selected clones. Primers were 
designed to amplify within coding sequence of EEF1A1 or EEF1A2 and V5 tag. GAPDH represents 
amplification control. No transcript detection was observed in negative controls (parental cells,                 
RT-, no template samples). Panel B represents Western blot detection of exogenous protein with the 










Expression of eEF1A1 or eEF1A2 proteins in selected lines was also confirmed 
with the anti-eEF1A1 or anti-eEF1A2 antibodies. Unexpectedly, preliminary Western                
blot assays for A1 clones indicated unchanged levels of eEF1A1 when compared                        
to the untransfected NIH-3T3 or vector transfected cells (Figure 3.7, panel A).                        
For  eEF1A2 stable cell lines (Figure 3.7, panel B), in contrast, parental cells or vector 
transfected cells showed minimal eEF1A2 presence while A2 7.2, A2 9.6 or A2 10.2 
lines showed clear overexpression at the protein level. 
 Samples for each line were analysed in triplicate to exclude the possibility                  
of artefacts and to increase experimental accuracy. Since the centre of the membrane 
shown in panel A was not fully accessible to the GAPDH antibody, immunostaining 
resulted in a very poor signal for clone A1 8.6 and to some extent for A1 10.2.                      
As a consequence, the column representing the relative amount of eEF1A1 for line A1 





































































































































































































































































































































































































































































Levels of eEF1A1 and eEF1A2 were also assessed in the remaining cell lines by 





         Figure 3.8   Expression of eEF1A1 or eEF1A2 protein in NIH-3T3 stable cell lines.  
         Ten representative eEF1A variants stable cell lines were screened for eEF1A1 presence and three 
lines of each A2, 2.2 or 1.2 clone were subjected to detection of eEF1A2 expression.  A HeLa cell 
lysate was used as a positive control for eEF1A2 expression.  
 
 
The findings from the above preliminary Western blots indicated that even             
when modest expression of the tagged construct was observed, the level of eEF1A1                            
in the stable cell lines was not changed when compared to the NIH-3T3 cells.                             
Two possible explanations for this result immediately come to mind.                                 
Firstly, could there be some negative feedback that blocks expression of eEF1A1 
at a certain threshold? Secondly, is it possible that the level of transfected human 
eEF1A1 is so low that an overall level of eEF1A1 appears not to change? Either way, 
answering these questions could potentially clarify whether eEF1A1 could be involved 
in oncogenesis. It is tempting to suggest that the cell might have some way of tightly 





oncogenesis, as this regulation would have to be overcome by the tumour.                                
In order to shed some light on these problems and distinguish between endogenous and 
exogenous eEF1A1 levels, quantitative real-time PCR was performed on selected stable 
cell lines, as this made it possible to quantify accurately the expression of the 
endogenous gene compared with the transgene.  
 
3.2.3.2 Optimization of real-time PCR  
 
In order to quantify expression of different eEF1A variants at the mRNA level, 
sets of primers were designed to recognise exclusively endogenous Eef1a1 or Eef1a2 
(mouse), exogenous EEF1A1 or EEF1A2 (human), total EEF1A1/Eef1a1                        
(residues conserved in both species) and finally total EEF1A (residues common for both 
forms and conserved in both species). Mouse TATA box binding protein (Tbp),                  
18S rRNA and β-2-microglobulin (B2m) were used as reference genes. To ensure that 
primers were amplifying desired fragments, conventional PCR was performed 
successfully on control cDNA, followed by agarose gel electrophoresis (data not 
shown). Subsequently, RNA was extracted from all stable cell lines, followed by cDNA 
synthesis. Minus RT samples along with no cDNA samples were always used as 
negative controls. Next, standard curves were conducted in order to obtain reaction 
efficiencies, optimize primer concentration and temperature of annealing along with 
optimal cDNA concentrations.  At the end of each standard curve, a melting curve was 
assessed to confirm single transcript amplification. The review of standard curves for all 











Figure 3.9 Standard curve calibration performed for quantitative real-time PCR (Part 1).                         
Graphs represent standard curves generated for primer sets amplifying 18S rRNA, Tbp,                        
B2m and Eef1a1 mRNA fragments, respectively.  Log starting quantity on the x-axis of each curve 
represents a log10 dilution series of the particular cDNA (in triplicate) used for calibration.                
Only PCR efficiencies between 90-110 % and correlation coefficient R
2 
>0.99 were considered 














Figure 3.10 Standard curve calibration performed for quantitative real-time PCR (Part 2).                         
Graphs represent standard curves generated for primer sets amplifying EEF1A1, total 
EEF1A1/Eef1a1, EEF1A2 and overall EEF1A mRNA fragments, respectively.  Log starting 
quantity on the x-axis of each curve represents a log10 dilution series of the particular                    
cDNA (in triplicate) used for calibration.  Amplification of PCR products with efficiency between 
90-110 % and correlation coefficient R
2 
> 0.99 for standard curves were obtained successfully.     
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Figure 3.11 Illustration of melting curves analysis. Melt curves for 18S rRNA, Tbp,                           
B2m, Eef1a1, EEF1A1, overall EEF1A1/Eef1a1, EEF1A2 and overall EEF1A mRNA primer couples 
were performed in order to confirm their specificity.  The presence of a single prominent peak 
corresponds to single amplicon detection exclusively. 
       
 
 18S rRNA Tbp 
                    B2m   Eef1a1 
   EEF1A1 Total 
EEF1A1/ 
Eef1a1 






 Analyses of real-time PCR results were determined by a standard curve method                   
to evaluate relative mRNA levels. The results of the reaction for each amplicon                
of interest were normalised against three reference genes and then exhibited in relation                            
to the empty vector transfected NIH-3T3 cells, valued as 1 relative unit. Every reaction 
was run in triplicate, and RT- along with no cDNA samples were always used as 
negative controls. 
 
3.2.3.3 Assessment of eEF1A variants at the mRNA and protein level in different 
eEF1A1 stable cell lines 
 NIH-3T3 stable cell lines A1 3.2, A1 8.6, A1 10.2, 1.1-9, 1.1-23, 2.1-1, 2.1-15 
and 2.1-18 were subjected to real-time PCR (Figure 3.12) and Western blot analysis 
(Figure 3.13) in order to characterize the relationship between exogenous eEF1A1, 
endogenous eEF1A1, total eEF1A1 or total eEF1A at the mRNA and protein level.  
 The ratios of exogenous EEF1A1 mRNA did not exceed 1 unit except in clone 
2.1-15 suggesting a tight regulation of excessive eEF1A1 amounts in the cell.                         
At the same time, levels of endogenous Eef1a1 mRNA were not drastically altered               
when compared to the vector and parental NIH-3T3 cells, except in all three 2.1 clones 
where an increase was observed. This suggests that constitutive expression                       
of the construct containing the 5‟UTR from EEF1A2 might in some way induce Eef1a1 
transcription.  
Surprisingly, the levels of total EEF1A1/Eef1a1 mRNA were unchanged in all 
cell lines, even in clone 2.1-15 where overexpression of the 2.1 construct                           
was the highest. Perhaps the human EEF1A1 transcript competes with mouse Eef1a1 
transcript in order to keep levels of total EEF1A1/Eef1a1 mRNA unchanged, or the level 
of the 2.1 constructs constitute just a small percentage of the total amount of eEF1A1. 
The levels of total EEF1A mRNA in A1, 1.1 or 2.1 cell lines suggest that cells 
corrected the amount of endogenous Eef1a1 according to the level of EEF1A1, again 


















































































































































































































































































Western blot analysis using an anti-V5 antibody showed a band of the expected 
52kDa size in every cell line (Figure 3.13). Bands for clones 1.1-9 and 2.1-1 were visible 
only after longer exposure. A close correspondence between mRNA and protein level 
was observed only for A1 10.2 and 2.1-15 clones. The construct carrying only eEEF1A1 
coding sequence was expressed in excess over the 1.1 and 2.1 plasmids.  
 To determine the effect of A1, 1.1 and 2.1 constructs on endogenous Eef1a1 
protein expression, a Western blot with an anti-eEF1A1 antibody was executed.                
Western blotting was conducted on the set of the same stable cell lines samples                 
and showed approximately unchanged levels of eEF1A1 expression (50kDa) when 
compared to the vector transfected or parental NIH-3T3 cells. Only clone 1.1-9 revealed 
a lower level of eEF1A1 protein but the GAPDH loading control was decreased as well. 
A similar trend was observed with a commercial anti-eEF1α antibody.            
This antibody is not specific to any eEF1A variant and so it recognises both eEF1A1         
and eEF1A2, and gives information on total eEF1A protein level. Mouse tissue 
expression controls (liver +/+, brain +/+, brain w/w, muscle +/+, muscle w/w)                         
were used for this antibody throughout the thesis to show immunodetection of both 
variants. Almost all stable cell lines along with parental or vector transfected cells 
showed uniformly equal levels of eEF1A (51kDa), except clone 2.1-1, 2.1-18                      



































































































































































































































3.2.3.4 Assessment of eEF1A variants at the mRNA and protein level in different 
eEF1A2 stable cell lines 
 
All selected eEF1A2 stable cell lines (A2 7.2, A2 9.6, A2 10.2, 2.2-1, 2.2-33, 
2.2-52, 1.2-2, 1.2-39, 1.2-59) were subjected to real-time PCR and Western blot analysis 
to determine any influence of the expression of exogenous eEF1A2 on total eEF1A              
or Eef1a1 at both- mRNA and protein level.  
 Exogenous eEF1A2 constructs expression was confirmed at the mRNA level               
in all selected stable cell lines but the lowest transcript levels were detected for 2.2 
clones (Figure 3.14). 
Next, the ratios of endogenous Eef1a1 mRNA were determined. The Eef1a1 
levels varied between clones but its expression was roughly comparable to that of 
controls. The levels of Eef1a1 transcript did not correspond to exogenous EEF1A2 
mRNA levels. 
 Investigation of total EEF1A transcript amount found it elevated in all stable cell 
lines when compared to the vector or NIH-3T3 controls. The biggest increase of total 
translation elongation factor 1A transcript was observed for A2 clones, slightly lower      






              
            Figure 3.14 Real-time RT-PCR analysis of RNA from selected eEF1A2 origin stable cell 
lines.  Red columns represent exogenous transcript, grey columns endogenous Eef1a1 transcript                
and green columns overall EEF1A mRNA. Values are the means ± SD of three independent 






 Western blot analysis of eEF1A2 stable cell lines with the anti-V5 antibody 
revealed expression of exogenous V5-tagged proteins (52kDa) in all samples                    
apart from negative controls (parental cells and vector transfected NIH-3T3) as showed 
in Figure 3.15. The expression of constructs without a 5‟UTR was higher in comparison 
to the remaining tagged proteins, consistent with data obtained from the pilot studies. 
Amounts of eEF1A2 at the mRNA level corresponded to those at the protein level.
 The anti-eEF1A2 antibody showed overexpression of the predicted protein              
at 51kDa. To ensure that this was not a protein of mouse origin, samples were checked 
at the RNA level for mouse Eef1a2 and relative expression ratios were confirmed                 
as negative (data not shown). The magnitude of eEF1A2 expression was not consistent 
with that seen with the anti-V5 antibody. Unexpectedly, an eEF1A2-specific band was 
detected in vector controls and parental cells, probably due to the over-confluence of the 
cells when samples were collected.  
Western blotting with an anti-eEF1α antibody determined the effect of 
constitutive expression of different eEF1A2 constructs on total eEF1A protein level. 
Lines A2, 2.2 and 1.2 showed a modest increase in total eEF1A protein expression 
(51kDa) when compared to the vector controls or the parental cell line. Expression                     







































































































































































































































3.2.4 Evaluation of the transiently expressed eEF1A variants at the mRNA                   
and protein level  
 
3.2.4.1 Pilot studies in NIH-3T3, Rat2 and HeLa cell lines 
 
The initial experiment with stable cell lines demonstrated unchanged levels               
of eEF1A1 in A1 clones and clear overexpression of eEF1A2 in A2 clones. With regard 
to the above observation, a pilot experiment was carried out on two rodent fibroblast cell 
lines (NIH-3T3 and Rat2) which were subjected to nucleofection with the A1-V5 
construct to see whether any effect is observed in a transient experiment. Exogenous 
eEF1A1 was detected with the anti-V5 antibody while eEF1A1 was confirmed using an 
anti-eEF1A1 antibody (Figure 3.16). Untransfected, vector or mock transfected cells 
were used as negative controls.  
Expression of exogenous eEF1A1 consistently decreased up to 4 or 6 days                 
post transfection in NIH3T3 and Rat2 cells, respectively. The level of eEF1A1 slightly 
decreased in samples from day 1 but then remained unchanged on subsequent days              




   Figure 3.16 Overexpression of eEF1A1 alters expression levels of endogenous Eef1a1 on the first 
day after transfection. NIH-3T3 and Rat2 cells were nucleofected with A1-V5 plasmid.                                 
Expression of human eEF1A1 and overall eEF1A1 was monitored for 7/8 consecutive days. GAPDH was 
used as a loading control. Band intensities measured for eEF1A1 were normalised against GAPDH 





While NIH-3T3 and Rat2 cells do not express eEF1A2, one more cell line               
was tested to monitor possible interaction between eEF1A1 and eEF1A2, as HeLa cells 
express both eEF1A forms. Cells were nucleofected either with A1-V5 construct                       
or empty vector as control. Expression of the exogenous construct was observed up to 5 
days (with some trace amounts on day 6 and 7) for the A1-V5 plasmid (Figure 3.17). 
Interestingly, when the A1-V5 plasmid was incorporated into HeLa cells,                 
there was a noticeable decrease in eEF1A2 expression on day 1 and 2 after transfection. 
The level of eEF1A1 in sample on day 1 is lower but this is likely to be a loading 





Figure 3.17 Overexpression of eEF1A1 or eEF1A2 indicates dynamic interplay between 
exogenous and endogenous variants of eEF1A on the first day after transfection.                    
HeLa cells were transiently transfected with A1-V5 plasmids and expression of V5-tagged, eEF1A1 
and eEF1A2 proteins was monitored up to 8 days. Relative ratios of eEF1A1 or eEF1A2 to GAPDH 
were calculated from band intensity measurements using ImageJ and put below appropriate blots.  





3.2.4.2 Transient transfections in NIH-3T3 cell line 
 
 Firstly, the mRNA and protein levels of different eEF1A variants were herein 
investigated in NIH-3T3 cell lines, after constitutive expression of different constructs 
had occurred. Next, dynamic interplay between two eEF1A variant forms existed when 
one of them exhibited overexpression, according to the above data obtained in initial 
experiments with three different cell lines. To understand the observations                
from these pilot experiments, NIH-3T3 cells were transfected with the plasmids used               
for stable cell line generation. Cell pellets were collected on 5 consecutive days              
or on 7 days after nucleofection and then subjected to analysis using real-time PCR              
or Western blotting, respectively. On this occasion, protein and mRNA of different 
eEF1A constructs were assessed in transiently transfected NIH-3T3 cells to determine 
possible relationships between exogenous and endogenous eEF1A variants immediately 
after the former are incorporated into cells. 
After real-time PCR assessment, each transcript‟s level was normalised to three 
mouse reference genes (Tbp, B2m, and 18S rRNA). Then relative units of expression                 
were calculated as a fold change, in a relation to the specific mRNA level in the control 
pcDNA3.1 or pDEST40 vector transfected cells (1 unit). Moreover, control real-time 
PCR for mouse Eef1a2 mRNA detection was performed and did not exhibit any of this 
transcript induction, as expected (data not shown).  
Cell lysates of nucleofected NIH-3T3 cells were subjected to Western blotting 
using anti-V5, anti-eEF1α and anti-eEF1A1 antibodies. GAPDH was always used                   
as a loading control. 
 
3. 2. 4. 2. 1    Effects of transient A1, 1.1 and 2.1 overexpression in NIH-3T3 cells 
 
The assessment of expression of the representative exogenous transcripts                       
(A1 and 1.1), Eef1a1 and overall EEF1A mRNA was shown in Figure 3.18. Similar 





Forced expression of the A1-V5 construct was confirmed up to fourth day               
post transfection whereas some remaining traces on day 5 were still seen for the 1.1                    
and 2.1 constructs. The highest relative expression at 9 hours was observed for 1.1 
(around 98 units) and 2.1 mRNA (42 units, data not shown) but for A1 transcript it was 
only 4 units. 
To determine what is happening with mouse Eef1a1 when the human counterpart 
was incorporated into the cells, real-time PCR was performed to amplify a 101 bp 
fragment of the endogenous transcript. Surprisingly, samples from 9 hours and day 1 
showed a small decrease in Eef1a1 mRNA expression among A1 transfectants                  
while more a distinguishable decline was seen at these time points within 1.1 and 2.1 
transfections. Apparently, the endogenous transcript was diminished when the EEF1A1 
transcript level was at its highest, indicating a strict regulation of the overall eEF1A1 
levels in the cell. As the exogenous transcript decrease was proceeding on the following 
days, endogenous Eef1a1 transcript amounts were increasing and reached a level 
comparable to that of controls.  
As expected, total EEF1A mRNA level in 1.1 and 2.1 transfectants was elevated 
for samples at 9 hours post nucleofection, in agreement with the highest levels of 
exogenous 1.1 and 2.1 at this particular time point, but then decreased on subsequent 
days as the exogenous transcript declined. Investigation of the total EEF1A transcript in 
A1-V5 transfected cells revealed that its level remained almost the same for up to three 
days, by which time exogenous EEF1A1 mRNA was barely present and then it slightly 
increased on fourth day as the eventual repression became relieved. Alternatively,                        
the human EEF1A1 mRNA might represent only a small percentage of the overall 






















































































































































































































































































Western blot analyses were performed on the same collection of samples                  
and are shown in Figure 3.19 for A1-V5 transfectants and in Figure 3.20 for NIH-3T3 
cells after nucleofection with 2.1 construct. Similar information was obtained for A1-V5 
and 1.1 samples. GAPDH showed equal amounts of the protein in every line.  
Membranes probed with anti-V5 antibody detected expression of exogenous A1 
and 1.1 protein of the expected size (52kDa) for four consecutive days after transfection, 
in agreement with their mRNA levels. Furthermore, ectopic expression of the 2.1 
construct was recorded for five consecutive days post transfection, also in close 
correspondence to its mRNA expression timing, but the highest protein amount was seen 
at day one. There were no bands in negative controls of parental cells or empty vector 
nucleofected NIH-3T3 cells.  
Endogenous Eef1A1 protein expression (50kDa) was confirmed with a specific 
anti-eEF1A1 antibody. A small decrease at 9 hours and then on the first day                        
post transfection for A1-transfected cells or just at 9 hours for 1.1 was seen.                         
At the remaining time points its levels were around the same level of expression 
exhibited for vector controls and parental cells. In contrast, levels of endogenous Eef1a1 
protein in 2.1 transfectants were slightly higher than controls at 9 hours, day 1 and day 2 
lysates but then dropped to the control levels.  
The anti-eEF1A1 antibody should also recognize the human plasmid. The bands 
of 52kDa were missing or were present in random A1, 1.1 and 2.1 lysates from 9 hours 
to day 6 or 7 but the intensity of these bands did not correspond to the decreasing 
amounts of the exogenous proteins after nucleofection. Even though bands were not seen 
in controls, perhaps the addition of the V5 tag changed the conformation of the protein 
and made the epitopes unrecognizable by antipeptide antibody. The possibility                        
of nonspecific immunostaining or the presence of additional nucleofection                          
stress-induced protein also cannot be excluded. 
The overall eEF1A protein detection (51kDa) was performed with the                  
anti-eEF1α antibody and its increased expression was observed mostly at 9 hours in A1, 





remained almost unchanged and was sustained at levels similar to that seen in parental 












































































































































































































































































































































































































































































































3. 2. 4. 2. 2    Effects of transient A2, 2.2 and 1.2 overexpression in NIH-3T3 cells 
 
The relationship between exogenous A2 or 2.2 transcripts and endogenous 
Eef1a1 or total EEF1A mRNA is shown in Figure 3.21. Similar information                
was obtained for 2.2 and 1.2 transfectants. 
The presence of A2 transcript was seen at all experimental time points                   
while expression of 2.2 and 1.2 mRNA was confirmed up to 3 days post transfection                  
(with almost undetectable amounts at day 4 and 5). As expected, the relative levels of A2 
(around 67.5 units), 2.2 or 1.2 (24.5 units) mRNA were significantly high at 9 hours 
after nucleofection and decreased thereafter. 
Interestingly, overexpression of eEF1A2 had also an effect on the levels                       
of endogenous Eef1a1 mRNA in NIH-3T3 cells; its decrease was observed at 9 hours 
and 1 day, at the times when the A2 transcript was in the highest excess. The Eef1a1 
transcript levels were diminished up to day 2 even more when the 2.2 construct                       
was overexpressed or up to day 3, coinciding with the highest 1.2 mRNA levels                  
(data not shown). Levels of endogenous Eef1a1 mRNA increased as soon as expression 
of the exogenous transcripts began to fall. This again suggests dynamic interaction at the 
RNA level between two eEF1A variants.  
The highest increase of overall EEF1A mRNA was observed for A2 
transfectants, in agreement with the presence of exogenous transcripts at specific time 
points. Relative ratios of overall EEF1A transcript were decreasing as the A2 transcript 
decreased in the cells. It is possible that total EEF1A mRNA would acquire values 
comparable with NIH-3T3 or vector transfected cells after day 5 post nucleofection, but 
these samples were not tested.  
As expected, the total EEF1A mRNA expression among 2.2 and 1.2 transfected 
cells was highest at 9 hours time point. The relative overall EEF1A transcript expression 
on day 1 is suggested to be a combination of exogenous transcripts and endogenous 
Eef1a1 mRNA. In contrast, the amounts seen at subsequent days possibly reflect only 
endogenous Eef1a1 transcript, or alternatively, the exogenous transcripts constitute only 



















































































































































































































































































The relationship between eEF1A forms at the protein level was subsequently 
investigated by Western blotting and representative immunoblot analysis for A2 or 2.2 
transfectants are shown in Figures 3.22 and 3.23, respectively. Similar data were 
received for 2.2 and 1.2 samples. GAPDH showed approximately equal amounts                         
of the proteins loading.  
 The presence of A2-V5 protein was confirmed with the anti-V5 antibody                       
and detection of 52kDa band was seen at all tested time points. Investigation                         
of the NIH-3T3 cells transfected with the chimeric 5‟UTR constructs shown that 2.2 
expression was sustained until the fifth day after nucleofection whereas bands                       
of the expected 52kDa size among 1.2 transfectants were confirmed up to the third day 
(data not shown). It is worth noting that the highest expression for 2.2 and 1.2 constructs 
was seen on day 1.  
 In order to test whether eEF1A2 overexpression can affect the levels                            
of endogenous Eef1a1 at the protein level, membranes were probed with a specific              
anti-eEF1A1 antibody. Interestingly, Eef1A1 expression (50kDa) remained                     
almost unchanged in A2-V5 transfected cells but it was slightly increased                               
in comparison to parental or vector controls (but note decrease in GAPDH loading). 
 In contrast, a noticeable decrease of endogenous Eef1a1 protein was observed                 
on the first day post transfection at the point where the exogenous 2.2 and 1.2 constructs 
show the highest level of expression. Similarly, a small decrease of Eef1a1 protein                
was seen in vector control but not at as low a level as in these samples.                                    
It cannot be excluded that this is a nucleofection-induced result, as both sample types 
were collected 24 hours post transfection. These results were not in agreement                   
with Eef1a1 transcript expression since a decrease in mRNA was mostly observed 
between the 9 hours and day 2 time points. Samples from subsequent days maintained 
almost unchanged levels of Eef1a1 protein, at approximately the same levels as seen           






 The overall levels of eEF1A protein were assessed by immunoblotting                       
with the anti-eEF1α antibody.  As expected, the highest levels of total eEF1A (51kDa) 
were observed at 9 hours for A2, 2.2 and 1.2 transfectants. On the following days, the 
expression level of eEF1A stayed almost unchanged, with slight variations between 



































































































































































































































































































































































































































































































 In order to elucidate any possible relationship between overexpression of 
eEF1A forms and the biological significance of their coexistence within cells,                      
a set of different constructs was designed and introduced into NIH-3T3 mouse 
fibroblasts that do not normally express eEF1A2. Characterization of expression of 
exogenous versus endogenous eEF1A forms was assessed by transient transfections to 
examine immediate effects and by stable transfections for potential long-term distance 
consequences.  
It was shown herein that the first 24 hours after nucleofection were crucial                
in terms of the relationship between endogenous and exogenous eEF1A forms 
expression. In this study, overexpression of all eEF1A1 origin constructs resulted                    
in significant repression of the endogenous Eef1a1 mRNA (mostly during 9 hours and 
the first day post transfection), however a bigger decline was seen if any of the 5‟UTRs 
was present. This was reflected by the small decrease in endogenous protein expression 
at a 9 hour time point, except for 2.1 transfectants where it was increased.                
When eEF1A2 origin constructs were overexpressed, a more substantial and longer 
decrease in Eef1a1 mRNA was observed in 2.2 and 1.2 transfected NIH-3T3 cells than 
for A2 counterparts. In contrast, the most significant decrease of Eef1a1 protein levels in 
2.2 and 1.2 samples coincided with the highest expression of exogenous proteins at first 
day post transfection but in A2 transfectants it stayed unchanged.  
Changes in endogenous transcripts levels when exogenous counterparts                  
are introduced into the cells are not unprecedented among translation-involved proteins.  
Wu and Bag showed that overexpression of HeLa cells with exogenous PABP mRNA 
with a compromised 5‟UTR caused repression of endogenous PABP mRNA.                        
In contrast, ectopic expression of PABP mRNA with the proper regulatory element in its 
5‟UTR did not produce similar effect on endogenous transcript, strongly suggesting 
involvement of a negative feedback mechanism in controlling expression of PABP 






 Data obtained from transient transfections suggested that incorporation                     
of human eEF1A1 or eEF1A2 into cells significantly altered the expression of 
endogenous Eef1a1 and that dynamic interplay between different eEF1A variants 
occurred within the first hours after nucleofection. Translation of both eEF1A forms‟ 
messages changed depending on the presence or lack of the chimeric 5‟UTRs.                          
It was consistent with primary observations where transfections of constructs carrying 
chimeric 5‟UTRs linked to eEF1A1 or eEF1A2 coding sequences resulted in less 
efficient expression in comparison to the plasmids containing coding sequences alone. 
Moreover, introduction of the 5‟UTR sequence originating from eEF1A2 in front of 
either eEF1A1 or eEF1A2 coding sequence caused less repression of exogenous proteins 
levels than from constructs with the eEF1A1 5‟UTR. A significant motif within the 
5‟UTR sequence of eEF1A1 has already been suggested to participate in modulation of 
its mRNA translation.  
The sequence of the 5‟UTR from eEF1A1 contains a cytidine residue followed 
by an uninterrupted sequence of 5 thymidines (Uetsuki et al., 1989, Slobin and Rao, 
1993). This unique structural hallmark is called a 5‟ terminal oligopyrimidine tract 
(5‟TOP) and therefore, eEF1A1 has been assigned to the family of  TOP mRNAs which 
encode not only ribosomal proteins (RP), most translation initiation and elongation 
factors but also other proteins associated with translational apparatus (Iadevaia et al., 
2008, Avni et al., 1997, Meyuhas, 2000, Yoshihama et al., 2002). Exchange of the single 
residues within the 5‟TOP sequence in rpS16 (40S ribosomal protein S16) or hnRNP A1 
(heterogeneous nuclear ribonucleoprotein A1) chimeric constructs indicates that the 
correct composition of this motif is extremely important for their translational control 
(Levy et al., 1991, Zhu et al., 2003). The TOP motif is a cis-acting regulatory element 
and is required for translational control of these mRNAs in conditions resulting from 
cellular stress or poor nutrient status (Caldarola et al., 2004, Hornstein et al., 2001, Avni 
et al., 1994, Levy et al., 1991). For instance, translational repression of eEF1A1 mRNA 





fibroblasts, murine erythroleukemia or NIH-3T3 cells (Avni et al., 1994, Avni et al., 
1997, Jefferies et al., 1994, Slobin and Rao, 1993, Thomas and Thomas, 1986). 
Interestingly, the 5‟terminal oligopyrimidine tract is not found within the mRNA 
sequence of eEF1A2 (Bischoff et al., 2000).  
 In conjunction with transient transfections, a comparison of the relative 
expression levels of different eEF1A variants was carried out in stable cell lines. During 
the long process of their generation, it was discovered that the yield of positive lines                 
with inserts of different eEF1A1 origin was far less successful than with eEF1A2.              
Even though levels of exogenous eEF1A1 full coding sequence construct were observed              
in the highest excess within the first 24 hours post transfection, it was almost impossible 
to achieve this expression magnitude in the stable cell lines. Such a problem was not 
encountered with the eEF1A2 coding sequence expression plasmid since the yield                  
of the stable cell lines was the highest, whereas numbers of positive clones were 
gradually lower for 2.2 or 1.2 transfectants. These observations suggest that 
incorporation of 5‟UTR from any of the eEF1A variants could have an influence                
on effective selection output. 
 There is some evidence to consider that this observation was not only restricted       
to NIH-3T3 cells. An attempt to produce stable cell lines with modest eEF1A1 
overexpression in Rat2 embryo fibroblasts as well as in HeLa cells was made                    
(note that HeLa express high levels of both eEF1A forms but Rat2 cells lack eEF1A2 
protein expression). Only four lines out of 34 Rat2 clones tested for exogenous eEF1A1 
were positive whereas HeLa cells did not even survive a selection process (personal 
observations, data not shown). Selective antibiotic resistance is not likely to be the cause 
since its concentration was successfully established in advance of the main experiments 
by performing killing curve assays on the parental cell lines. Furthermore,                        
other researchers encountered similar difficulties (Amiri et al., 2007). On the other hand,          
a few groups successfully performed experiments in HEK293 cells or similar BALB/c 
3T3 mouse fibroblasts stably expressing exogenous eEF1A1 (Duttaroy et al., 1998, 





whether high levels of eEF1A1 are toxic to the cells or whether cellular feedback exists                       
that blocks expression of eEF1A1 at a certain threshold, or perhaps whether it is a matter              
of the experimental cell system specificity.  
 In all A1 or 1.1 NIH-3T3 stable cell lines, the average amounts of endogenous 
Eef1a1, at both- mRNA and protein level, were roughly the same as in the control line 
but slightly higher in 2.1 clones (similarly to the observation of 2.1 construct transient 
transfection). In the majority of eEF1A2 origin stable cell lines Eef1a1 transcript levels 
were marginally lower or equal to the controls, but the levels of endogenous protein 
remained unchanged again. The combined cellular expression of eEF1A was increased 
in 2.1 lines and all eEF1A2 origin clones at mRNA and protein level. 
The attempts to overexpress human eEF1A1 or eEF1A2 in NIH-3T3 cells 
resulted in preservation of endogenous Eef1a1 at a roughly constant level, suggesting 
that eEF1A1 expression might be subjected to the strict autoregulation. There may be at 
least three explanations for this mechanism to consider.  
First, it should be kept in mind that in circumstances of any eEF1A variant 
upregulation, eEF1A1 could shift some of its mRNA into a translationally inactive state 
due to the regulatory 5‟TOP sequence within its 5‟UTR (Uetsuki et al., 1989, Slobin and 
Rao, 1993) .   
Alternatively, the possibility of other regulatory sites within eEF1A1 5‟UTR 
cannot be ruled out. These would allow mRNA of eEF1A1 to maintain a balance 
between translational repression or enhancement, depending on the cell‟s requirements                      
or external/internal stimuli. The PABP is an excellent example of mRNA that has two 
well characterized cis-acting elements in its 5‟UTR, that is a 5‟terminal oligopyrimidine 
tract followed by A-rich sequence (ARS) (Hornstein et al., 1999, Wu and Bag, 1998).            
It is believed that these two elements regulate translation of the PABP mRNA                         
in a distinct manner. While 5‟TOP seems to enhance translation due to increased growth 
requirements, ARS is more predisposed to monitor overall levels of cellular PABP               






In addition, Ørom and co-workers confirmed that the 5‟TOP sequence of RP 
mRNAs and microRNA miR-10a are functionally interconnected. Moreover, miR-10a 
binds immediately downstream of the 5‟TOP motif of RP mRNAs and favours their 
translational enhancement over repression. Therefore, overexpression of miR-10a 
enhanced RPs synthesis whereas inhibition of endogenous miR-10a resulted in 
decreased production of RPs. They suggest a mechanism whereby miR-10a competes 
with a negative acting factor of unknown identity for direct binding downstream                  
of the 5‟TOP motif. Interestingly, the supplementary data of this paper contain a table                        
of the top 100 mRNAs from miR-10a pull-out experiments in which eEF1A1 was 
assigned to position 26 (Ørom et al., 2008). The theoretical strength of interaction 
between eEF1A1 and miR-10a was calculated using RNAhybrid 2.1 and this prediction 
was illustrated in Figure 3.34 (Ørom et al., 2008, Rehmsmeier et al., 2004). These data 
require further experimental validation. 
 
 
miR-10a            3'      UAA                          U  5'        ∆G = -21 kcal/mol 
                      GUGUU   GCCUAGA           UGUCC CA                                
eEF1A1 5’UTR          |:|||   |||:|:|           ||||| || 
Human        5' CUUUUUCGCAA---CGGGUUUGCCGCCAGAACACAGGUGUCGUGAAAACUACCCCUAA----AAGCCAAA 3' 
Mouse           CUUUUUCGCAA---CGGGUUUGCCGUCAGAACGCAGGUGUUGUGAAAACCACCGCUAAUUCAAAGCAAAA  
Rat           UUCUUUUUCGCAA---CGGGUUUGCCGUCAGAACGCAGGUGUUGUGAAAGCCACCGCUAAUUCAAAGCAAAA 
Horse          CUUUUUUCGCAA---CGGGUUUGCCGCCAGAACACAGGUGUCGUGAAAACCACCGCAAAAUCUAAGCCAAA 
 
 
Figure 3.34 Predicted interaction between hsa-miR-10a and eEF1A1 5’UTR sequence. 
Thermodynamic calculation of ∆G was performed by RNAhybrid 2.1. Sequences of 5‟untranslated 
regions from mouse, rat and horse were shown additionally to indicate evolutionary conserved residues 
within potential interaction sites. 
  
 Finally, a more complex translational regulation mechanism could be involved 
that requires the assistance of the eEF1A1 3‟UTR. Mechanisms of translational control 
are commonly defined by interactions of different cis- or trans-regulatory factors               
within 5‟- or 3‟- untranslated regions of mRNAs (Pickering and Willis, 2005, Mazumder 
et al., 2003, de Moor et al., 2005, Wilkie et al., 2003). For instance cross-talk between 





effect on translational efficiency of Her-2 (Mehta et al., 2006). On the other hand 
Kobayashi and Yonehara reported that the 5‟UTR was more important for the 
downregulation of eEF1A1 seen in tetraploid cells than its 3‟UTR (Kobayashi and 
Yonehara, 2008). Nevertheless, the generation of constructs (and possibly stable cell 
lines) with both eEF1A forms coding sequences linked to their own or reciprocal 
3‟UTRs would be undoubtedly of great assistance to address this enquiry. 
Therefore, the cellular level of eEF1A1 mRNA may dictate how big a pool                 
of the cytoplasmic transcripts will be subjected further to translation. As a consequence, 
eEF1A1 could be a crucial regulator and/or sensor of total eEF1A amounts in the cells, 
determining its expression level under normal growth circumstances or during extreme 
conditions.  
On the other hand, since a close correspondence was seen between Eef1a1 
mRNA and protein levels it cannot be excluded that exogenous overexpression of 
human counterparts did not induce any changes in translational efficiency of the 
endogenous form. Therefore, even though the combined cellular level of eEF1A was 
enhanced by the addition of the human eEF1A variants, the cells could be still able to 
accept that increase without disruption to the performance of their biological functions. 
 
The precise mechanism of eEF1A1-mediated regulation is not fully understood 
and needs to be further elucidated. More accurate information about the relationships 
between both eEF1A variants and their exogenous counterparts in stably or transiently 
transfected NIH-3T3 (or even in a different cell system) could be provided                       
by polysome profile analysis. It would be advantageous to subject cell lysates                        
from these cells to centrifugation in 10-50% sucrose gradients in order to capture                
the precise mRNA and protein distribution signatures of exogenous versus endogenous 
eEF1A forms in different fractions.  
 It is also noteworthy that eEF1A1 comprises up to 3% of the total protein 
content within the cell, hence it is already in a high excess over the other translational 





of eEF1A1 are necessary to maintain its various cellular functions as it is a moonlighting 
protein (Ejiri, 2002). Even though small excess amounts over this threshold might                 
be still tolerated by the cells and allow for normal growth, significant upregulation                    
over a certain limit and an eventual increase in total eEF1A could be deleterious.                           
As eEF1A1 overexpression and downregulation have been implicated                        
in triggering apoptosis (Ruest et al., 2002), expression of both eEF1A forms is only seen 
in cultured cells and tumours, and unchanged levels of EEF1A1 transcript were already 
observed in certain malignancies and cancer cell lines (Anand et al., 2002,                               
Cao et al., 2009), maintaining eEF1A1 levels unchanged would be undoubtedly 
beneficial from the eEF1A2-driven oncogenesis point of view. 
Although the biological meaning of overall eEF1A overexpression is unknown, 
inappropriate expression of other translation factors, for instance eEF1Bδ and eEF1Bγ    
as well as eIF3e, eIF3f or eIF3h subunits of the eIF3 factor, have been linked to cancer.  
Moreover, these factors also belong to the 5‟TOP family (Lei et al., 2002, Zhang et al., 
2007, Zhang et al., 2008, Iadevaia et al., 2008, Mimori et al., 1995, Frazier et al., 1998, 
Mathur et al., 1998). Therefore, it was interesting to know whether incorporation                
of 5‟UTRs from both eEF1A forms independently in front of the eEF1A2 coding 
sequence, could promote any changes is transformed phenotype of eEF1A2-
overexpressing cells or whether a similar effect would be seen for cell lines stably 





Chapter 4: In vitro systems for investigation of eEF1A1  




4.1  Introduction 
 
 Increased motility, loss of contact inhibition and gain of anchorage independent 
growth are significant hallmarks of neoplastic cells and characterize the general 
phenotypes of an oncogene.  
 In order to investigate the potential role or differences between eEF1A1 and 
eEF1A2 in oncogenesis, a variety of eEF1A plasmids was constitutively overexpressed 
in NIH-3T3 mouse fibroblasts as described in Chapter 3. Selected stable cell lines were 
then subjected to different transformation assays, including foci formation, anchorage 
independent growth in soft agar and proliferation. In some of these lines, transformed 
properties were observed that led further to an analysis of their in vitro migration and 
invasion abilities. 
 As the mechanism underlying induction of eEF1A2-driven oncogenesis has not 
been completely elucidated, it was hypothesized that its oncogenic potential might be 
associated with its conventional role in translation or alternatively with its non-canonical 
functions like, for example, modifications of the cytoskeleton. The rate of global 
translation was determined in the stable cell lines of different eEF1A1 or eEF1A2 origin 
in order to establish whether increased expression of either variant caused an overall 









4.2.1 In vitro transformation assays 
 
4.2.1.1 Focus formation indicates a transforming phenotype 
 
 To investigate and compare the oncogenic potential of both eEF1A forms, 
focus formation assays were performed on selected NIH-3T3 stable cell lines.                       
A transformed phenotype should be observed as a multilayered, crisscrossed growth of 
spindle-shaped cells (Pastan and Willingham, 1978). Equal numbers of mouse 
fibroblasts stably expressing A1, A2, 1.1, 2.1, 2.2 or 1.2 were seeded in 10-cm dishes 
and cultured under standard conditions for 3 weeks. Next, NIH-3T3 cells were fixed in 
methanol and stained with crystal violet in order to evaluate the morphology of the cells 
on every plate. If a transformed phenotype was observed, the foci on a dish were 
counted and photographed.  
  
4.2.1.1.1 Foci formation in A1, 1.1 or 2.1 expressing NIH-3T3 mouse fibroblast cells    
 
 As reviewed in Table 3.2, three A1 stable cell lines, two 1.1 lines and three 2.1 
clones were subjected to a focus formation assay. NIH-3T3 fibroblasts stably expressing 
empty vector pDEST40 (vector 2) were used as a negative control whereas EJTF2 cells 
that stably express the H-Ras
G12V
 oncogene were used as a positive control.  
 Three weeks after plating, there were no foci in the vector control dishes              
(Figure 4.2) whereas distinct foci were observed on the experimental plates as shown            
in Figures 4.1, 4.2 and 4.3. NIH-3T3 cells from the negative control dishes grew                 
in an organized monolayer with contact inhibition while examination of transformed foci 
revealed cells that had changed shape into spindles and disorganized, multilayered 
structures, with similar morphology to the positive control of EJTF2 cells. Transforming 
efficiencies of the H-Ras
G12V 
control in this study were comparable to those reported                 




















































































































































































































































































































































































































































































































































































































































































































 Figure 4.4 shows that overexpression of A1 in NIH-3T3 cells resulted in the 
acquisition of a transformed phenotype by clones 8.6 and 10.2 but to a lesser extent by 
clone 3.2 where foci formation was only about 8% of the positive control.  It is difficult 
to explain why this particular line behaved differently; especially it exhibited                          
a moderate level of A1 expression.   
  In contrast, overexpression of 1.1 or 2.1 caused less efficient foci formation               
as seen in the 1.1-9, 1.1-23, 2.1-1, 2.1-15 and 2.1-18 clones where transformation was 
around 12, 31, 8, 39 and 37 % of the positive control of EJTF2 cells.                               
The A1 3.2, 1.1-9, 2.1-1 and 2.1-18  transformants exhibited disorganized orientation, 
piling up of the cells and very subtle or light-small foci, which were clearly more 
refractile than the pronounced, sharp-edged foci in A1 8.6, A1 10.2 or 2.1-15 clones. 
 A summary of the average foci per cell line relative to positive                           


































Figure 4.4 Foci formation assay in stable cell lines of eEF1A1 origin. NIH-3T3 cells stably expressing 
A1, 1.1 or 2.1 variants were monitored for loss of contact inhibition. Formed foci were fixed, stained              
and counted 3 weeks after plating. Results are shown as a mean of three independent experiments 




Table 4.1 Summary of the focus formation assay results for different stable cell lines of eEF1A1 origin 
 




CELL LINE PER 10-cm PLATE (EJTF2) (versus EJTF2) (versus vector) 
  (±SEM)       
  A1 3.2        2.4 ± 0.34           8.3 <0.001 0.0018 
  A1 8.6      28.5 ± 4.43         97.0 0.8638 0.0002 
  A1 10.2      17.6 ± 1.61         60.0 0.0014 <0.001 
  1.1-9        3.4 ± 0.67         11.7 <0.001 0.0031 
  1.1-23        9.1 ± 1.81         30.9 <0.001 0.0015 
  2.1-1        2.2 ± 0.52           7.5 <0.001 0.0230 
  2.1-15      11.4 ± 2.68         38.9 0.0002 0.0037 
  2.1-18      10.7 ± 1.67         36.6 <0.001 0.0003 
  vector         0.6 ± 0.33           2.3 <0.001   
  EJTF2      29.4 ± 2.48        100.0   <0.001 
         
a 
Student‟s t- test, two-tailed 
 
 These results suggest that presence of expression of A1, 1.1 and 2.1 constructs                
in normal NIH-3T3 mouse fibroblasts leads to loss of contact inhibition                        
and neoplastic phenotype resulting as foci formation. Overexpression of 1.1 or 2.1                  
does not correspond to complete loss of in vitro clonogenicity and is still sufficient to 
alter morphology of the cells but these lines exhibit less potential to produce foci than 
















4.2.1.1.2 Effect of A2, 2.2 or 1.2 variant overexpression on NIH-3T3 cell foci formation 
 
 Three representative A2, 2.2 or 1.2 NIH-3T3 stable cell lines (as presented               
in Table 3.2) were monitored in terms of contact inhibition loss for 21 days.                    
Mouse fibroblasts harboring a constitutively active H-Ras
G12V 
oncogene were used               
as a positive control. NIH-3T3 mouse fibroblasts stably expressing pcDNA3.1 (vector 1) 
or pDEST40 (vector 2) were used as negative controls. 
 After three weeks of culture it was found that cells overexpressing A2, 2.2                  
or 1.2 gave rise to foci while cells stably transfected with vectors did not exhibit                         
a transformed phenotype. These cells grew in a monolayer and had a normal fibroblast 
shape as shown in Figure 4.2. In contrast, the cells on the dishes with noticeable foci 
revealed highly disoriented crisscrossed morphology and multilayered growth,                      





















































































































































































































































































































































































































































































































































































































































































The morphologies of all three A2 clones, 2.2-1, 2.2-52 or 1.2-39 lines                   
were observed as highly condensed and piled up groups of crisscrossed cells with 
enormous foci. Foci of the 2.2-33, 1.2-2 and 1.2-59 lines were also spindle-shaped with 
sharp edges but they displayed smaller dimensions. 
 Enhanced expression of A2 in NIH-3T3 cells resulted in an increased level               
of focus forming ability when compared to the EJTF2 control. As showed in Figure 4.8, 
the number of foci in the 7.2, 9.6 and 10.2 lines was elevated by 23, 25 and 32 %, 
respectively over the positive control. In contrast, overexpression of 2.2 was less 
transforming, and focus production in lines 2.2-1 and 2.2-33 was approximately 51 and 
30 % of the EJTF2 cells control. Unexpectedly, clone 2.2-52 showed a dramatic increase 
in foci production by 204% of the positive control level.  Additionally, elevated 
expression of 1.2 in lines 1.2-2, 1.2-39 and 1.2-59 appeared to cause a reduction of 
transformation and foci formation in these lines consisted about 48, 25 and 27 % of the 
H-Ras
G12V
 harboring cells, respectively. A summary of the results from the focus 










































Figure 4.8 Assessment of foci formation ability within stable cell lines of eEF1A2 origin.                      
Normal mouse fibroblasts stably overexpressing A2, 2.2 or 1.2 variants were subjected to analysis                   
of transformed phenotype induction. After 21 days of culture, NIH-3T3 cells were fixed and stained and 
foci were counted. Graph represents mean number of foci originating from three individual experiments 





Table 4.2 Review of focus formation assay for NIH-3T3 stable cell lines of different eEF1A2 origin 




CELL LINE PER 10-cm PLATE (EJTF2) (versus EJTF2) (versus vector) 
  (±SEM)       
   A2 7.2        36.3 ± 1.96       123.4 0.0453 <0.001 
   A2 9.6        36.8 ± 2.36       124.9 0.0479 <0.001 
   A2 10.2        38.8 ± 2.06       131.7 0.0108 <0.001 
   2.2-1        15.0 ± 0.78         50.9 0.0003 <0.001 
   2.2-33          8.9 ± 0.72         30.2 <0.001 <0.001 
   2.2-52        89.6 ± 5.63       304.2 <0.001 <0.001 
   1.2-2        14.0 ± 0.6         47.5 <0.001 <0.001 
   1.2-39          7.4 ± 0.9         25.3 <0.001 <0.001 
   1.2-59          8.0 ± 0.78         27.2 <0.001 <0.001 
 vector 1          0.2 ± 0.15           0.7 <0.001   
 vector 2          0.7 ± 0.33           2.3 <0.001   
   EJTF2        29.4 ± 2.48          100   <0.001 
            a 
Student‟s t-test, two-tailed 
 
 The above data indicate that overexpression of the A2 variant resulted in the 
acquisition of a transformed phenotype in vitro by NIH-3T3 cells. Also cells 
overexpressing 2.2 constructs lost contact inhibition and produced foci but with a lower 
capacity than A2 coding sequence lines, except clone 2.2-52. The stable induction of 1.2 
into mouse fibroblasts was sufficient to form marked foci although level of 














4.2.1.2  Anchorage independent growth in soft agar is a hallmark of neoplastic  
 transformation 
 
 Following selection in G418 (Geneticin®) or Zeocin™ and isolation of the cell 
lines overexpressing different eEF1A variants, some clones gained a specific cell 
morphology and lost contact inhibition as described in Section 4.2.1.1. Consistent with 
these findings, it was determined whether other neoplastic phenotypes could occur              
in selected transfectants. The capacity of the cells to proliferate in the absence                       
of attachment to a solid surface and to form colonies in soft agar are well-known 
characteristics of the transformed phenotype (Shin et al., 1975). In order to evaluate                  
the oncogenicity of eEF1A variants in vitro, cells were suspended in a layer of medium-
enriched agar and cultured for 3 weeks. Subsequently, colonies were counted                        
in individual wells and representative cell aggregates were photographed. 
 
4.2.1.2.1    Overexpression of eEF1A1 causes transformation of NIH-3T3 fibroblast cells 
 
 Three A1 stable cell lines, three 2.1 clones and two 1.1 lines (Table 3.2)                 
were tested in the anchorage independent growth assay to check whether eEF1A1                 
can act as an oncogene. The EJTF2 cell line stably expressing H-ras
G12V 
was used                 
as a positive control while empty vector transfected NIH-3T3 fibroblasts served                 
as a negative control, as before. 
 Following 21 days of culture, cells expressing empty vector did not form 
colonies in soft agar but occasionally 1 or 2 colonies were observed among single cells 
in a few wells. These were considered as a background level and no increase of their size 
was seen when dishes were left in culture longer than three weeks.  
 Interestingly, all three A1 clones evidently provoked colony formation in soft 
agar whereas cell lines originating from constructs with incorporated 5‟UTRs exhibited 
very poor activity in terms of neoplastic phenotype in comparison to the positive control 
(Figure 4.9). Again, 1.1 or 2.1 colonies did not change their size over the expanded 







Figure 4.9 Overexpression of eEF1A1 induces oncogenic transformation in NIH-3T3 mouse 
fibroblasts.  Stable cell lines of eEF1A1 origin were used in an anchorage independent growth assay          
by culturing cells in a semisolid layer of 0.3% agar over 3 weeks. The parental cells or clones stably 
expressing empty vector were negative controls whereas EJTF2 cells stably expressing H-Ras were used 
as a positive control. Colony pictures were taken 21 days after plating (magnification 10x). eEF1A1 
transfectants and EJTF2 cells displayed a clear transformed phenotype while only single cells were 
observed for 1.1, 2.1 or vector transfected lines. Names of the photographed lines are documented in the 





 The average number of colonies for A1 3.2, A1 8.6 and A1 10.2 clones were 
73, 106 and 79, respectively. As shown in Figure 4.10,  only 3 colonies were produced 
by either by 1.1-9 or 1.1-23 clones whilst 4, 8 and 1 colonies were produced by 2.1-1, 
2.1-15 and 2.1-18 lines respectively. It cannot be excluded that this corresponds simply 
to background. In contrast, the positive control of EJTF2 cells gave rise to around 150 
colonies per well. The number of colonies per cell line expressed                                      








































    Figure 4.10 Assessment of transformation abilities of eEF1A1 origin stable cell lines. Colonies 
formed by indicated cell lines were counted after 21 days of culture. At least three independent 
experiments were performed per cell line and each technical repeat was prepared in triplicate.                   












    Table 4.3  Anchorage independent growth assay in vector alone, A1, 1.1 and 2.1 stably transfected       














                                                               
a
 Student‟s t-test, two-tailed         
 
 
Unfortunately, a high variation in colony numbers counted within A1 clones             
was observed between all experimental repeats, even though the same protocol was used 
every time. There were six separate experiments of the soft agar assay performed on A1 
cell lines and each was carried out in triplicate. Figure 4.11 shows colony counts after 
each independent assay. It is hard to determine why colony numbers were so high after 
the first round of experiment whereas counts of colonies decreased over subsequent 




















 (versus vector) 
     A1 3.2      73 ± 17.00      48.7 0.0007 0.0010 
     A1 8.6    106 ± 31.50      71.0 0.2044 0.0052 
     A1 10.2      79 ± 14.50      52.7 0.0004 0.0001 
     1.1-9        3 ±  0.60        2.0 <0.001 0.3860 
     1.1-23        3 ±  0.50        2.0 <0.001 0.4375 
     2.1-1        4 ±  1.00        2.9 <0.001 0.0544 
     2.1-15        8 ±  1.30        5.3 <0.001 0.0012 
     2.1-18        1 ±  0.30        0.7 <0.001 0.1809 
     vector        2 ±  9.50        1.3 <0.001  







       Figure 4.11 Soft agar assay performed on three A1 stable cell lines demonstrating variability                     
in anchorage independent colony formation over six experimental repeats. Graphs represent 
the mean counts of colonies per well (± SEM) from six consecutive assays performed in triplicate. 







 From different eEF1A1 origin clones and related controls it was observed              
that A1 clones formed markedly more colonies in agar than 1.1 or 2.1 clones but not           
as many as the positive control. It may suggest that the incorporation of a 5‟UTR into                   
the construct, regardless its eEF1A variant origin, was sufficient to cause almost 
complete abolition of the ability of the lines to produce soft agar colonies, such as were 
observed in A1 overexpressing lines.  
 
4.2.1.2.2    Overexpression of all eEF1A2 origin constructs promotes colony formation in soft agar 
 
 Three of each A2, 2.2 or 1.2 cell lines (as reviewed in Table 3.2) were subjected 
to the anchorage independent growth assay in order to monitor any oncogenic potential, 
when different eEF1A2 variants were overexpressed in the cells. Control cell lines               
were as before. The main question addressed in this study was whether lack of 
translational repression of eEF1A2 might contribute to its role in tumourigenesis.                              
Does the incorporation of a 5‟UTR (regardless its eEF1A variant origin) in front of the 
eEF1A2 coding sequence alter the extent of transformation of the cells? 
 
 As expected, after 3 weeks of culture, all eEF1A2 overexpressing transfectants 
developed colonies in soft agar and no colonies were detected within vector controls             
as shown in Figure 4.12. Again, an occasional colony was noticed in the wells with 
vector stable cell lines but these did not change size when cultured for more than three 
weeks. These are likely to represent the background level of the assay or perhaps                  
an artefact of randomly assembled cells when they were poured over the layer of agar.     
In contrast, 2.2 and 1.2 cell lines provoked substantially fewer colonies than EJTF2 
control or A2 clones over the same period of time. Interestingly, 2.2 clones exhibited 












Figure 4.12 Ectopic expression of all eEF1A2 variants in NIH-3T3 cells induces anchorage 
independent growth. Following 21 days of culture in 0.3% layer of agar, colonies were counted and 
photographed (magnification 10x). NIH-3T3 cells stably transfected with empty vector were used                          
as a negative control and 3 weeks after plating, single cells were observed within these wells.  
 






 As shown in Figure 4.13, the average number of colonies produced by clones           
A2 7.2, A2 9.6 and A2 10.2 were 119, 131 and 207, respectively, or 79%, 88% and 
138% the number of colonies formed by control EJTF2 cells (Table 4.4). In the presence 
of the eEF1A2 5‟UTR (2.2) these numbers decreased to only 26, 17 and 22 colonies for 
the three tested cell lines. In contrast, in the presence of the eEF1A1 5‟UTR,                        















































Figure 4.13 Stable overexpression of 2.2 and 1.2 variants gives rise to a neoplastic phenotype                            
as measured by the anchorage independent growth assay. Colony formation in representative A2, 
2.2 and 1.2 stable cell lines was assessed after 3 weeks by counting viable colonies in individual wells. 
The results are shown as a mean number of colonies per well (± SEM) from at least three separate 









Table 4.4  Anchorage independent growth assay in vector alone, A2, 2.2 and 1.2 stably transfected 
NIH-3T3 cell lines 
        
a 
Student‟s t-test, two-tailed 
 
 The above results suggest that after 21 days, NIH-3T3 mouse fibroblasts lost 
contact inhibition and acquired anchorage independence to grow as colonies in soft agar 
when either A2, 2.2 or 1.2 variants were overexpressed. The three A2 cell lines 
produced a substantial number of colonies whereas incorporation of a 5‟UTR altered 










COLONIES/WELL             
(± SEM) 







 (versus vector) 
      A2 7.2       119 ± 10.09         79.3 0.0317 <0.001 
      A2 9.6       131 ± 12.15         87.9 0.2793 <0.001 
      A2 10.2       207 ± 12.85       138.3 0.0010 <0.001 
      2.2-1         26 ±  5.23         17.3 <0.001 0.0003 
      2.2-33         17 ±  2.45         11.6 <0.001 <0.001 
      2.2-52         22 ±  1.47         14.4 <0.001 <0.001 
      1.2-2         43 ±  2.97         29.0 <0.001 <0.001 
      1.2-39         56 ±  4.34         37.3 <0.001 <0.001 
      1.2-59         21 ±  1.93         13.9 <0.001 <0.001 
      vector 1           1 ±  0.47           0.9 <0.001  
      vector 2           2 ±  0.58           1.3 <0.001  




4.2.2 Effect of overexpressed eEF1A variants on proliferation rate of NIH-3T3 
cells 
 
 After several lines acquired a transformed phenotype in vitro (see section 4.2.1 
for details), it was necessary to assess the effect of any eEF1A variant overexpression on 
cells growth rate. The AlamarBlue® assay was used to determine proliferation of 
selected stable cell lines over 8 consecutive days. This non-toxic assay is based on the 
ability of growing cells to induce a chemical reduction of the dye‟s indicator, observed 
as a shift of culture media colour from blue to pink. AlamarBlue® dye was applied                 
to the growing cells at indicated time points and fluorescence intensity was measured. 
The fluorescent signal reflects the magnitude of the reduced environment when a viable 
cell‟s growth is still maintained. AlamarBlue® dye was added to the medium without 
cultured cells as a blank control for the assay. 
 
4.2.2.1  Growth kinetics of eEF1A1 origin clones 
 
 Cellular proliferation rates were compared for three A1 stable cell lines, 
pDEST40 empty-vector control and EJTF2 cells that stably express H-Ras
G12V
,             
as shown in Figure 4.14.  It was observed that the proliferation magnitude of A1 3.2,              
A1 8.6 and A1 10.2 clones was less than for EJTF2 cells but became distinguishably 
greater than that of the vector control between the fifth and sixth day after seeding.     
All three A1 lines showed a trend approximately similar to the vector control on first 4 
days of culture. It is worth noting that line A1 10.2 showed almost no change in 
proliferation rate when compared to the vector control and this was the line with the 
lowest level of exogenous construct expression of the three lines. 
 When two 1.1 stable cell lines were examined in terms of proliferation             
(Figure 4.15), it was revealed that clone 1.1-9 grew almost as fast as EJTF2 cells until 
day 4. Subsequently, proliferation decreased but still showed a greater rate than the 




level than line 1.1-9 revealed a trend of proliferation similar to vector transfected cells 
only until day 4 but subsequently the rate was almost as high as for EJTF2 cells. 
 Three clones expressing different levels of 2.1 construct were characterized by 
different proliferation rates as presented in Figure 4.16. Clone 2.1-15 that was shown        
to have the highest expression of exogenous plasmid, exhibited the highest growth,               
with a trend similar to the EJTF2 line. The proliferation of line 2.1-18 that showed              
a moderate expression of the 2.1 construct, was almost in agreement with the rate of the 
vector cells until day 4 but then increased on following days to levels similar to those 
observed for EJTF2 cells. Clone 2.1-1 exhibited proliferation comparable with vector 
control rates, compatible with the extremely low level of 2.1 construct expression. 
 These data indicate that forced expression of A1, 1.1 or 2.1 variants in                   
NIH-3T3 fibroblasts altered the proliferation rate of the cells but only one line (2.1-15) 










Figure 4.14  Proliferation rate of NIH-3T3 fibroblasts stably overexpressing A1.  Three A1 stable cell 
lines (A1 3.2, A1 8.6, A1 10.2) along with control EJTF2 cells or empty-vector lines were cultured         
in standard conditions up to 8 days during which they were subjected to the AlamarBlue® assay. 
Proliferation magnitude is expressed as the fluorescence intensity at indicated time points. Results are 







Figure 4.15  Proliferation rate of NIH-3T3 fibroblasts stably overexpressing 1.1.  Two 1.1 stable cell 
lines (1.1-9, 1.1-23) along with control EJTF2 cells or empty-vector lines were subjected to the 
AlamarBlue® assay. Proliferation magnitude is expressed as the fluorescence intensity at indicated time 






Figure 4.16  Proliferation rate of NIH-3T3 fibroblasts stably overexpressing 2.1.  Three 2.1 stable cell 
lines (2.1-1, 2.1-15, 2.1-18) along with control EJTF2 cells or empty-vector lines were cultured tested in 






4.2.2.2  Growth kinetics of eEF1A2 origin clones 
 
The effects of A2 overexpression on proliferation rate were also assessed                                
in three A2 stable cell lines and compared with controls as before. As shown                         
in Figure 4.17, the proliferation rates of A2 7.2, A2 9.6 and A2 10.2 lines were 
considerably higher than that of both control cell lines.  
 Next, the growth of 2.2 stable cell lines was evaluated (Figure 4.18) and found 
to be noticeably enhanced for line 2.2-52, expressing the lowest levels of exogenous 
construct amongst the three clones. The proliferation rate for this cell line was 
considerably higher than for vector transfected or EJTF2 cells, however, an inexplicable 
decrease on day 5 and immediate increase on day 6 was observed. Transfectants of the 
line 2.2-1 proliferated at a faster rate than line 2.2-33 but with a trend similar to EJTF2 
cells.  Growth rates for clone 2.2-33 were less than control cells but greater than vector 
transfectants. 
 Cellular proliferation was also monitored in three representative 1.2 stable cell 
lines as presented in Figure 4.19. It was observed that all three clones showed enhanced 
cell growth, more than in the vector transfected line. It is noteworthy that clone 1.2-2 
which expressed the highest levels of exogenous construct seemed to proliferate at the 
fastest rate. Line 1.2-39 expressing the lowest level of 1.2 grew at the slowest rate out of 
three tested lines and showed a similar effect as an empty vector control. 
 These findings suggest that overexpression of A2 construct markedly 
stimulated NIH-3T3 proliferation when compared to the effects observed in 2.2 and 1.2 
variants. Forced expression of both, 2.2 and 1.2 variants affected the growth rate of 
mouse fibroblasts in comparison to vector transfectants but not to the same extent as 





Figure 4.17 Effect of A2 overexpression on NIH-3T3 cells proliferation.  Three stable A2 mouse 
fibroblast cell lines were subjected to determination of growth rate under standard culture conditions. 
Proliferation of A2 clones (A2 7.2, A2 9.6, A2 10.2) was compared to the stable lines of empty-vector           
or EJTF2 cells. AlamarBlue® dye was applied to the culture media of the cells and fluorescence                    
was measured up to 8 days after seeding. The results of growth magnitude are represented as the average 
fluorescence intensity at indicated time point (±SEM) calculated from three separate experiments                





Figure 4.18 Effect of 2.2 overexpression on NIH-3T3 cells proliferation. Proliferation of 2.2 clones 
(2.2-1, 2.2-33, 2.2-52) was compared to the stable lines of empty-vector or EJTF2 cells.  The results of 
growth magnitude are represented as the average fluorescence intensity at indicated time point (±SEM) 





Figure 4.19 Effect of 1.2 overexpression on NIH-3T3 cells proliferation.  Proliferation of A2 clones 
(1.2-2, 1.2-39, 1.2-59) was compared to the stable lines of empty-vector or EJTF2 cells. The results of 
growth magnitude are represented as the average fluorescence intensity at indicated time point (±SEM) 






4.2.3 Consequences of ectopic eEF1A variants overexpression  on  in  vitro 
migration and invasion in different eEF1A origin stable cell lines 
 
Cell migration is required for a variety of biological processes and alterations         
in regulation of migration lead to many diseases, including cancer. Increased cell 
motility and invasion are hallmarks of a metastatic phenotype (Yamaguchi et al., 2005, 
Sahai, 2005). In order to determine whether any of eEF1A variants plays a role in cell 
metastasis, selected stable cell lines (as reviewed in Table 3.2) were tested in established 
in vitro invasion and migration systems (Albini et al., 1987, Terranova et al., 1986). 
Both types of in vitro assays were performed as pilot studies and the experiment was 
carried out on 8 stable cell lines of eEF1A1 origin, on 9 stable cell lines of eEF1A2 
origin and on control empty vector transfected lines. Highly motile HT-1080 cells were 
used as a positive control (Rasheed et al., 1974, Albini et al., 1987). Each cell line was 
tested in triplicate but cells for each repeat originated in individual culture dishes, each 
dish representing an individual aliquot from liquid nitrogen storage. 
 The motility of the cells was assessed in a transwell system where cells 
migrated through a porous membrane towards the lower chamber. In this instance,               
the chamber was filled with a serum-supplemented medium that acted as an attractant.                               
As expected, the positive control of HT-1080 cells achieved a high level of motility 
values indicating a successful outcome. 
 Figure 4.20 illustrates the migration rate determined for NIH-3T3 stable cell 
lines of eEF1A1 origin. Quantification of the stable cell lines‟ motility showed that they 
were not migrating in a distinguishably different fashion from that of empty vector 
transfected cells; the percentages of motility in a relation to the negative control are 
summarized in Table 4.5. There was insufficient evidence to declare a difference in 
migration rates between A1 3.2 (P=0.165), A1 10.2 (P=0.061), 1.1-9 (P=0.840), 1.1-23 
(P=0.124), 2.1-1 (P=0.206), 2.1-18 (P=0.377) cell lines and vector control group,                         
however overexpression of exogenous plasmids had a significant effect on the migration                  
of A1 8.6 (P=0.034) and  2.1-15 (P=0.036) in comparison to the vector transfected cells. 




























































































Figure 4.20 In vitro studies of migration on selected NIH-3T3 stable cell lines of eEF1A1 origin. 
Cell motility was determined in transwell chambers by plating equal numbers of the cells into                  
the upper compartment and subsequent incubation for 24 hours with serum supplemented media                  
in the lower compartment as an attractant element. Cells that migrated through the membrane                  
were stained with fluorescent dye and the intensity of the fluorescence reflects motility.                          
A1 8.6 and 2.1-15 lines showed a significant increase in cell motility compared with vector 
transfected control (*P<0.05, Student‟s t-test, two-tailed). The average fluorescence of three repeats 
within one experiment is given for each cell line (± SEM) 
          
                       Table 4.5 Summary of different eEF1A1 stable cell lines motility rate expressed  
                        as percentages in relation to the vector transfected cells control 
 
Cell line 
% of the 
control 
   A1 3.2           119 
   A1 8.6           160 
   A1 10.2             93 
   1.1-9             99 
   1.1-23           109 
   2.1-1             94 
   2.1-15           115 
   2.1-18             95 
   vector            100 
      * 




 Additionally, the rates of the migration were evaluated for different stable cell 
lines of eEF1A2 origin as shown in Figure 4.21. The quantification of the migration 
rates for certain lines showed a small increase compared with the negative control                    
as summarized in Table 4.6. There was no evidence of a difference in migration between 
A2 9.6 (P=0.519), A2 10.2 (P=0.581), 2.2-1 (P=0.737), 2.2-33 (P=0.789), 1.2-2 
(P=0.318), 1.2-39 (P=0.482), 1.2-59 (P=0.459) lines and negative control cells, however 
there was an effect on migration of A2 7.2 (P=0.0499) and 2.2-52 (P=0.042) when 

































































































Figure 4.21 Quantification of in vitro motility within stable cell lines of different eEF1A2 origin. 
The cells that did not pass through the membrane were discarded whereas cells from the other side of 
the laminin membrane were fluorescently stained. The strength of the fluorescent signal reflected the 
magnitude of the cells migration capacities. The average fluorescence of three repeats within one 









                   Table 4.6 Evaluation  of  the  migration  rates  for different  eEF1A2 stable  cell  lines     
                   expressed as percentage values relative to empty vector transfected NIH-3T3 cells 
 
Cell line 
% of the 
control 
     A2 7.2          126 
     A2 9.6          106 
     A2 10.2          116 
     2.2-1            95 
     2.2-33            97 
     2.2-52            80 
     1.2-2            84 
     1.2-39            95 
     1.2-59          109 
    vector 1          100 
    vector 2          100 
 
 
 To further investigate any possible association between increased cell motility 
and invasive potential of the cell lines, an in vitro invasion assay was performed.               
On this occasion, the capacity of the cells to migrate through a laminin coated layer 
towards serum supplemented medium (an attractant) was evaluated. The laminin coated 
layer served as a barrier to discriminate non-invasive from invasive cells. The HT-1080 
cell line exhibited enhanced invasion capacity and was used as a positive control.  
 The invasiveness of different stable cell lines of eEF1A1 origin is shown               
in Figure 4.22. The lines were almost as invasive as the vector control cells. Statistical 
analysis showed no significant changes in invasion for A1 3.2 (P=0.601), A1 8.6 
(P=0.153), A1 10.2 (P=0.052), 2.1-1 (P=0.384), 2.1-15 (P=0.375) and 2.1-18 (P=0.076) 
stable cell lines. There was a significant decrease in the invasive potential of 1.1-9 
(P=0.037) and 1.1-23 (P=0.012) lines compared to the empty vector transfected control 
cells. The percentage difference in invasion ability between experimental and control 







Figure 4.22 In vitro invasiveness assay of different eEF1A1 expressing NIH-3T3 stable cell 
lines. Cells were evaluated for their ability to invade laminin towards an attractant of serum 
supplemented DMEM in a Boyden chamber. The results are expressed as average invasion capacity             
(± SEM) calculated from three determinations for each cell line.  * Significant difference between 
cell line and vector control (P<0.05, Student‟s t-test, two-tailed). 
 
 
                 
                 Table 4.7  Quantification of  the invasion capacity of different eEF1A1 stable  cell  lines     
expressed as  the  percentage values  in  comparison  to empty vector transfected control 
 
Cell line 
% of the 
control 
   A1 3.2          93 
   A1 8.6          83 
   A1 10.2          73 
   1.1-9          69 
   1.1-23          44 
   2.1-1          80 
   2.1-15          90 
   2.1-18          75 
   vector         100 
 
 
   * 




 Next, the invasive potential of different eEF1A2 expressing NIH-3T3 stable 
cell lines was determined as shown in Figure 4.23. Stable overexpression of A2, 2.2 or 
1.2 constructs altered the invasion capacities of the cells when compared to the empty 
vector control. The ability of the cells to invade the laminin layer was significantly 
changed for A2 7.2 (P=0.0002), 2.2-52 (P=0.038) and 1.2-39 (P=0.017) lines but there 
was no significant change for A2 9.6 (P=0.407), A2 10.2 (P=0.099), 2.2-1 (P=0.894), 
2.2-33 (P=0.433), 1.2-2 (P=0.459) and 1.2-59 (P=0.377) cell lines in comparison to the 
vector transfected control. The percentage difference in invasion between vector control 




Figure 4.23 Invasive potential of different eEF1A2 origin stable cell lines across laminin-coated 
transwell chambers. Equal number of cells for each line were seeded on the top of the chamber‟s upper 
compartment and left for 24 hours to invade through the layer of laminin. The results are exhibited as the 
average ability to invade (± SEM) calculated from three determinations. * Significant difference compared 
to vector controls with P<0.05, Stuent‟s t-test, two-tailed 
 
* 
   * 





         Table 4.8  Evaluation of   the  in  vitro invading  capacities  for different  eEF1A2 stable cell lines  
exhibited  as  the  percentage  difference  between  the  vector  control  and  experimental  samples 
 
Cell line 
% of the 
control 
   A2 7.2        125 
   A2 9.6        130 
   A2 10.2          76 
   2.2-1          98 
   2.2-33          89 
   2.2-52          68 
   1.2-2        114 
   1.2-39          57 
   1.2-59          80 
   vector 1        100 























4.2.4 Investigation of the possible mechanism responsible for oncogenic potential               
of eEF1A forms 
 
 Anand and co-workers demonstrated the oncogenic potential of eEF1A2 
showing that its ectopic expression in rodent fibroblasts resulted in anchorage 
independent growth, enhanced focus formation and gave rise to tumours when ES-2 
ovarian cells expressing eEF1A2 were injected into nude mice (Anand et al., 2002). 
Intriguingly, is still unknown how eEF1A2 contributes to tumourigenesis. It was shown 
that gene amplification is not the only mechanism responsible for eEF1A2 
overexpression and no activating mutations have been found. Moreover,  there was also 
no correlation between methylation status and eEF1A2 expression as exhibited                        
in a panel of ovarian tumours (Tomlinson et al., 2007). It is possible that the oncogenic 
properties of eEF1A2 might be associated with its conventional role in translation                
(i.e. increased protein synthesis rate) or perhaps with non-canonical functions that differ 
from those of the eEF1A1 form. On contrary, very little in this field is known about 
eEF1A1.  
 
4.2.4.1 Influence of different eEF1A variants overexpression on the global protein 
synthesis 
 
 As both eEF1A variants act in the same way during translation elongation and 
they both are pivotal components of the translational machinery (Pan et al., 2004, 
Bischoff et al., 2000, Kahns et al., 1998), it was crucial to investigate whether any 
increase in global protein synthesis occurred while different eEF1A forms were 
overexpressed. Levels of total translation elongation factor 1A protein were elevated in 
2.1 stable cell lines and all stable cell lines of eEF1A2 origin (as described in Sections 
3.2.3.3 and 3.2.3.4 of Chapter 3).  
  In order to shed some light on this problem, determination of the protein 






methionine/cysteine labelling of the cell lines stably expressing eEF1A1 or eEF1A2. 
Subsequently, incorporation of the radiolabelled amino acids into newly synthesized 
polypeptides was measured and the results of this assay are shown in Figure 4.24. 
 
 The rates of global protein synthesis for experimental samples were compared               
to controls (the lines transfected with empty vectors). High variation between cell lines 
was observed. The overall protein synthesis rates were not distinguishably higher than 
the levels seen in negative controls. Incorporation of radioactive amino acids was 
slightly increased for 2.1-1 (P=0.747), 2.1-18 (P=0.632) lines of eEF1A1 origin                                       
and for A2 7.2 (P=0.719), A2 10.2 (P=0.548), 2.2-52 (P=0.517), 1.2-2 (P=0.249),                               
1.2-59 (P=0.750) lines of eEF1A2 origin but these differences were not statistically 
significant from the vector controls. A minor decrease in global translation rate was seen 
for A1 3.2 (P=0.210), A1 8.6 (P=0.103), A1 10.2 (P=0.482), 1.1-9 (P=0.618), 2.1-15 
(P=0.742), A2 9.6 (P=0.772), 2.2-1 (P=0.310) and 2.2-33 (P=0.162) stable cell lines but 























































































































































































































































































































































































































































































































































































In order to investigate whether any relationship between global protein synthesis 
or overall eEF1A protein expression and transformed phenotype observations exists in 
the tested stable cell lines, Pearson‟s correlation coefficient (r) was computed.                        
There was no association between translation rate and number of colonies                                
(r = -0.247, n=19, P>0.05) or number of foci (r = 0.181, n=19, P>0.05) or in vitro 
invasion (r = -0.261, n=19, P>0.05) as summarized in scatter plots in Figure 4.25.                      
A moderate negative association was seen between global protein synthesis rate and                      
in vitro migration (r = -0.499, n=19, P<0.05). Cell lines with low levels of translation 
had a tendency to show increased migration, and conversely lines with a high protein 
synthesis rate had a tendency to show low levels of migration. 
 Interestingly, lines 2.1-1, 2.1-18, A2 7.2, A2 10.2, 2.2-52, 1.2-2 and 1.2-59              
that had increased levels of total eEF1A, exhibited increase in overall protein synthesis 
rate. In contrast, lines 2.1-15, A2 9.6, 2.2-1, 2.2-33 and 1.2-39 which had increased 
eEF1A protein expression, were not characterized by elevated protein synthesis. 
Subsequently, a moderate positive association was confirmed between global protein 
translation and overall levels of the eEF1A protein (r= 0.454, n=19, P<0.05). Stable cell 
lines expressing high levels of overall eEF1A protein had a tendency to exhibit increased 
rate of global translation. However, there was no association between overall eEF1A 
protein expression and number of colonies (r = -0.200, n=19, P>0.05) or number of foci 
(r = 0.258, n=19, P>0.05) or in vitro migration (r = -0.371, n=19, P>0.05) or in vitro 





Figure 4.25 Scatter plots of the relationships between protein synthesis rate and number                           
of colonies (A), number of foci (B), rate of in vitro migration (C), in vitro invasion (D) or total eEF1A 
protein levels (E). Pearson product moment correlation coefficient (r) was calculated for each relationship                           















Figure 4.26  Scatter plots of the relationship between total eEF1A protein expression and                 
number of colonies (A), number of foci (B), rate of in vitro migration (C) or in vitro invasion (D).                          
Pearson product moment correlation coefficient (r) for each relationship is shown in the corner of the 













 There is contradictory and incomplete evidence to link inappropriately 
regulated or expressed eEF1A1 with an involvement in tumourigenesis. For example, 
EEF1A1 gene expression was significantly higher in primary glioblastomas                    
(Scrideli et al., 2008) but it is noteworthy that eEF1A1 is predominantly expressed in 
glial cells (Pan et al., 2004, Newbery et al., 2007). Furthermore, eEF1A1 at the mRNA 
level stayed unchanged in cancers which overexpressed eEF1A2 (Anand et al., 2002, 
Cao et al., 2009).  In contrast, eEF1A2 has been recognized as a potential oncogene in 
human malignancies of breast, lung, ovary, pancreas or liver (Tomlinson et al., 2005,                  
Li et al., 2006, Anand et al., 2002, Cao et al., 2009, Schlaeger et al., 2008) and in mouse 
plasmacytomas (Li et al., 2010). Although the two eEF1A forms act in an equivalent 
manner at the elongation step of translation (Kahns et al., 1998), it has not yet been 
determined whether they exhibit any similarities for oncogenic capacity. Mechanisms 
used by eEF1A2 to transform cells have not been fully exploited and a major issue               
is whether oncogenicity is driven through changes in its conventional role in translation 
or rather by altered non-canonical functions.  
 Even though the effect of increased eEF1A2 expression has been studied                   
in detail within various cell line systems, the consequences of eEF1A2 variants               
with chimeric 5‟UTRs on cancer biology are unknown. Here, an attempt to 
simultaneously compare eEF1A1 and eEF1A2 in a panel of various in vitro 
transformation assays has been also shown for the first time and the possible meaning of 
the data obtained for the oncogenic potential of both eEF1A forms has been discussed. 
Overall trends among all of the stable cell lines clones that were observed in 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































The discovery that even low ectopic expression of eEF1A1 (as seen in the A1 
clones) provoked transformed cell morphology, followed by foci and soft agar colonies 
formation was intriguing. However, some fragmentary knowledge exists,  suggesting the 
possibility of eEF1A1 connection to cancer (Thornton et al., 2003). In addition, Tatsuka 
reported a mouse fibroblast cell line variant, constitutively expressing eEF1A1, that was 
highly susceptible to chemically or physically induced neoplastic transformation 
(Tatsuka et al., 1992). This can be explained by the fact that in the majority of studies 
with eEF1A1 performed in the past, antibodies or DNA probes that did not distinguish 
between the two eEF1A forms were used. The numbers of foci and colonies induced in 
soft agar by A1 lines were not as high as in A2 clones; however, expression of A2 
construct was higher than A1 construct. Moreover, the stimulatory effect of eEF1A1 on 
the oncogenic potential of NIH-3T3 cells did not correlate with dramatically increased 
proliferation in comparison to the vector control lines. It is possible that eEF1A1 
activation might be an early event during neoplastic transformation and that other 
mutagens are necessary to promote tumour (Thornton et al., 2003). 
  Incorporation of chimeric 5‟UTRs in front of the eEF1A1 coding sequence 
resulted in a significant decrease of foci formation and almost complete abolition               
of the anchorage-independence in 1.1 and 2.1 stable cell lines. Although these cell lines 
have acquired a morphology characteristic of transformed cells, it was not reflected by 
malignant transformation. The proliferation rates of 1.1 and 2.1 lines were in excess over 
A1 clones and the increase in growth appeared to be proportional to the magnitude of the 
exogenous variant expression within particular clones. Clones with the 5‟UTR from 
eEF1A2 (2.1) showed heightened proliferation compared with their counterpart clones 
with the 5‟UTR from eEF1A1 (1.1). Importantly, only clone 2.1-15 showed                               
a proliferation rate almost as high as positive control of NIH-3T3 cells stably expressing 
H-Ras
G12V
. It cannot be excluded that different mechanisms confer proliferation and 
malignant transformation. 
 The finding showed herein, that plain eEF1A2 coding sequence overexpression 
was driving the transformed phenotype in NIH-3T3 cells was consistent with previous 




A2 9.6 and A2 10.2, characterised by constant overexpression of the eEF1A2 coding 
sequence, demonstrated not only loss of contact-inhibition capacity but also provoked 
foci formation and anchorage-independent growth. This sequence of events correlated 
with increased rates of proliferation within all three A2 clones.  
 Likewise, 2.2 and 1.2 lines displayed oncogenic phenotypes but the numbers                
of foci or colonies in soft agar were significantly lowered in comparison to the A2 
clones, except clone 2.2-52. Moreover, 2.2 clones showed a similar trend of foci 
formation to that of 1.2 lines but the 1.2 clones acquired a higher clonogenicity in soft 
agar than 2.2 lines. Surprisingly, their proliferation rates were less pronounced than in 
clones with the 5‟UTR from eEF1A2. Therefore, incorporation of any eEF1A 5‟UTR 
led to a substantial but incomplete constraint of the in vitro oncogenic potential within 
the 2.2 and 1.2 stable cell lines. All three A2 clones proliferation exceeded the rates seen 
in EJTF2 cells whereas almost similar growth between 2.2 clones and this positive 
control was mostly observed, suggesting that the 5‟UTR of eEF1A2 is necessary for 
regulatory purposes in growth stimulation, and substituting it for the 5‟UTR of eEF1A1 
led to a more efficient transforming phenotype.  
 The oncogenic potential of ectopic expression of different A1, 2.2 or 1.2 
variants in NIH-3T3  cells could be explored further by in vivo studies in xenograft 
models in nude mice (Blair et al., 1983). Currently, it remains undetermined whether               
the expressed amounts of these variants are sufficient to induce more of the transformed 
phenotype. It is noteworthy that cells stably expressing eEF1A2 gave rise to tumours 
when injected into nude mice (Anand et al., 2002, Cao et al., 2009). 
 Next, the potential for in vitro migration and invasion was assessed for selected 
stable cell lines of different eEF1A origin. In this study, the intensity of fluorescence 
reflected the motility of the cells through a porous membrane and laminin layer, 
respectively. 
 Motility was significantly increased only for A1 8.6 and 2.1-15 clones 
(expressing the highest V5-tagged constructs levels) whereas the remaining eEF1A1 
origin lines did not display any significant changes. Similarly, all the stable cell lines            




even though A2 clones showed the highest proliferation rates. There was also no 
apparent elevation of in vitro invasion among different eEF1A variant stable cell lines, 
except line A2 7.2 (significant), A2 9.6 and 1.2-2 (not significant due to high variation 
between the samples). These observations were puzzling since Amiri and colleagues 
have shown that eEF1A2 overexpressed in BT-549 cells was an enhancer of migration 
and invasion in a PI3K/Akt dependent manner (Amiri et al., 2007). Moreover, the above 
results were also inconsistent with the increased in vitro cell motility and invasion 
reported for pancreatic adenocarcinoma SW1990 cell line, overexpressing eEF1A2, 
however there was no significance difference in adherence of these cells on laminin 
coated surfaces (Cao et al., 2009). It is possible that NIH-3T3 cells overexpressing 
different eEF1A variants show little affinity for laminin, hence the use of fibronectin or 
collagen layer as a crossing barrier could be more reliable. NIH-3T3 cells are not 
considered as invasive until transfected with activating oncogenes (Albini et al., 1987) 
but herein, even overexpression of eEF1A2 resulted in invasion efficiencies comparable 
to those of the negative control. 
  First, it should be kept in mind that invasion assays performed by Cao or Amiri 
were done on already transformed cell lines, hence a specific genetic background might 
be necessary to induce a high invasive potential of eEF1A2. Alternatively, mechanisms 
responsible for regulation of cellular proliferation and migration rates might be different 
from those that provoke invasive potential and transformed phenotype, depending                
on the cellular system used for experiments. To shed some light on this issue, the use             
of a 3D in vitro invasion model, for example by embedding cells between two collagen 
layers that resembles the tumour microenvironment situation in vivo more realistically, 
could be advantageous  (Brekhman and Neufeld, 2009).  
 Currently, mechanisms considered for eEF1A2-driven oncogenesis propose              
that its upregulation causes either overall increase in protein synthesis or translation                   
of a specific subset of proteins. Increased expression of the elements involved in 
assembling the translational machinery has been already well documented and linked to 
cancer (Ruggero and Pandolfi, 2003). When the intracellular stoichiometry for 




available for immediate use, certain proteins that are normally poorly translated                                   
(for example due to their highly structured 5‟UTR sequence) can increase their 
expression (Koromilas et al., 1992a). This exact mechanism activates many                     
proto-oncogenes along with growth- or survival-related genes (Le Quesne et al., 2009, 
Ruggero and Pandolfi, 2003, Mamane et al., 2007). 
 For instance, elevated expression of tRNAi
Met
 or five subunits of the eukaryotic 
translation initiation factor 3 (eIF3a, eIF3b, eIF3c, eIF3h and eIF3i) stimulated global 
translation and subsequently led to oncogenic transformation of mouse embryonic 
fibroblasts. This stimulation of translational capacity caused an increase in synthesis                   
of  growth-regulating proteins like cyclin D1, c-Myc, ODC or FGF-2 (Marshall et al., 
2008, Zhang et al., 2007).  
One of assumption was that stable expression of any construct of eEF1A origin 
could lead to increase in overall level of eEF1A protein expression within the cells. 
Hence, a higher activity of combined eEF1A could provoke an increase in the global 
protein synthesis rate and perhaps more robust translation of mRNAs involved in growth 
and proliferation. In a few cell lines, for instance A2 7.2, A2 10.2 or 1.2-39, clearly high 
levels of eEF1A coincided with enhanced translation and fit perfectly with their ability 
to elevate cell growth and transformed phenotype. Therefore, it would be advantageous 
to determine the mRNA and protein levels of c-Myc or cyclin D1 in those stable cell 
lines in comparison to vector control lines. Moreover, it would be also interesting to 
know whether eEF1A is the only increased translational component or whether the 
translational apparatus is elevated in general. 
Interestingly, on a few occasions or even within lines expressing the same 
construct, there was some inconsistency and clones A2 9.6, 2.2-1 or 2.2-33 expressed                
an increased level of overall eEF1A but did not show enhanced translation. However, 
these lines still presented oncogenic potential, suggesting that different mechanisms 
responsible for their higher proliferation rate and transformation could occur,                 
despite the eEF1A status in the cells. 
Results from assays performed on stable cell lines of eEF1A1 origin suggest that 




of increase in eEF1A protein levels seen in the cells and a decreased translation rate. 
These results were in contrast with the A2 clones, suggesting that transformed 
phenotype is executed in a different manner. The oncogenic potential of overexpression 
of A1 constructs was diminished by incorporation of chimeric 5‟UTRs. The most 
outstanding lines were 2.1-15 and 2.1-18 which had increased levels of total eEF1A 
protein, subtly enhanced global translation rates and higher proliferation, but did not 
necessarily display a transformed phenotype. 
The notion that overexpression of different eEF1A variants could lead to general 
activation of cellular eEF1A, therefore promoting translational efficiency of certain 
oncogenic mRNAs seemed unlikely for some cell lines. They exhibited increased 
activity of eEF1A and a transformed phenotype but were not characterized                        
by dramatically altered proliferation. Unfortunately, there was no significant association 
between rates of the protein synthesis and transformed phenotype among tested stable 
cell lines.                          
These inconsistencies among cell lines of the same type were puzzling but                 
it might just underline that translation regulation of eEF1A is even more complex                                   
and multilayered; therefore perhaps each cell line‟s situation should be considered 
separately. All five determinations of the protein synthesis rates were done according to 
the same protocol, at the same time of the day and using stable cell lines in the 
logarithmic phase of growth. Perhaps change to a more reliable and non-radioactive 
method would give more consistent and explicable data.  For example, a new method                      
to monitor protein synthesis has been developed by Schmidt and co-workers                                 
as an advantageous alternative to the radioactive metabolic labelling (Schmidt et al., 
2009). Surface sensing of translation (SUnSET) technique uses labelling of the cells 
with small and safe dosages of puromycin, a structural analogue of aminoacylated 
tRNAs, instead of conventional introduction of [
35
S] methionine/cysteine to the cells. 
Puromycin incorporation into newly produced proteins is detected by monoclonal 
antibodies and allows monitoring and quantification of rates of global translation not 




Alternatively, even though all plasmids constitutively present in the stable cell 
lines were expressed from the same CMV promoter and clones for independent 
constructs were generated from the same nucleofection batch, it is likely that during 
transfection cDNA integrated into distinct sites within chromosomes. The problems                
of the clonal variation might be suppressed in future experiments by simultaneous usage 
of tetracycline or doxycycline inducible stable cell lines. 
 Although assessment of eEF1A1 oncogenic potential in vitro by transformation 
assays has not previously been shown, eEF1A2 was experimentally characterized as 
legitimate oncogene. NIH-3T3 and ES2 (ovarian clear cell carcinoma) cells generated                       
to stably overexpress eEF1A2 gave rise to tumours when injected into nude mice 
(Anand et al., 2002). Constitutive overexpression of eEF1A2 in the SW1990 pancreatic 
adenocarcinoma cell line also resulted in colony formation in soft agar and increased 
proliferation rate (Cao et al., 2009). Ectopic expression of eEF1A2 in the SK-OV-3 clear 
cell carcinoma line provoked elevated proliferation (Pinke et al., 2008), therefore the 
oncogenic effects of eEF1A2 is not restricted exclusively to the rodent fibroblasts cell 
system.  
All three cell lines- ES2, SW1990 and SK-OV-3, are of cancerous origin where 
presence of eEF1A2 was either not confirmed at the mRNA level or its expression at the 
protein level was very poor. However, it is noteworthy that many cancer lines already 
carry activated oncogenes, and are predisposed to transformation (Perucho et al., 1981).  
Therefore careful consideration should be taken with evaluation of eEF1A2 
transformation abilities when taking advantage of cell lines established from human 
tumours. Nevertheless, if the transformed phenotype seen in these studies is due to the 
genetic background of NIH-3T3 cells, it would be reasonable to determine 
overexpression effects in other immortal cell line systems like Rat2 or Chinese hamster 
ovary cells (CHO-K1). 
Results from A1, 1.1 and 2.1 stable cell lines provided a framework to conclude 
that the 5‟UTR of eEF1A1 is sufficient to prevent neoplastic transformation.                                 
As the situation is less clear for eEF1A2, an alternative mechanism responsible for 




upregulated by phosphorylation.  Interestingly, upregulation of eIF3a, eIF3b and eIF3c 
increased the overall level of eIF3, but upregulation of the eIF3h and eIF3i subunits did 
not cause such an increase, even though enhanced protein synthesis was still observed.  
It was revealed, that the oncogenic potential of eIF3h was stimulated by phosphorylation 
at Ser183 (Zhang et al., 2007, Zhang et al., 2008). 
Certain other translation-involved factors, for instance eIF2α and eIF4E that have 
been recognized as oncogenes, are able to drive transformation as a result of alterations                 
in their phosphorylation status. Either disruption in eIF2α phosphorylation                              
by RNA-inducible kinase (PKR) or overexpression of eIF2α causing increase                         
in levels of unphosphorylated initiation factor, promotes cellular proliferation                    
and neoplastic transformation (Donze et al., 1995, Koromilas et al., 1992b, Tejada et al., 
2009). By contrast, increased phospho-eIF4E levels promoted tumourigenesis               
(Lazaris-Karatzas et al., 1990, Wendel et al., 2007). 
Both eEF1A1 and eEF1A2 appear to be capable of phosphorylation at a number 
of different residues (Soares et al., 2009), however it has not been yet elucidated whether 
there is any definite connection with transformation. Interestingly, amino acid sequence 
alignment of both eEF1A forms in a range of higher order eukaryotes showed three 
serine residues highly conserved in eEF1A2 (Ser 358, 393, 445) but not in eEF1A1.                   
The last two amino acid sites achieved high probability scores of phosphorylation                    
by PKC (protein kinase C) as determined by NetPhos prediction webtool (Soares et al., 
2009). Additionally, Lamberti et al. showed Ser and Thr (Ser18, 157, 316, 383 and Thr 
242, 432) as the most probable phosphorylation sites for C-Raf in their 3D model of 
human eEF1A, hypothesizing that it increases cell survival activity and cellular stability 
of the translation factor (Lamberti et al., 2007). Potential differences in phosphorylation 
status between eEF1A1 and eEF1A2 could shed some light whether this type of protein 
regulation might have some influence on transformed phenotype of eEF1A2.  
Before proper identification of the phosphorylated residues in eEF1A forms                
by mass spectrometry could be carried out, a pilot assay needed to be performed.             
HeLa cells transiently transfected with A1 or A2 constructs could be chosen                                 




serine residues. Attempts to investigate phosphorylation status of eEF1A2 were taken                        
with anti-phosphoserine antibody as described by Lamberti (Lamberti et al., 2007),                   
but without success (data not shown). Even though immunoprecipitation stage (IP)               
was efficient and the amounts of pulled down eEF1A proteins with antibodies directed 
against different epitope tags were satisfactory, this particular anti-phosphoserine 
antibody was not able to show any bands when IP reactions were subjected to 
immunoblotting. Although all precautions were taken to avoid unwanted 
dephosphorylation during preparation of cell lysates and phosphatase inhibitors were 
present in buffers for cell lysates production, these samples gave a range of nonspecific 
bands. Perhaps another antibody to detect proteins phosphorylated at serine residues 














Chapter 5: Immunohistochemical studies of the eEF1A    







Currently, the overexpression of eEF1A2 protein has been linked to a high 
proportion of tumours of several types, including breast, ovarian and pancreatic 
carcinomas (Tomlinson et al., 2005, Tomlinson et al., 2007, Pinke et al., 2007,                           
Cao et al., 2009). However, to date, no extensive studies have been reported analysing 
the expression and distribution of eEF1A1 and eEF1A2 in colorectal cancer                           
or hepatocellular and cutaneous malignancies. Initial immunohistochemical studies 
performed earlier in the laboratory suggested the possibility of eEF1A2 upregulation                
in a significant subset of primary colorectal carcinomas. In order to shed some light                 
on this, immunohistochemistry was performed on commercially manufactured tumour 
microarrays (TMA) containing collections of liver, skin or colon cancers.                        
Where possible, the relationship between eEF1A variants expression and clinical 





















An array containing a panel of multiple normal human organ sections was used 
as a control for staining with the anti-eEF1A1 and anti-eEF1A2 antibodies and to assess 
expression of eEF1A forms in normal liver, colon and skin tissues.                                           
The expression of eEF1A1 and eEF1A2 was then examined independently by 
immunohistochemistry in different commercial tumour microarrays containing cores 
either from hepatocellular carcinoma, malignant melanoma or colorectal tumours. One 
of the arrays from the same batch was incubated with the anti-eEF1A1 antibody and               
the other one was stained with the anti-eEF1A2 antibody. 
Staining was assessed in relation to tumour free cores indicated as „normal‟                 
in the array description. The arrays were scored by two independent observers and if any 
discrepancy in the assessment of the cores occurred, they were reviewed to obtain                 
an agreed score. Multiplying the staining intensity level (1-3) by the percentage of 
tumour cells present within that level was used to calculate a final histoscore. 
Histoscores of 0, 1-100, 101-200 and 201-300 were classified as negative, weak, 
moderate and strong, respectively. In addition, where clinical information was available 
for a commercial array, a Fisher‟s exact test was used to investigate any association 
between levels of eEF1A expression and clinicopathological characteristics. 















Figure 5.1 eEF1A1 and eEF1A2 immunostaining in normal human liver, colon and skin.                       
Third column displays sections stained without primary antibodies (negative control). Liver shows no 
expression for eEF1A2 as expected. eEF1A2 was detected in the single cells of colonic crypts (marked 
with arrows). Similar pattern of eEF1A1 and eEF1A2 staining is present for cutaneous tissue. 
Magnification: 20x.  
 
5.2.1 Immunohistochemistry of hepatocellular carcinoma TMA 
 
 The intensity of eEF1A1 and eEF1A2 expression was investigated in 41 
hepatocellular carcinomas (HCC) on a commercial tumour microarray (Folio 
Biosciences). A large proportion of tumours showed no staining and so 30 of 41 tumours 
(73%) and 33 of 41 tumours (80%) were negative for eEF1A1 and eEF1A2, 
respectively. Twenty seven percent showed weak staining for eEF1A1 and 20% of HCC 





On eleven of the eEF1A1 weak staining tumours, only 2 cores overlapped with the weak 
expression of eEF1A2. 
 
 
 Table 5.1  Expression of eEF1A1 and eEF1A2 in primary hepatocellular carcinoma array 
 
 
eEF1A1 was expressed uniformly across the sections and eEF1A2 was either seen in 
patches of cells or stained evenly across the core. Both eEF1A variants showed a diffuse 
cytoplasmic pattern within adenomous hepatocytes. Representative examples of staining 

















negative % weak % moderate % strong % 
eEF1A1 41 30 73 11 27 0 0 0 0 





Figure 5.2 Expression of eEF1A1 and eEF1A2 in primary hepatocellular carcinoma. Staining of 
tumours with the eEF1A1 antibody was weak and uniform across the sections (left column). Expression of 
eEF1A2 in corresponding cores (right column) was negative or weak, or very rarely, in patches of 





Only two clinicopathological characteristics were available with this tumour 
array: age and sex. Neither the age nor the gender of the donors was significantly 
associated with the expression levels of eEF1A1 or eEF1A2, as displayed in Table 5.2. 
 




                               eEF1A1 
 Staining  intensity  
 negative weak moderate Strong P
a 
sex F 4 0 0 0 0.559
 
 M 26 11 0 0  
       
age 0-40 8 0 0 0 0.052
 
 41-60 18 11 0 0  
 >60 4 0 0 0  
       
 
    Characteristic 
                               eEF1A2 
 Staining  intensity  
 negative weak moderate Strong P
a 
sex F 5 0 0 0 0.563
 
 M 28 8 0 0  
       
age 0-40 8 0 0 0 0.182
 
 41-60 21 8 0 0  
 >60 4 0 0 0  
a 




5.2.2 Immunohistochemistry on malignant melanoma TMA 
 
 
Immunohistochemical staining of malignant melanoma with eEF1A1                       
and eEF1A2 antibodies was performed on two tumour microarrays manufactured                   
by different companies (Biomax and Folio Biosciences). One tumour core                        
on the Biomax array was non-scorable for both antibodies due to the high melanisation 




 It is noteworthy that eEF1A1 and eEF1A2 appeared to be expressed in the basal 
layer of epidermis-the layer where undifferentiated keratinocytes undergo a constant 
proliferation process (see Figure 5.1). Representative illustrations of eEF1A1 and 
































Figure 5.3 Representative examples of eEF1A1 and eEF1A2 immunostaining in malignant 
melanoma array. In majority of cases, weak uniform expression was observed for eEF1A1 whereas 
eEF1A2 was expressed in patches of cells or in the whole tumour section (A, B, D). No eEF1A1 staining 
other than in normal tissue was seen in neoplastic intraepidermal nests of melanocytes (C) whereas it was 










Figure 5.4 Expression of eEF1A1 and eEF1A2 in malignant melanoma was equally weak or equally 
moderate in a few tumour sections (G, H). In addition, several cores showed negative staining for 
eEF1A1 whereas eEF1A2 was moderately expressed (E). There were also sections negative for eEF1A2 









On the Biomax array, weak eEF1A1 staining was observed in 9 of 39 (23%) 
cases whereas negative tumours represented 30 of 39 (77%) cores as shown in                 
Table 5.3. For the Folio Biosciences array, 2 of 31 tumours (6%) showed strong 
immunoreactivity, 5 of 31 tumours showed moderate staining (16%) and 24 of 31 cores 
(77%) showed weak staining, respectively (Table 5.5). Positive staining was uniform 
across the core and showed a diffuse cytoplasmic pattern. No stromal staining was 
observed.  
For eEF1A2 staining on the Biomax array (Table 5.3), one tumour demonstrated 
strong expression, 2 tumours moderate expression, 13 cores weak expression (33%) and 
23 tumours displayed negative staining (59%), respectively. Six of thirty one (19%) 
tumours showed strong immunoreactivity, 8 of 31 (26%) displayed moderate staining, 
13 of 31 (42%) weak staining and 4 tumours were negative (13%) on the Folio 
Biosciences array (Table 5.5). Immunohistochemistry with the eEF1A2 antibody 
showed a diffuse cytoplasmic subcellular localisation which was either uniform across 
the section or was seen in patches of cells. No stromal staining was observed.  
Eleven tumours with weak eEF1A1 or eEF1A2 expression, 2 cores with 
moderate and one core with strong staining were overlapping between eEF1A1 and 
eEF1A2 positive tumour samples on Folio Biosciences array. Biomax array contained 
21 cores negative and 5 cores with weak expression for eEF1A1 as well as for eEF1A2.  
Tables 5.4 and 5.6 summarize the relationship between eEF1A variant 
expression and clinicopathological features; however, only age and sex were available 
for both commercial TMAs. There was no significant correlation between either 





















negative % weak % moderate % strong % 
eEF1A1 39 30 77 9 23 0 0 0 0 




Table 5.4 Relationship between eEF1A1 or eEF1A2 expression and clinicopathological characteristics 
 
                                 eEF1A1 
 Characteristic           Staining  intensity     
    negative weak moderate strong P
a 
sex F 14 3 0 0 0.704
 
 M 16 6 0 0  
       
age 0-40 6 2 0 0 0.886
 
 41-60 14 3 0 0  
  >61 10 4 0 0   
       
                                    eEF1A2 
 Characteristic                          Staining  intensity  
    negative weak moderate strong P
a 
sex F 9 7 1 0 0.797
 
 M 14 6 1 1  
       
age 0-40 3 5 0 0 0.102
 
 41-60 13 3 0 1  
  >61 7 5 2 0   
a 




















negative % weak % moderate % strong % 
eEF1A1 31 0 0 24 77 5 16 2 7 




Table 5.6 Association between expression of eEF1A1 or eEF1A2 and clinicopathological features 
 
                                 eEF1A1 
 Characteristic Staining  intensity  
  negative weak moderate strong P
a 
sex F 0 10 3 1 0.812
 
 M 0 14 2 1  
       
age 0-40 0 4 1 0 0.999
 
 41-60 0 12 2 1  
 >61 0 8 2 1  
                                 eEF1A2 
 Characteristic Staining  intensity  
  negative weak moderate strong P
a 
sex F 1 8 3 3 0.588
 
 M 3 5 5 3  
       
age 0-40 0 1 3 1 0.177
 
 41-60 2 6 5 2  
 >61 2 6 0 3  
a 









5.2.3 Immunohistochemistry on colorectal carcinoma TMA 
 
Tumour microarrays containing colorectal adenocarcinomas were obtained from 
Zymed and BioChain. Of the 26 tumour samples on the Zymed array                                 
(Table 5.7), one showed moderate expression of eEF1A1 (4%), 11 showed weak 
expression (42%) and the remainder was negative. For eEF1A2 immunostaining,               
4 of 26 tumours (15%) displayed strong staining, 7 of 26 (27%) showed moderate 
staining, 9 of 26 (35%) showed weak staining and 6 tumours showed no eEF1A2 
overexpression.  
The same three tumour cores showed weak staining for eEF1A1 and for eEF1A2 
and other 4 cores were negative for both eEF1A variants. Detailed clinical information 











negative % weak % moderate % strong % 
eEF1A1 26 14 54 11 42 1 4 0 0 




For the BioChain array, 14 of 61 of tumours (23%) displayed strong eEF1A2 
staining, 12 (20%) showed moderate staining, 20 (33%) showed weak staining               
and the remaining 15 tumours (24%) were negative (Table 5.8). Initially, there were 64 
tumours on this array but due to loss or damage of three cores, these were considered as 














negative % weak % moderate % strong % 
eEF1A2 61 15 24 20 33 12 20 14 23 
 
 
Unfortunately, it was impossible to perform immunohistochemical evaluation of 
the eEF1A1 expression on this array. The batch of the anti-eEF1A1 antibody which was 
generally available in the laboratory lost its specificity at the time when this particular 
array was delivered and concomitantly, the newly generated batch was still undergoing 
the optimisation process. To give a general overview of eEF1A1 expression in colorectal 
cancer, immunohistochemistry analysis obtained previously by Dr Julia Boyd                             
(a former member of Professor Cathy Abbott group) is presented in Figure 5.5, 



















































































































































































































































































































































































The expression of eEF1A1 in normal colon was widespread; however staining 
was not very strong. Within a given section of normal colon, up to two cells per crypt 
showed moderate eEF1A2 expression and these cells were localised toward the base of 
the crypt (see Figure 5.1). This was in agreement with previous observations                                       
in the laboratory and the similar pattern that is also seen in mice (Newbery et al., 2007); 
these cells are almost certainly enteroendocrine cells.  
In the tumour sections, no stromal staining was seen for either eEF1A variant. 
Tumour staining with the eEF1A1 antibody was uniform across the whole section. 
Positive staining of eEF1A2 in tumours was observed in cells of epithelial origin; 
however, the pattern of staining differed between tumours. The most common pattern 
was characterised by ubiquitous cytoplasmic expression of eEF1A2 in a large area of the 
core. In a smaller proportion of tumours, clear perinuclear staining in single entrapped 
cells, an accumulation of granular species on the one side of the nucleus in all 
neighbouring cells and distinct cytoplasmic staining in patches of cells were additionally 
observed. The perinuclear accumulation of eEF1A2 appears to reflect the staining 
pattern seen in neuroendocrine cells and as such may be a surrogate phenotype for 
cancer rather than any biological function of eEF1A2 (personal communication with 
Professor David Harrison, pathologist). Representative images of eEF1A2 expression 













Figure 5.7 Representative illustrations of different patterns for eEF1A2 expression in colorectal 
tumours.  (A, B, C) Diffuse cytoplasmic staining of the tumour cells in a large proportion of the cancer 
section. (D) Granular staining within neoplastic epithelial cells. The right column (10x) represents selected 










Figure 5.8 Examples of the heterogonous expression of the eEF1A2 protein in a panel of colorectal 
tumours. (E, F) Granular staining of the eEF1A2 is located on one side of the nuclei of the neighbouring 
cells. (G, H) Neoplastic cells show a moderate cytoplasmic staining but strong perinuclear staining in 
neuroendocrine cells as indicated by arrows. Illustrations on the right are a higher magnification                     









Clinical diagnostic data, including patient age, sex, primary tumour assessment, 
tumour differentiation, lymph node status and metastasis were available for the samples 
on the BioChain TMA; therefore, a relationship between eEF1A2 expression and these 
clinical variables could be determined as shown in Table 5.9. There was no significant 
correlation between these clinical features and eEF1A2 level, except that there appeared 
to be an association between eEF1A2 expression and a small number of positive lymph 
nodes (P = 0.024, Fisher‟s exact test). This suggests that overexpression of eEF1A2 




























Table 5.9 Relationship between expression of eEF1A2 and clinicopathological variables in colorectal 
tumour array 
 
                               eEF1A2 
Characteristic Staining  intensity  
  negative weak moderate strong P
a 
sex F 5 9 6 6 0.863
 
 M 10 11 6 8  
       
age 0-40 1 2 2 0 0.462
 
 41-60 4 6 5 8  
 >61 10 12 5 6  
       
T Tx 1 1 0 0 0.248
 
(primary tumour classification) 
T1 0 0 0 0  
T2 7 12 4 8  
 T3 6 4 8 6  
 T4 1 3 0 0  
       
N N0 13 12 6 10 0.024
 
(regional lymph nodes) 
N1 0 0 4 0  
N2 1 6 1 3  
N3 1 2 0 1  
 N4 0 0 1 0  
       
M M0 14 17 10 11 0.726
 
(distant metastasis) 
M1 1 3 2 3  
      
       
tumour  
differentiation 
poorly 2 1 1 1 0.412
 
 moderately 5 9 4 6  
 well 8 10 5 4  
 other 0 0 2 3  
       
a 








This study describes the immunohistochemical analysis of eEF1A1 and eEF1A2 
expression in liver, skin and colorectal tumour microarrays, as in the literature,                      
there is very little information about possible engagement or expression pattern of 
eEF1A forms in these cancer types. A combination of multiple tumours in one array 
provides a simple and comprehensive tool to assess the expression pattern of a candidate 
biomarker between different stages of a specific cancer or allows expression of one 
biomarker to be compared to that of another candidate in the same experimental setting 
(Nocito et al., 2001). 
 
Analysis of eEF1A1expression in a panel of hepatocellular carcinomas showed 
that about 27% of tested cores displayed weak staining and the remainder appeared to 
have no more staining than normal liver. Thus, it is tempting to speculate that 
aberrations in eEF1A1 expression are not commonly seen in hepatocellular carcinoma. 
Interestingly, weak staining was found in an equally small percentage of cases for 
eEF1A2 expression and only two cores showing weak expression of eEF1A1 exhibited 
weak staining of eEF1A2. Investigation of eEF1A variant-specific expression at the 
protein level has not been previously reported. However, some information is available 
about the levels of eEF1A variant expression at the RNA level in HCC. Based on 
LongSAGE analyses of gene specific tag hits, 104 genes were found to be significantly 
upregulated in HCC when compared to their expression profile in normal liver, 
including EEF1A1 with an approximate fold change of 26 (Dong et al., 2009) but it is 
not known how many hepatocellular carcinoma samples were used in this experiment.        
In addition, the EEF1A2 gene was amplified in HCC according to the array-based CGH 
performed on 67 hepatocellular carcinoma cases and also found to be overexpressed by 
real time-PCR in 20 HCC cell line samples (Schlaeger et al., 2008). Would these 
alterations in gene expression be reflected at the protein level? What are the levels of 
EEF1A1 or EEF1A2 expression in tumours which showed in study herein only low 




Is there any functional significance of eEF1A1 or eEF1A2 expression at low levels in 
HCC? It is all not that clear but eEF1A1 was identified as an interacting partner for 
DLC1 (deleted in liver cancer 1) by protein precipitation and mass spectrometry                
(Zhong et al., 2009). The SAM (sterile alpha motif) domain of DLC1 was implicated in 
the suppression of cell migration by the recruitment of eEF1A1 to the cell membrane 
periphery and ruffles. SAM mutants failed to recruit eEF1A1 and did not affect cell 
migration. DLC1 is a Rho-GTPase-activating protein and a candidate tumour suppressor 
which is commonly deleted in liver or breast tumours (Zhong et al., 2009).  Since only 
two HCC cores with positive expression for eEF1A1 and eEF1A2 overlapped in my IHC 
study, it is tempting to speculate that eEF1A variants could have different biological 
meaning (if any) in liver cancer. Based on a real-time PCR approach, EEF1A2 
overexpression was  reported in two hepatocellular carcinoma cases which harboured 
mutations in PIK3CA (PI3K, catalytic alpha polypeptide) along with activation of the 
Akt pathway (Boyault et al., 2007). As eEF1A2 has been associated with the mediation 
of cell motility in a PI3K/Akt dependent manner (Amiri et al., 2007), it is possible that 
upregulation of eEF1A2 might foster Akt signalling which is activated in a large 
proportion of human HCC (Schlaeger et al., 2008), but this requires further analysis. 
   
Using immunohistochemistry on two malignant melanoma arrays, this study 
showed that overall, eEF1A1 was significantly overexpressed only in 10% of tumours 
(7/71) whereas eEF1A2 was highly abundant in about 24% (17/71) cases.                            
There are no other reports about expression of eEF1A1 and eEF1A2 at the protein level. 
As for the gene analyses, abundance of EEF1A2 transcript was reported for two highly 
metastatic malignant melanoma cell lines but not for the poorly metastatic 1F6 line 
(Joseph et al., 2004, de Wit et al., 2002). On the other hand, a gradual increase in mRNA 
expression of eEF1A2 was seen in patients‟ lesions representing chronological stages of 
melanocytic tumour progression (de Wit et al., 2002). The engagement of eEF1A                   
in malignant melanoma remains unclear; however, it would be interesting to test 
expression of eEF1A2 at the protein level at different stages of melanoma progression, 




expression correlates with any tumour stage. There were more cases with moderate and 
strong staining for both eEF1A forms on the array obtained from Folio Biosciences than 
on the array from Biomax. Even though clinicopathological features other than age and 
sex were not provided, it is very likely that the cores on each array represent different 
proportions of tumour staging, which might explain discrepancies between arrays,                 
if indeed expression of eEF1A2 is dependent on tumour progression. As these arrays 
were manufactured by different companies, it is also possible that any discrepancies                      
in tissue fixation or storage could have an influence on the overall outcome of the 
eEF1A staining. 
 
The most obvious differences between expression of eEF1A variants were 
observed in the immunostaining of colorectal cancer arrays. Overall, only 4% of 
colorectal tumours showed significant overexpression of eEF1A1; however, only 26 
cancers were tested for eEF1A1 immunopositivity in the studies herein. In contrast, 
upregulated eEF1A2 was seen in a high proportion (43%; 37/87) of primary colorectal 
tumours. The majority of tumours presented with a lack of regional lymph node 
metastasis, which was significantly associated with eEF1A2 expression (negative and 
weak). As the number of tumour-positive lymph nodes increased, there were as many 
tumours exhibiting negative or weak eEF1A2 staining as cores displaying moderate and 
strong eEF1A2 expression. A similar association was noticed between the lack of distant 
metastasis and eEF1A2 immunostaining; however, this relationship was not statistically 
significant. Even though this needs to be confirmed with a larger number of samples, 
along with clinical information, these preliminary data suggest that eEF1A2 expression 
status might be associated with early events in colorectal carcinogenesis.  
How eEF1A2 could contribute to colorectal cancer remains unclear but these 
immunohistochemical studies support the observations obtained earlier in the laboratory, 
as in these studies too, eEF1A2 was found to be upregulated in a high proportion of 
primary colorectal carcinoma cases. In addition, analyses of EEF1A2 copy number and 
methylation status by real-time PCR and bisulfite-PCR in a few CRC cell lines indicated 




drive eEF1A2 overexpression (Jan Bergmann, unpublished data). Another possible 
explanation is that upregulation of eEF1A2 is triggered by changes in the specific 
microRNA expression pattern. More recently, using a combination of sequence-based 
matches and hybridization energy, Lee and colleagues identified a new class of 
microRNAs called miBridge which have the ability to interact simultaneously with 
specific sites in the 5‟ and 3‟ UTR of target mRNAs. Among the predicted mRNAs, 
eEF1A2 was a potential target of miBridge candidate miR-663 (Lee et al., 2009a).  
Interestingly, miR-663 belongs to the colorectal microRNAome and was implicated              
as a tumour suppressor since it was downregulated in 5 human gastric cancer cell lines 
when compared to normal gastric cells profile (Cummins et al., 2006b, Pan et al., 2010). 
When miR-663 was re-introduced into BGC823 and SNU5 gastric cancer cell lines, 
decreased proliferation in vitro, chromosomal aberrations alongside mitotic catastrophe,                       
and reduced tumour growth in vivo in xenografted mice were reported (Pan et al., 2010). 
Since the in situ predicted interaction sites for miR-663 are within both untranslated 
regions of eEF1A2 (Lee et al., 2009a), it suggests this microRNA might be a critical 
regulator of eEF1A2 abundance in the cell. This is highly intriguing, especially that 
resveratrol treatment of SW480 colon adenocarcinoma cells resulted in upregulation                  
of miR-663 (Tili et al., 2010). Resveratrol (trans-3,4‟,5-trihydroxystilbene)                           
is an antioxidant derived from grapes and other plants which has shown cardiovascular 
and cancer preventive properties and is used in the human cancer prevention preclinical 
studies. It induces apoptosis through upregulation of proapoptotic genes and 
concurrently reduces expression of anti-apoptotic genes (Tili et al., 2010). Furthermore, 
NIH-3T3 cells stably transfected with eEF1A2 exhibited reduced anchorage independent 
growth after treatment with resveratrol and resveratrol downregulated eEF1A2                  
in insulin- or serum- stimulated PA-1 ovarian cancer cells (Lee et al, 2009b). It would be 
interesting to assess experimentally whether eEF1A2 is a true target for miR-663 and              
if there are any correlations in expression between them in normal colon, colorectal 
tumours and colorectal cancer cell lines. 
On the other hand, if upregulated eEF1A2 is indeed engaged in the early events 




cytoskeletal rearrangements. Such changes in the cytoskeleton contribute to an increase 
in carcinoma cell motility and a more aggressive tumour phenotype. In a yeast                     
two-hybrid approach of a mouse brain cDNA library, eEF1A2 was used as bait and 
fascin was reported as an interacting partner alongside other cytoskeleton proteins,                
for example ABP280 (filamin) and RanBPM (Ran-binding protein in the microtubule-
organizing center) (Chang and Wang, 2006). Fascin is an actin-bundling protein which 
is absent from normal colorectal epithelial cells but shows significant cytoplasmic 
subcellular distribution when these become neoplastic. Since it is upregulated in benign 
adenomas and promotes motility in adenoma cells in vitro, fascin is implicated                
as an early biomarker for more aggressive colorectal adenocarcinomas (Hashimoto et al., 
2006, Qualtrough et al., 2009). It would be interesting to establish whether these two 
proteins cooperate in colorectal tumours and whether there is any functional significance 
in this interaction for tumour invasion and metastasis. 
 
In summary, eEF1A2 was expressed in a large proportion of colorectal tumours 
(43%) at a moderate to high level but no obvious upregulation of this elongation factor 
was observed among cutaneous and hepatocellular malignancies. In contrast, eEF1A1 
expression remained near constant in colorectal, skin and liver cancers when compared 
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Chapter 6: General discussion 
 
6.1 Summary of results 
  
 Protein synthesis is crucial for the proper functioning of cells and alterations in 
the activity and control of translational machinery have been implicated in multiple 
diseases, including cancer (Le Quesne at al., 2009). Eukaryotic translation elongation 
factor 1A is responsible for the delivery of the aa-tRNA to the A-site of the ribosome 
upon guanine nucleotide exchange but apart from its obvious role in protein synthesis,               
it has been linked to other cellular processes. During the last decade, eEF1A2 has been 
implicated as an oncogene (Anand et al., 2002). Despite numerous studies on the role 
and expression status of eEF1A2 in tumourigenesis, the precise mechanism responsible 
for oncogenicity remains unknown. Furthermore, there is currently no detailed 
information about any contribution of eEF1A1 to cancer progression. The main 
objectives of this project were to compare the significance of both eEF1A forms in 
oncogenesis, and to establish their distribution in cancer types in which eEF1A 
expression has not previously been investigated in detail. 
 In order to look at eEF1A1 and eEF1A2 properties in cells, constructs carrying 
each variant coding sequence with or without its own 5‟UTR, and each variant with the 
5‟UTR from the other eEF1A form, were introduced to NIH-3T3 fibroblasts either 
transiently or constitutively. The data from transient experiments revealed that 
incorporation of human eEF1A1 and eEF1A2 led to a decrease in endogenous eEF1A1 
expression at the mRNA and protein level. A more substantial decline was seen when 
any of the 5‟UTR was present. Dynamic interplay between eEF1A forms was identified 
within the first 24 hours after transfection but once the expression of the exogenous 
variants started to decrease, endogenous eEF1A1 returned to the same level as that seen 
in controls. In almost all stable cell lines, the levels of endogenous eEF1A1 remained 
roughly the same, at both the mRNA and protein level, as in control clones.                       
Overall, cellular levels of eEF1A1 appear to be subjected to tight regulation.  
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Stable cell lines which were generated in this thesis were subjected to various             
in vitro tumourigenicity assays.  NIH-3T3 cells developed neoplastic transformation 
upon ectopic expression of eEF1A1 by producing foci and gaining anchorage-
independent growth in soft agar. They did not, however, show any substantial increase 
in proliferation. The incorporation of chimeric 5‟UTRs into the eEF1A1 construct 
almost completely abolished clonogenicity in soft agar and reduced foci formation, even 
though these lines displayed increased proliferation rates. On the other hand, forced 
expression of eEF1A2 into mouse fibroblasts resulted in the most aggressive phenotype 
and heightened proliferation. Significantly lowered transforming capacity was seen in 
eEF1A2 clones with the addition of any of the 5‟UTRs, but it did not result in the full 
annulment of the neoplastic phenotype.  The 5‟UTR from eEF1A2 appeared to influence 
cellular proliferation and clones with its addition were characterised by a higher growth 
rate than clones carrying constructs with the 5‟UTR derived from eEF1A1.                         
With the exception of a few clones, there was no apparent increase in migration and 
invasion of the cell lines stably expressing eEF1A. Increased levels of overall eEF1A 
protein in different stable cell lines appeared to correlate only partially with elevated 
protein synthesis rate but not with transformed phenotype. Therefore, another 
mechanism than eEF1A-mediated increase in protein synthesis might be responsible for 
driving oncogenesis. Alterations in phosphorylation of either eEF1A1 or eEF1A2                               
are an attractive possibility linking eEF1A and tumourigenesis (Soares et al., 2009,                 
Lin at al., 2010).  
 In this study, moderate to high expression of eEF1A2 protein was observed     
in 43% of colorectal cancers analysed. In one of the colorectal tumour arrays,                         
the level of eEF1A2 expression appeared to be inversely correlated (P = 0.024)                       
with metastasis in lymph nodes. Furthermore, no substantial upregulation of eEF1A2          
at the protein level was seen in hepatocellular carcinoma and malignant melanoma 
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6.2  Future work 
 
6.2.1 The role of eEF1A in oncogenesis 
 
More extensive analyses are necessary to shed light on mechanisms by which 
eEF1A1 and eEF1A2 could act as oncogenes. As the data from studies on translation 
rates in stable cell lines were variable, it is necessary to repeat these experiments.                 
In addition, HCT116 colorectal cancer cell lines (which express both eEF1A forms)   
with constitutive knockdowns of eEF1A1 and eEF1A2 are available in the laboratory. 
They could be used to determine whether lowered expression of any eEF1A variant is 
sufficient to abolish the transformed phenotype and whether there is any effect on 
overall protein synthesis rate. Methods described within this thesis could be performed 
to verify the above issues. 
Moreover, the A2 stable cell lines described herein were subjected to analysis 
using mouse whole-genome expression microarrays by fellow PhD student Mariam 
Fida. She investigated changes in gene expression which occur when eEF1A2 is 
constantly upregulated and searched for candidates correlating with human 
tumourigenesis.  Several plausible candidates were indentified, including Srpx2 (Sushi 
repeat containing protein, X-linked 2) and Tpd52 (tumour protein D52) genes which 
were upregulated by more than 2-fold, whereas Rhox5 (reproductive homeobox on the X 
chromosome 5) was lowered almost 5-fold.  SRPX2 is overexpressed in human gastric 
cancer cells and is associated with enhanced cellular motility and adhesion (Tanaka et 
al., 2009). TPD52 is upregulated in many cancers and when it is ectopically 
overexpressed in mouse fibroblasts, a neoplastic phenotype and progression to 
metastasis were observed (Lewis at al., 2007). RHOX5 was reported to be upregulated 
by therapeutic epigenetic drugs in breast and colon cancer cells                                                    
(Li et al., 2009).  It would be of interest to look whether changes at the mRNA level 
reflect alterations at the protein levels, for example using stable isotope labelling by 
amino acids in cell culture (SILAC) approach (Ong et al., 2002). It could be also verified 
at the RNA and protein level whether similar changes in expression of the above 
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candidates are seen in eEF1A2-transiently transfected cells. Some of these experiments 
are currently in progress (Mariam Fida). If alterations in plausible candidates expression 
are not observed in transient experiments but indeed, only in A2 stable cell lines,                   
then perhaps eEF1A2 upregulation has more long-term impact on these candidates and 
inappropriately expressed eEF1A2 is a prerequisite for the sequence of events which 
lead to tumour development. If so, then it is interesting to test whether these proteins 
could interact directly or indirectly with eEF1A2 in vitro and in vivo using yeast                      
two-hybrid and co-localisation approaches. In case where interaction with eEF1A2          
is confirmed, it would be essential to look if transformed phenotype is affected.                       
The experiments would involve searching for cell lines with high and low levels of 
candidates and eEF1A2 in order to create stable double knockdowns and double 
overexpressions. Stable cell lines would be then tested for response to apoptosis, rates of 
proliferation, alterations in neoplastic phenotype along with migration and invasion. 
 
6.2.2 The mechanism responsible for eEF1A2 oncogenicity 
 
The precise mechanism by which eEF1A2 becomes upregulated in different 
tumours remains unclear but perhaps looking into any differences in the phosphorylation 
status between tumour and normal tissues would give some clues.  Two serine residues 
(Ser358 and Ser393) appear to be attractive candidates for such modification, especially 
as they are strictly conserved in other species that express eEF1A2 and because these are 
equally well conserved as alanine and phenylalanine in eEF1A1 (Soares et al., 2009). 
Phosphorylation of these sites could be confirmed by mass spectrometry and specific 
phospho-antibodies could also be raised to investigate any possible association with 
tumourigenesis. If there is any difference in phosphorylation pattern at these residues 
between normal and cancer cells, phosphorylation mimics could be created through 
mutagenesis of serines to aspartic acid, glutamic acid and also to the non-
phosphorylatable equivalent residues of eEF1A1. Such generated cell lines could be 
subsequently tested in a repertoire of transformation assays as described herein. It would 
                                                                                                                            
211 
 
be also informative to determine whether eEF1A2 was phosphorylated at these candidate 
residues in the neoplastic stable cell lines described in this thesis.  
Potentially, any differences in the phosphorylation pattern between eEF1A forms 
might shed some light into their oncogenic capacity. Threonines at positions 217 and 
227 are eEF1A1-specific candidate residues for phosphorylation (Soares et al, 2009).  In 
order to address these questions, similar experiments could be executed as described 
above for the eEF1A2 variant. In addition, to gain more knowledge about the 
phosphorylation status of eEF1A1, it would be interesting to check the phosphorylation 
of serine at residue 300 in transformed eEF1A1 stable cell lines and different tumours or 
cancer cell lines. Lin et al. observed that TβR-I (transforming growth factor β type I 
receptor)-mediated phosphorylation of eEF1A1 at Ser300 is associated with inhibition of 
protein synthesis and proliferation. Phosphorylation of Ser300 was also decreased in 
human breast tumours (Lin et al., 2010). It is noteworthy that this serine position and the 
surrounding amino acids are exactly the same in both eEF1A1 and eEF1A2 sequence. 
Hence, it should be determined whether a similar functional significance is true for 
eEF1A2, but as the amino acid context is identical, it becomes more difficult to track the 
biological meaning for eEF1A variants independently. Cell lines with mimicked 
versions of candidate phosphorylation sites in eEF1A1 and eEF1A2 need to be tested for 
possible alterations in protein synthesis rates. 
Currently many studies of the development of different tumours show alterations 
in the microRNA expression pattern between normal and cancer tissues.                           
Therefore, significant upregulation of eEF1A2 in cancer could be mediated by                        
the inappropriate expression of specific microRNAs, and candidates discussed                     
in Chapters 1 and 5 would be the obvious choices to investigate. This would initially 
involve looking into the correlation between expression levels of eEF1A2 and let-7f       
or miR-663 in normal and tumour cell lines of different origins using real-time PCR. 
Plausible candidates could be then either overexpressed or downregulated                          
using precursor molecules or inhibitors to see if they trigger any differences in eEF1A2 
expression at the mRNA and protein level. It cannot be ruled out that a microRNA-
mediated effect on eEF1A2 abundance is driven indirectly, therefore using                       
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co-transfections of precursors or inhibitors with expression vectors containing a reporter 
linked to the 3‟UTR (and 5‟UTR for experiments with miR-663) from eEF1A2 could 
shed some light on this.  
Ultimately, if there is no correlation between eEF1A2 upregulation and these 
candidates, microRNA microarrays could be applied to cell lines with eEF1A2 knock 
down and overexpression to search for new candidates for eEF1A2 control.  
 
6.2.3 Expression of eEF1A in colon, liver and skin cancer 
 
Immunohistochemical analysis of eEF1A2 expression in colorectal tumours 
suggests it could be a useful biomarker in this malignancy. Expanding these studies to a 
larger number of tumour samples and to the relationships between levels of protein 
expression and histopathological variables would give more insight into the role of 
eEF1A2 in colon cancer. Professor David Harrison has established a library of several 
hundred clinical samples of colorectal carcinoma cases, supported with clinical features 
and follow up history.  eEF1A2 expression could be therefore monitored on a large scale 
at the protein and mRNA levels and survival prognosis could be established.                                
As studies in the normal colon show that eEF1A2 is present in single cells of colonic 
crypts, it is intriguing how this expression pattern changes and expands in colorectal 
tumours. Hence, it is necessary to test the expression status of eEF1A2 at different 
stages of this cancer development to establish the exact point at which eEF1A2 becomes 
inappropriately expressed.  Moreover, this study showed that there was no significant 
upregulation of eEF1A2 in hepatocellular carcinoma and melanoma cases. 
Consequently, it would be interesting to test what exactly happens with eEF1A2 in liver 
and skin cancers that makes it of less importance in these particular malignancies.                    
It would require to screen for any changes in eEF1A2 expression at the mRNA level and 
to look into gene amplification status, methylation status or any mutations of eEF1A2 in 
tumour samples and corresponding tumour cell lines. Are there any direct inhibitors of 
eEF1A2 upregulation in these malignancies? Is there only one dominant mechanism or 
is it rather a multilayered deregulation that drives the oncogenicity of eEF1A2 in 
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different tumours? Are these mechanisms cancer type specific and do they depend on 
genetic background? These questions remain open for further investigation. 
These studies have to be simultaneously expanded to eEF1A1 expression in more 
cases of colon, skin and liver tumours in order to determine whether eEF1A1 remains 
truly unchanged at the mRNA and protein level. If so, it is necessary to investigate what 
mechanism could be responsible for such an effect. Using real-time PCR and Western 
blotting would help to establish whether this level is quantitatively comparable to that 
seen in the corresponding normal tissues as, for example, liver is an organ with a very 
high abundance of eEF1A1. On the other hand, what is the biological significance of 
eEF1A1 if it is only slightly upregulated as shown in several tumour cases within this 
study? As eEF1A1 is implicated in pro-apoptotic functioning, is this some sort of a 
defence mechanism that is induced to protect this organ from cancer? Answers to these 
questions remain unknown. 
 
 
6.3 Concluding remarks 
 
This study provides further insight into how eEF1A1 and eEF1A2 function                 
in transformation, looks into the relationship between eEF1A and translation and cancer, 
elucidates the expression status of eEF1A proteins in certain tumours, and for the first 
time, shows that eEF1A1 can act as an oncogene under certain circumstances. 
Undoubtedly, further investigation is necessary to determine the specific mechanism by 
which eEF1A2 is upregulated and linked to development of various neoplasms.                
More work is also required to establish to what extent a vast repertoire of non-canonical 
functions is shared between eEF1A variants and whether these functions have any 














ABRAMOFF, M. D., MAGELHAES, P. J. & RAM, S. J. 2004. Image Processing with ImageJ. 
Biophotonics International, 11, 36-42. 
 
ALBINI, A., IWAMOTO, Y., KLEINMAN, H. K., MARTIN, G. R., AARONSON, S. A., 
KOZLOWSKI, J. M. & MCEWAN, R. N. 1987. A rapid in vitro assay for quantitating the invasive 
potential of tumor cells. Cancer Res, 47, 3239-45. 
 
ALON, U., BARKAI, N., NOTTERMAN, D. A., GISH, K., YBARRA, S., MACK, D. & LEVINE, A. J. 
1999. Broad patterns of gene expression revealed by clustering analysis of tumor and normal 
colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A, 96, 6745-50. 
 
AMERICAN CANCER SOCIETY. Cancer facts and figures 2010. Atlanta: American Cancer 
Society 2010. 
 
AMIRI, A., NOEI, F., JEGANATHAN, S., KULKARNI, G., PINKE, D. E. & LEE, J. M. 2006. 
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. 
Oncogene, 26, 3027-40. 
 
ANAND, N., MURTHY, S., AMANN, G., WERNICK, M., PORTER, L. A., CUKIER, I. H., 
COLLINS, C., GRAY, J. W., DIEBOLD, J., DEMETRICK, D. J. & LEE, J. M. 2002.                          
Gene encoding protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. 
Nature Genetics, 31, 301-305. 
 
ANDERSEN, G. R., PEDERSEN, L., VALENTE, L., CHATTERJEE, I., KINZY, T. G., 
KJELDGAARD, M. & NYBORG, J. 2000. Structural basis for nucleotide exchange and 
competition with tRNA in the yeast elongation factor complex eEF1A:eEF1Balpha.                                 
Mol Cell, 6, 1261-6. 
 
ANDERSEN, G. R., VALENTE, L., PEDERSEN, L., KINZY, T. G. & NYBORG, J. 2001.             
Crystal structures of nucleotide exchange intermediates in the eEF1A-eEF1Balpha complex.      
Nat Struct Biol, 8, 531-4. 
 
ANDERSEN, K. M., MADSEN, L., PRAG, S., JOHNSEN, A. H., SEMPLE, C. A., HENDIL, K. B. 
& HARTMANN-PETERSEN, R. 2009. Thioredoxin Txnl1/TRP32 is a redox-active cofactor of the 
26 S proteasome. J Biol Chem, 284, 15246-54. 
 
ANN, D. K., LIN, H. H., LEE, S., TU, Z. J. & WANG, E. 1992. Characterization of the statin-like 
S1 and rat elongation factor 1 alpha as two distinctly expressed messages in rat.                                    
J Biol Chem, 267, 699-702. 
 
ANN, D. K., MOUTSATSOS, I. K., NAKAMURA, T., LIN, H. H., MAO, P. L., LEE, M. J., CHIN, 
S., LIEM, R. K. & WANG, E. 1991. Isolation and characterization of the rat chromosomal gene 
for a polypeptide (pS1) antigenically related to statin. J Biol Chem, 266, 10429-37. 
 
ARAVALLI, R. N., STEER, C. J. & CRESSMAN, E. N. 2008. Molecular mechanisms of 
hepatocellular carcinoma. Hepatology, 48, 2047-63. 
 
                                                                                                                            
215 
 
AUST, D. E., MUDERS, M., KOHLER, A., SCHMIDT, M., DIEBOLD, J., MULLER, C.,               
LOHRS, U., WALDMAN, F. M. & BARETTON, G. B. 2004. Prognostic relevance of 20q13 gains 
in sporadic colorectal cancers: a FISH analysis. Scand J Gastroenterol, 39, 766-72. 
 
AVNI, D., BIBERMAN, Y. & MEYUHAS, O. 1997. The 5' terminal oligopyrimidine tract confers 
translational control on TOP mRNAs in a cell type- and sequence context-dependent manner. 
Nucleic Acids Res, 25, 995-1001. 
 
AVNI, D., SHAMA, S., LORENI, F. & MEYUHAS, O. 1994. Vertebrate mRNAs with a 5'-terminal 
pyrimidine tract are candidates for translational repression in quiescent cells: characterization of 
the translational cis-regulatory element. Mol Cell Biol, 14, 3822-33. 
 
BAG, J. 2001. Feedback inhibition of poly(A)-binding protein mRNA translation. A possible 
mechanism of translation arrest by stalled 40 S ribosomal subunits. J Biol Chem, 276, 47352-60. 
 
BALMANA, J., CASTELLS, A. & CERVANTES, A. 2010. Familial colorectal cancer risk: ESMO 
Clinical Practice Guidelines. Ann Oncol, 21 Suppl 5, v78-81. 
 
BASSELL, G. J., POWERS, C. M., TANEJA, K. L. & SINGER, R. H. 1994. Single mRNAs 
visualized by ultrastructural in situ hybridization are principally localized at actin filament 
intersections in fibroblasts. J Cell Biol, 126, 863-76. 
 
BATULAN, Z., SHINDER, G. A., MINOTTI, S., HE, B. P., DOROUDCHI, M. M., 
NALBANTOGLU, J., STRONG, M. J. & DURHAM, H. D. 2003. High threshold for induction of 
the stress response in motor neurons is associated with failure to activate HSF1.                                    
J Neurosci, 23, 5789-98. 
 
BISCHOFF, C., KAHNS, S., LUND, A., JORGENSEN, H. F., PRAESTEGAARD, M., CLARK, B. 
F. & LEFFERS, H. 2000. The human elongation factor 1 A-2 gene (EEF1A2): complete 
sequence and characterization of gene structure and promoter activity. Genomics, 68, 63-70. 
 
BLAIR, D. G., COOPER, C. S., OSKARSSON, M. K., EADER, L. A. & VANDE WOUDE, G. F. 
1983. Tumorigenesis by transected cells in nude mice: a new method for detecting cellular 
transforming genes. Prog Clin Biol Res, 119, 79-90. 
 
BOARDMAN, P. E., SANZ-EZQUERRO, J., OVERTON, I. M., BURT, D. W., BOSCH, E., FONG, 
W. T., TICKLE, C., BROWN, W. R., WILSON, S. A. & HUBBARD, S. J. 2002. A comprehensive 
collection of chicken cDNAs. Curr Biol, 12, 1965-9. 
 
BOHNSACK, M. T., REGENER, K., SCHWAPPACH, B., SAFFRICH, R., PARASKEVA, E., 
HARTMANN, E. & GORLICH, D. 2002. Exp5 exports eEF1A via tRNA from nuclei and 
synergizes with other transport pathways to confine translation to the cytoplasm.                              
EMBO J, 21, 6205-15. 
 
BOLAND, C. R. & GOEL, A. 2010. Microsatellite instability in colorectal cancer. 
Gastroenterology, 138, 2073-2087 e3. 
 
BOYAULT, S.,RICKMAN, D.S., de REYNIES, A., BALABAUD, C., REBOUISSOU, S., 
JEANNOT, E., HERAULT, A., SARIC, J., BELGHITI, J., FRANCO, D., BIOULAC-SAGE, P., 
LAURENT-PUIG, P., ZUCMAN-ROSSI, J. 2007. Transcriptome classification of HCC is related 
to gene alterations and to new therapeutic targets. Hepatology, 45, 42-52. 
 
                                                                                                                            
216 
 
BRAAKHUIS, B. J., TABOR, M. P., KUMMER, J. A., LEEMANS, C. R. & BRAKENHOFF, R. H. 
2003. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical 
implications. Cancer Res, 63, 1727-30. 
 
BREKHMAN, V. & NEUFELD, G. 2009. A novel asymmetric 3D in-vitro assay for the study of 
tumor cell invasion. BMC Cancer, 9, 415. 
 
BUNNEY, T. D. & KATAN, M. 2010. Phosphoinositide signalling in cancer: beyond PI3K and 
PTEN. Nat Rev Cancer, 10, 342-52. 
 
CALADO, A., TREICHEL, N., MULLER, E. C., OTTO, A. & KUTAY, U. 2002. Exportin-5-
mediated nuclear export of eukaryotic elongation factor 1A and tRNA. EMBO J, 21, 6216-24. 
 
CALDAROLA, S., AMALDI, F., PROUD, C. G. & LORENI, F. 2004. Translational regulation of 
terminal oligopyrimidine mRNAs induced by serum and amino acids involves distinct signaling 
events. J Biol Chem, 279, 13522-31. 
 
CALDERWOOD, S. K., KHALEQUE, M. A., SAWYER, D. B. & CIOCCA, D. R. 2006. Heat shock 
proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci, 31, 164-72. 
 
CANS, C., PASSER, B. J., SHALAK, V., NANCY-PORTEBOIS, V., CRIBLE, V., AMZALLAG, N., 
ALLANIC, D., TUFINO, R., ARGENTINI, M., MORAS, D., FIUCCI, G., GOUD, B., MIRANDE, M., 
AMSON, R. & TELERMAN, A. 2003. Translationally controlled tumor protein acts as a guanine 
nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci U 
S A, 100, 13892-7. 
 
CAO, H., ZHU, Q., HUANG, J., LI, B., ZHANG, S., YAO, W. & ZHANG, Y. 2009. Regulation and 
functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun, 380, 11-6. 
 
CARNEIRO, N. P., HUGHES, P. A. & LARKINS, B. A. 1999. The eEFIA gene family is 
differentially expressed in maize endosperm. Plant Mol Biol, 41, 801-13. 
 
CARR-SCHMID, A., VALENTE, L., LOIK, V. I., WILLIAMS, T., STARITA, L. M. & KINZY, T. G. 
1999. Mutations in elongation factor 1beta, a guanine nucleotide exchange factor, enhance 
translational fidelity. Mol Cell Biol, 19, 5257-66. 
 
CHAMBERS, D. M., PETERS, J. & ABBOTT, C. M. 1998. The lethal mutation of the mouse 
wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation 
elongation factor 1alpha, encoded by the Eef1a2 gene. Proc Natl Acad Sci U S A, 95, 4463-8. 
 
CHANG, R. & WANG, E. 2007. Mouse translation elongation factor eEF1A-2 interacts with Prdx-
I to protect cells against apoptotic death induced by oxidative stress.                                                             
J Cell Biochem, 100, 267-78. 
 
CHEKULAEVA, M. & FILIPOWICZ, W. 2009. Mechanisms of miRNA-mediated post-
transcriptional regulation in animal cells. Curr Opin Cell Biol, 21, 452-60. 
 
CHEN, E., PROESTOU, G., BOURBEAU, D. & WANG, E. 2000. Rapid up-regulation of peptide 
elongation factor EF-1alpha protein levels is an immediate early event during oxidative stress-
induced apoptosis. Exp Cell Res, 259, 140-8. 
 
 
CHODNIEWICZ, D. & KLEMKE, R. L. 2004. Guiding cell migration through directed extension 
and stabilization of pseudopodia. Exp Cell Res, 301, 31-7. 




CHUANG, S. M., CHEN, L., LAMBERTSON, D., ANAND, M., KINZY, T. G. & MADURA, K. 
2005. Proteasome-mediated degradation of cotranslationally damaged proteins involves 
translation elongation factor 1A. Mol Cell Biol, 25, 403-13. 
 
CIOCCA, D. R. & CALDERWOOD, S. K. 2005. Heat shock proteins in cancer: diagnostic, 
prognostic, predictive, and treatment implications. Cell Stress Chaperones, 10, 86-103. 
 
CONDEELIS, J. 1995. Elongation factor 1 alpha, translation and the cytoskeleton.                        
Trends Biochem Sci, 20, 169-70. 
 
CREW, J. P., FUGGLE, S., BICKNELL, R., CRANSTON, D. W., DE BENEDETTI, A. & HARRIS, 
A. L. 2000. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and 
its correlation with vascular endothelial growth factor expression and tumour progression. Br J 
Cancer, 82, 161-6. 
 
CRICK, F. 1970. Central dogma of molecular biology. Nature, 227, 561-3. 
 
CUMMINS, D. L., CUMMINS, J. M., PANTLE, H., SILVERMAN, M. A., LEONARD, A. L. & 
CHANMUGAM, A. 2006a. Cutaneous malignant melanoma. Mayo Clin Proc, 81, 500-7. 
 
CUMMINS, J. M., HE, Y.,  LEARY, R. J., PAGLIARINI, R.,  DIAZ, L. A., SJOBLOM, T.,  BARAD, 
O., BENTWICH, Z., SZAFRANSKA, A. E., LABOURIER, E., RAYMOND, C. K., ROBERTS, B. 
S., JUHL, H., KINZLER, K. W., VOGELSTEIN, B. & VELCULESCU, V. E. 2006b. The colorectal 
microRNAome. Proc Natl Acad Sci U S A, 103, 3687-92. 
 
DAHIYA, N., SHERMAN-BAUST, C. A., WANG, T. L., DAVIDSON, B., SHIH IE, M., ZHANG, Y., 
WOOD, W., 3RD, BECKER, K. G. & MORIN, P. J. 2008. MicroRNA expression and identification 
of putative miRNA targets in ovarian cancer. PLoS One, 3, e2436. 
 
DAKUBO, G. D., JAKUPCIAK, J. P., BIRCH-MACHIN, M. A. & PARR, R. L. 2007. Clinical 
implications and utility of field cancerization. Cancer Cell Int, 7, 2. 
 
DE MOOR, C. H., MEIJER, H. & LISSENDEN, S. 2005. Mechanisms of translational control by 
the 3' UTR in development and differentiation. Semin Cell Dev Biol, 16, 49-58. 
 
DE WIT, N. J., BURTSCHER, H. J., WEIDLE, U. H., RUITER, D. J. & VAN MUIJEN, G. N. 2002. 
Differentially expressed genes identified in human melanoma cell lines with different metastatic 
behaviour using high density oligonucleotide arrays. Melanoma Res, 12, 57-69. 
 
DEMMA, M., WARREN, V., HOCK, R., DHARMAWARDHANE, S. & CONDEELIS, J. 1990. 
Isolation of an abundant 50,000-dalton actin filament bundling protein from Dictyostelium 
amoebae. J Biol Chem, 265, 2286-91. 
 
DEVER, T. E., COSTELLO, C. E., OWENS, C. L., ROSENBERRY, T. L. & MERRICK, W. C. 
1989. Location of seven post-translational modifications in rabbit elongation factor 1 alpha 
including dimethyllysine, trimethyllysine, and glycerylphosphorylethanolamine.                                         
J Biol Chem, 264, 20518-25. 
 
DEVER, T. E., GLYNIAS, M. J. & MERRICK, W. C. 1987. GTP-binding domain: three consensus 
sequence elements with distinct spacing. Proc Natl Acad Sci U S A, 84, 1814-8. 
DHARMAWARDHANE, S., DEMMA, M., YANG, F. & CONDEELIS, J. 1991. 
Compartmentalization and actin binding properties of ABP-50: the elongation factor-1 alpha of 
Dictyostelium. Cell Motil Cytoskeleton, 20, 279-88. 




DJE, M. K., MAZABRAUD, A., VIEL, A., LE MAIRE, M., DENIS, H., CRAWFORD, E. & BROWN, 
D. D. 1990. Three genes under different developmental control encode elongation factor 1-alpha 
in Xenopus laevis. Nucleic Acids Res, 18, 3489-93. 
 
DONG, H., GE, X., SHEN, Y., CHEN, L., KONG, Y., ZHANG, H., MAN, X., TANG, L., YUAN, H., 
WANG, H., ZHAO, G. & JIN, W. 2009. Gene expression profile analysis of human hepatocellular 
carcinoma using SAGE and LongSAGE. BMC Med Genomics, 2, 5. 
 
DONG, X. Y., RODRIGUEZ, C., GUO, P., SUN, X., TALBOT, J. T., ZHOU, W., PETROS, J., LI, 
Q., VESSELLA, R. L., KIBEL, A. S., STEVENS, V. L., CALLE, E. E. & DONG, J. T. 2008. 
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with 
clinically significant prostate cancer. Hum Mol Genet, 17, 1031-42. 
 
DONZE, O., JAGUS, R., KOROMILAS, A. E., HERSHEY, J. W. & SONENBERG, N. 1995. 
Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation 
of NIH 3T3 cells. Embo J, 14, 3828-34. 
 
DURSO, N. A. & CYR, R. J. 1994. A calmodulin-sensitive interaction between microtubules and 
a higher plant homolog of elongation factor-1 alpha. Plant Cell, 6, 893-905. 
 
DUTTAROY, A., BOURBEAU, D., WANG, X. L. & WANG, E. 1998. Apoptosis rate can be 
accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 
alpha. Exp Cell Res, 238, 168-76. 
 
ECKHARDT, K., TROGER, J., REISSMANN, J., KATSCHINSKI, D. M., WAGNER, K. F., 
STENGEL, P., PAASCH, U., HUNZIKER, P., BORTER, E., BARTH, S., SCHLAFLI, P., 
SPIELMANN, P., STIEHL, D. P., CAMENISCH, G. & WENGER, R. H. 2007. Male germ cell 
expression of the PAS domain kinase PASKIN and its novel target eukaryotic translation 
elongation factor eEF1A1. Cell Physiol Biochem, 20, 227-40. 
 
EDMONDS, B. T., MURRAY, J. & CONDEELIS, J. 1995. pH regulation of the F-actin binding 
properties of Dictyostelium elongation factor 1 alpha. J Biol Chem, 270, 15222-30. 
 
EDMONDS, B. T., WYCKOFF, J., YEUNG, Y. G., WANG, Y., STANLEY, E. R., JONES, J., 
SEGALL, J. & CONDEELIS, J. 1996. Elongation factor-1 alpha is an overexpressed actin 
binding protein in metastatic rat mammary adenocarcinoma. J Cell Sci, 109 ( Pt 11), 2705-14. 
 
EJIRI, S.-I. 2002. Moonlighting functions of polypeptide elongation factor 1: from actin bundling 
to zinc finger protein  R1- associated nuclear localization. Biosci. Biotechnol. Biochem., 66, 1-21. 
 
ESQUELA-KERSCHER, A. & SLACK, F. J. 2006. Oncomirs - microRNAs with a role in cancer. 
Nat Rev Cancer, 6, 259-69. 
 
FARAZI, P. A. & DEPINHO, R. A. 2006. Hepatocellular carcinoma pathogenesis: from genes to 
environment. Nat Rev Cancer, 6, 674-87. 
 
FECHER, L. A., CUMMINGS, S. D., KEEFE, M. J. & ALANI, R. M. 2007. Toward a molecular 
classification of melanoma. J Clin Oncol, 25, 1606-20. 
 
FERLAY, J., PARKIN, D. M. & STELIAROVA-FOUCHER, E. 2010a. Estimates of cancer 
incidence and mortality in Europe in 2008. Eur J Cancer, 46, 765-81. 
 
                                                                                                                            
219 
 
FERLAY, J., SHIN, H. R., BRAY, F., FORMAN, D., MATHERS, C. & PARKIN, D. M. 2010b. 
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (ahead of 
print). 
 
FRAZIER, M. L., INAMDAR, N., ALVULA, S., WU, E. & KIM, Y. H. 1998. Few point mutations in 
elongation factor-1gamma gene in gastrointestinal carcinoma. Mol Carcinog, 22, 9-15. 
 
GOLDSTEIN, B. G. & GOLDSTEIN, A. O. 2001. Diagnosis and management of malignant 
melanoma. Am Fam Physician, 63, 1359-68, 1374. 
 
GONEN, H., SMITH, C. E., SIEGEL, N. R., KAHANA, C., MERRICK, W. C., CHAKRABURTTY, 
K., SCHWARTZ, A. L. & CIECHANOVER, A. 1994. Protein synthesis elongation factor EF-1 
alpha is essential for ubiquitin-dependent degradation of certain N alpha-acetylated proteins and 
may be substituted for by the bacterial elongation factor EF-Tu.                                                          
Proc Natl Acad Sci U S A, 91, 7648-52. 
 
GRANT, A. G., FLOMEN, R. M., TIZARD, M. L. & GRANT, D. A. 1992. Differential screening of 
a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased 
transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer, 50, 740-5. 
 
GRASSI, G., SCAGGIANTE, B., FARRA, R., DAPAS, B., AGOSTINI, F., BAIZ, D., ROSSO, N.  
& TIRIBELLI, C. 2007. The expression levels of the translational factors eEF1A 1/2 correlate 
with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different 
differentiation grade. Biochimie, 89, 1544-52. 
 
GROSS, S. R. & KINZY, T. G. 2005. Translation elongation factor 1A is essential for regulation 
of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol, 12, 772-8. 
 
GROSS, S. R. & KINZY, T. G. 2007. Improper organization of the actin cytoskeleton affects 
protein synthesis at initiation. Mol Cell Biol, 27, 1974-89. 
 
GROSSHANS, H., HURT, E. & SIMOS, G. 2000. An aminoacylation-dependent nuclear tRNA 
export pathway in yeast. Genes Dev, 14, 830-40. 
 
HARRIS, M. N., OZPOLAT, B., ABDI, F., GU, S., LEGLER, A., MAWUENYEGA, K. G., TIRADO-
GOMEZ, M., LOPEZ-BERESTEIN, G. & CHEN, X. 2004. Comparative proteomic analysis of all-
trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute 
promyelocytic leukemia. Blood, 104, 1314-23. 
 
HASHIMOTO, Y., SKACEL, M., LAVERY, I. C., MUKHERJEE, A. L., CASEY, G. & ADAMS, J. 
C. 2006. Prognostic significance of fascin expression in advanced colorectal cancer:                          
an immunohistochemical study of colorectal adenomas and adenocarcinomas.                                    
BMC Cancer. 6, 241-51. 
 
HERSHEY, J. W. 1991. Translational control in mammalian cells. Annu Rev Biochem, 60,                  
717-55. 
 
HORNSTEIN, E., GIT, A., BRAUNSTEIN, I., AVNI, D. & MEYUHAS, O. 1999. The expression of 
poly(A)-binding protein gene is translationally regulated in a growth-dependent fashion through  
a 5'-terminal oligopyrimidine tract motif. J Biol Chem, 274, 1708-14. 
 
HORNSTEIN, E., TANG, H. & MEYUHAS, O. 2001. Mitogenic and nutritional signals are 
transduced into translational efficiency of TOP mRNAs. Cold Spring Harb Symp Quant Biol, 66, 
477-84. 




HOUGHTON, A. N. & POLSKY, D. 2002. Focus on melanoma. Cancer Cell, 2, 275-8. 
 
HOVEMANN, B., RICHTER, S., WALLDORF, U. & CZIEPLUCH, C. 1988. Two genes encode 
related cytoplasmic elongation factors 1 alpha (EF-1 alpha) in Drosophila melanogaster with 
continuous and stage specific expression. Nucleic Acids Res, 16, 3175-94. 
 
IADEVAIA, V., CALDAROLA, S., TINO, E., AMALDI, F. & LORENI, F. 2008. All translation 
elongation factors and the e, f, and h subunits of translation initiation factor 3 are encoded by 5'-
terminal oligopyrimidine (TOP) mRNAs. Rna, 14, 1730-6. 
 
INFANTE, C., ASENSIO, E., CANAVATE, J. P. & MANCHADO, M. 2008. Molecular 
characterization and expression analysis of five different elongation factor 1 alpha genes in the 
flatfish Senegalese sole (Solea senegalensis Kaup): differential gene expression and thyroid 
hormones dependence during metamorphosis. BMC Mol Biol, 9, 19. 
 
ISOLA, J. J., KALLIONIEMI, O. P., CHU, L. W., FUQUA, S. A., HILSENBECK, S. G., 
OSBORNE, C. K. & WALDMAN, F. M. 1995. Genetic aberrations detected by comparative 
genomic hybridization predict outcome in node-negative breast cancer.                                                
Am J Pathol, 147, 905-11. 
 
JACKSON, R. J., HELLEN, C. U. & PESTOVA, T. V. 2010. The mechanism of eukaryotic 
translation initiation and principles of its regulation. Nat Rev Mol Cell Biol, 11, 113-27. 
 
JASKUNAS, S. R., LINDAHL, L. & NOMURA, M. 1975. Identification of two copies of the gene 
for the elongation factor EF-Tu in E. coli. Nature, 257, 458-62. 
 
JEFFERIES, H. B., THOMAS, G. & THOMAS, G. 1994. Elongation factor-1 alpha mRNA is 
selectively translated following mitogenic stimulation. J Biol Chem, 269, 4367-72. 
 
JEGANATHAN, S. & LEE, J. M. 2007. Binding of elongation factor eEF1A2                                       
to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol                  
4-phosphate generation. J Biol Chem, 282, 372-80. 
 
JEGANATHAN, S., MORROW, A., AMIRI, A. & LEE, J. M. 2008. Eukaryotic elongation factor 
1A2 cooperates with phosphatidylinositol-4 kinase III beta to stimulate production of filopodia 
through increased phosphatidylinositol-4,5 bisphosphate generation. Mol Cell Biol, 28, 4549-61. 
 
JOHNSSON, A., ZEELENBERG, I., MIN, Y., HILINSKI, J., BERRY, C., HOWELL, S. B. & LOS, 
G. 2000. Identification of genes differentially expressed in association with acquired cisplatin 
resistance. Br J Cancer, 83, 1047-54. 
 
JOSEPH, P., O'KERNICK, C. M., OTHUMPANGAT, S., LEI, Y. X., YUAN, B. Z. & ONG, T. M. 
2004. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. 
Mol Carcinog, 40, 171-9. 
 
KAHNS, S., LUND, A., KRISTENSEN, P., KNUDSEN, C. R., CLARK, B. F., CAVALLIUS, J. & 
MERRICK, W. C. 1998. The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and 
characterization of the protein. Nucleic Acids Res, 26, 1884-90. 
 
KALLIONIEMI, A., KALLIONIEMI, O. P., PIPER, J., TANNER, M., STOKKE, T., CHEN, L., 
SMITH, H. S., PINKEL, D., GRAY, J. W. & WALDMAN, F. M. 1994. Detection and mapping of 
amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl 
Acad Sci U S A, 91, 2156-60. 




KANDA, A., KAWAI, H., SUTO, S., KITAJIMA, S., SATO, S., TAKATA, T. & TATSUKA, M. 2005. 
Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation.                           
Oncogene, 24, 7266-72. 
 
KATO, M. V., SATO, H., NAGAYOSHI, M. & IKAWA, Y. 1997. Upregulation of the elongation 
factor-1alpha gene by p53 in association with death of an erythroleukemic cell line.                            
Blood, 90, 1373-8. 
 
KHACHO, M., MEKHAIL, K., PILON-LAROSE, K., PAUSE, A., COTE, J. & LEE, S. 2008. eEF1A 
is a novel component of the mammalian nuclear protein export machinery.                                           
Mol Biol Cell, 19, 5296-308. 
 
KHALYFA, A., BOURBEAU, D., CHEN, E., PETROULAKIS, E., PAN, J., XU, S. & WANG, E. 
2001. Characterization of elongation factor-1A (eEF1A-1) and eEF1A-2/S1 protein expression in 
normal and wasted mice. J Biol Chem, 276, 22915-22. 
 
KIDO, T. & LAU, Y. F. 2008. The human Y-encoded testis-specific protein interacts functionally 
with eukaryotic translation elongation factor eEF1A, a putative oncoprotein. Int J Cancer, 123, 
1573-85. 
 
KIM, S. & COULOMBE, P. A. 2010. Emerging role for the cytoskeleton as an organizer and 
regulator of translation. Nat Rev Mol Cell Biol, 11, 75-81. 
 
KINZLER, K. W. & VOGELSTEIN, B. 1996. Lessons from hereditary colorectal cancer. Cell, 87, 
159-70. 
 
KNUDSEN, S. M., FRYDENBERG, J., CLARK, B. F. & LEFFERS, H. 1993. Tissue-dependent 
variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of 
a cDNA encoding a novel variant of human elongation-factor 1 alpha.                                                  
Eur J Biochem, 215, 549-54. 
 
KOBAYASHI, M., ISHIDA, H., SHINDO, T., NIWA, S., KINO, M., KAWAMURA, K., KAMIYA, N., 
IMAMOTO, T., SUZUKI, H., HIROKAWA, Y., SHIRAISHI, T., TANIZAWA, T., NAKATANI, Y. & 
ICHIKAWA, T. 2008. Molecular analysis of multifocal prostate cancer by comparative genomic 
hybridization. Prostate, 68, 1715-24. 
 
KOBAYASHI, Y. & YONEHARA, S. 2008. Novel cell death by downregulation of eEF1A1 
expression in tetraploids. Cell Death Differ, 16, 139-150. 
 
KOROMILAS, A. E., LAZARIS-KARATZAS, A. & SONENBERG, N. 1992a. mRNAs containing 
extensive secondary structure in their 5' non-coding region translate efficiently in cells 
overexpressing initiation factor eIF-4E. Embo J, 11, 4153-8. 
 
KOROMILAS, A. E., ROY, S., BARBER, G. N., KATZE, M. G. & SONENBERG, N. 1992b. 
Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. 
Science, 257, 1685-9. 
 
KULKARNI, G., TURBIN, D. A., AMIRI, A., JEGANATHAN, S., ANDRADE-NAVARRO, M. A., 
WU, T. D., HUNTSMAN, D. G. & LEE, J. M. 2007. Expression of protein elongation factor 
eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat, 102, 31-41. 
 
                                                                                                                            
222 
 
KURIYAMA, R., SAVEREIDE, P., LEFEBVRE, P. & DASGUPTA, S. 1990. The predicted amino 
acid sequence of a centrosphere protein in dividing sea urchin eggs is similar to elongation 
factor (EF-1 alpha). J Cell Sci, 95 ( Pt 2), 231-6. 
 
LAM, D. C., GIRARD, L., SUEN, W. S., CHUNG, L. P., TIN, V. P., LAM, W. K., MINNA, J. D. & 
WONG, M. P. 2006. Establishment and expression profiling of new lung cancer cell lines from 
Chinese smokers and lifetime never-smokers. J Thorac Oncol, 1, 932-42. 
 
LAMBERTI, A., LONGO, O., MARRA, M., TAGLIAFERRI, P., BISMUTO, E., FIENGO, A., 
VISCOMI, C., BUDILLON, A., RAPP, U. R., WANG, E., VENUTA, S., ABBRUZZESE, A., 
ARCARI, P. & CARAGLIA, M. 2007. C-Raf antagonizes apoptosis induced by IFN-alpha in 
human lung cancer cells by phosphorylation and increase of the intracellular content of 
elongation factor 1A. Cell Death Differ, 14, 952-62. 
 
LAU, J., CASTELLI, L. A., LIN, E. C. & MACAULAY, S. L. 2006. Identification of elongation 
factor 1alpha as a potential associated binding partner for Akt2. Mol Cell Biochem, 286, 17-22. 
 
LAZARIS-KARATZAS, A., MONTINE, K. S. & SONENBERG, N. 1990. Malignant transformation 
by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature, 345, 544-7. 
 
LE QUESNE, J. P., SPRIGGS, K. A., BUSHELL, M. & WILLIS, A. E. 2009. Dysregulation of 
protein synthesis and disease. J Pathol, 220, 140-51. 
 
LEE, I., AJAY, S. S., YOOK, J. I., KIM, H. S., HONG, S. H., KIM, N. H., DHANASEKARAN, S. 
M., CHINNAIYAN, A. M. & ATHEY, B. D. 2009a. New class of microRNA targets containing 
simultaneous 5’-UTR and 3’-UTR interaction sites. Genome Res, 19, 1175-83.  
 
LEE, J. M. 2003. The role of protein elongation factor eEF1A2 in ovarian cancer.                              
Reprod Biol Endocrinol, 1, 69. 
 
LEE, M. H., CHOI, B. Y., KUNDU, J. K., SHIN, Y. K., NA, H. K. & SURH, Y. J. 2009b. 
Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine 
xenograft model: eukaryotic elongation factor 1A2 as a potential target.                                           
Cancer Res, 69, 7449-58. 
 
LEE, M. H. & SURH, Y. J. 2009. eEF1A2 as a putative oncogene. Ann N Y Acad Sci, 1171,                
87-93. 
 
LEE, S., ANN, D. K. & WANG, E. 1994. Cloning of human and mouse brain cDNAs coding for 
S1, the second member of the mammalian elongation factor-1 alpha gene family: analysis of a 
possible evolutionary pathway. Biochem Biophys Res Commun, 203, 1371-7. 
 
LEE, S., FRANCOEUR, A. M., LIU, S. & WANG, E. 1992. Tissue-specific expression in 
mammalian brain, heart, and muscle of S1, a member of the elongation factor-1 alpha gene 
family. J Biol Chem, 267, 24064-8. 
 
LEE, S., LEBLANC, A., DUTTAROY, A. & WANG, E. 1995. Terminal differentiation-dependent 
alteration in the expression of translation elongation factor-1 alpha and its sister gene, S1, in 
neurons. Exp Cell Res, 219, 589-97. 
 
LEE, S., STOLLAR, E. & WANG, E. 1993a. Localization of S1 and elongation factor-1 alpha 
mRNA in rat brain and liver by non-radioactive in situ hybridization.                                                           
J Histochem Cytochem, 41, 1093-8. 
 
                                                                                                                            
223 
 
LEE, S., WOLFRAIM, L. A. & WANG, E. 1993b. Differential expression of S1 and elongation 
factor-1 alpha during rat development. J Biol Chem, 268, 24453-9. 
 
LEFEVER, S., VANDESOMPELE, J., SPELEMAN, F. & PATTYN, F. 2009. RTPrimerDB: the 
portal for real-time PCR primers and probes. Nucleic Acids Res, 37, D942-5. 
 
LEI, Y. X., CHEN, J. K. & WU, Z. L. 2002. Blocking the translation elongation factor-1 delta with 
its antisense mRNA results in a significant reversal of its oncogenic potential.                                 
Teratog Carcinog Mutagen, 22, 377-83. 
 
LEVY, S., AVNI, D., HARIHARAN, N., PERRY, R. P. & MEYUHAS, O. 1991. Oligopyrimidine 
tract at the 5' end of mammalian ribosomal protein mRNAs is required for their translational 
control. Proc Natl Acad Sci U S A, 88, 3319-23. 
 
LEWIS, J. D., PAYTON, L. A., WHITFORD, J. G., BYRNE, J. A., SMITH, D. I., YANG, L. & 
BRIGHT, R. K. 2007. Induction of tumorigenesis and metastasis by the murine orthologue of 
tumor protein D52. Mol Cancer Res, 5, 133-44. 
 
LI, B. D., LIU, L., DAWSON, M. & DE BENEDETTI, A. 1997. Overexpression of eukaryotic 
initiation factor 4E (eIF4E) in breast carcinoma. Cancer, 79, 2385-90. 
 
LI, Q., BARTLETT, D. L., GORRY, M. C., O’MALLEY, M. E. & GUO, Z. S. 2009. Three 
epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and 
distinct molecular mechanisms. Mol Pharmacol, 76, 1072-81.  
 
LI, R., WANG, H., BEKELE, B. N., YIN, Z., CARAWAY, N. P., KATZ, R. L., STASS, S. A. & 
JIANG, F. 2006. Identification of putative oncogenes in lung adenocarcinoma by a 
comprehensive functional genomic approach. Oncogene, 25, 2628-35. 
 
LI, Z., QI, C. F., SHIN, D. M., ZINGONE, A., NEWBERY, H. J., KOVALCHUK, A. L., ABBOTT, 
C. M. & MORSE, H. C., 3RD 2010. Eef1a2 promotes cell growth, inhibits apoptosis and 
activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS One, 5, e10755. 
 
LIN, K. W., YAKYMOVYCH, I., JIA, M., YAKYMOVYCH, M. & SOUCHELNYTSKYI, S. 2010. 
Phosphorylation of eEF1A1 at Ser300 by TβR-I results in inhibition of mRNA translation.                          
Curr Biol, 20, 1615-25. 
 
LIU, G., GRANT, W. M., PERSKY, D., LATHAM, V. M., JR., SINGER, R. H. & CONDEELIS, J. 
2002. Interactions of elongation factor 1alpha with F-actin and beta-actin mRNA: implications for 
anchoring mRNA in cell protrusions. Mol Biol Cell, 13, 579-92. 
 
LIU, G., TANG, J., EDMONDS, B. T., MURRAY, J., LEVIN, S. & CONDEELIS, J. 1996. F-actin 
sequesters elongation factor 1alpha from interaction with aminoacyl-tRNA in a pH-dependent 
reaction. J Cell Biol, 135, 953-63. 
 
LIU, Y. & WU, F. 2010. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk 
assessment. Environ Health Perspect, 118, 818-24. 
 
LIVINGSTONE, M., ATAS, E., MELLER, A. & SONENBERG, N. 2010. Mechanisms governing 
the control of mRNA translation. Phys Biol, 7, 021001. 
 
LUND, A., KNUDSEN, S. M., VISSING, H., CLARK, B. & TOMMERUP, N. 1996. Assignment of 
human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 
20q13.3. Genomics, 36, 359-61. 




LUND, E., GUTTINGER, S., CALADO, A., DAHLBERG, J. E. & KUTAY, U. 2004. Nuclear export 
of microRNA precursors. Science, 303, 95-8. 
 
LUTSEP, H. L. & RODRIGUEZ, M. 1989. Ultrastructural, morphometric, and 
immunocytochemical study of anterior horn cells in mice with "wasted" mutation.                                   
J Neuropathol Exp Neurol, 48, 519-33. 
 
MADSEN, H. O., POULSEN, K., DAHL, O., CLARK, B. F. & HJORTH, J. P. 1990. 
Retropseudogenes constitute the major part of the human elongation factor 1 alpha gene family. 
Nucleic Acids Res, 18, 1513-6. 
 
MAMANE, Y., PETROULAKIS, E., MARTINEAU, Y., SATO, T. A., LARSSON, O., 
RAJASEKHAR, V. K. & SONENBERG, N. 2007. Epigenetic activation of a subset of mRNAs by 
eIF4E explains its effects on cell proliferation. PLoS One, 2, e242 
 
MANSILLA, F., FRIIS, I., JADIDI, M., NIELSEN, K. M., CLARK, B. F. & KNUDSEN, C. R. 2002. 
Mapping the human translation elongation factor eEF1H complex using the yeast two-hybrid 
system. Biochem J, 365, 669-76. 
 
MARKOWITZ, S. D., DAWSON, D. M., WILLIS, J. & WILLSON, J. K. 2002. Focus on colon 
cancer. Cancer Cell, 1, 233-6. 
 
MARSHALL, L., KENNETH, N. S. & WHITE, R. J. 2008. Elevated tRNA(iMet) synthesis can 
drive cell proliferation and oncogenic transformation. Cell, 133, 78-89. 
 
MARTELLI, A. M., FAENZA, I., BILLI, A. M., MANZOLI, L., EVANGELISTI, C., FALA, F. & 
COCCO, L. 2006. Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new 
mechanisms for tumorigenesis and protection against apoptosis? Cell Signal, 18, 1101-7. 
 
MATEYAK, M. K. & KINZY, T. G. 2010. eEF1A: thinking outside the ribosome. J Biol Chem, 285, 
21209-13. 
 
MATHUR, S., CLEARY, K. R., INAMDAR, N., KIM, Y. H., STECK, P. & FRAZIER, M. L. 1998. 
Overexpression of elongation factor-1gamma protein in colorectal carcinoma.                                
Cancer, 82, 816-21. 
 
MAZUMDER, B., SESHADRI, V. & FOX, P. L. 2003. Translational control by the 3'-UTR: the 
ends specify the means. Trends Biochem Sci, 28, 91-8. 
 
MEHTA, A., TROTTA, C. R. & PELTZ, S. W. 2006. Derepression of the Her-2 uORF is mediated 
by a novel post-transcriptional control mechanism in cancer cells. Genes Dev, 20, 939-53. 
 
MEYLE, K. D. & GULDBERG, P. 2009. Genetic risk factors for melanoma. Hum Genet, 126, 
499-510. 
 
MEYUHAS, O. 2000. Synthesis of the translational apparatus is regulated at the translational 
level. Eur J Biochem, 267, 6321-30. 
 
MICHIELSEN, P. P., FRANCQUE, S. M. & VAN DONGEN, J. L. 2005. Viral hepatitis and 
hepatocellular carcinoma. World J Surg Oncol, 3, 27. 
 
                                                                                                                            
225 
 
MIMORI, K., MORI, M., TANAKA, S., AKIYOSHI, T. & SUGIMACHI, K. 1995.                                 
The overexpression of elongation factor 1 gamma mRNA in gastric carcinoma. Cancer, 75, 
1446-9. 
 
MITA, K., MORIMYO, M., ITO, K., SUGAYA, K., EBIHARA, K., HONGO, E., HIGASHI, T., 
HIRAYAMA, Y. & NAKAMURA, Y. 1997. Comprehensive cloning of Schizosaccharomyces 
pombe genes encoding translation elongation factors. Gene, 187, 259-66. 
 
MIYAGI, Y., SUGIYAMA, A., ASAI, A., OKAZAKI, T., KUCHINO, Y. & KERR, S. J. 1995. 
Elevated levels of eukaryotic translation initiation factor eIF-4E, mRNA in a broad spectrum of 
transformed cell lines. Cancer Lett, 91, 247-52. 
 
MOHLER, J. L., MORRIS, T. L., FORD, O. H., 3RD, ALVEY, R. F., SAKAMOTO, C. & 
GREGORY, C. W. 2002. Identification of differentially expressed genes associated with 
androgen-independent growth of prostate cancer. Prostate, 51, 247-55. 
 
MOLINA, H., HORN, D. M., TANG, N., MATHIVANAN, S. & PANDEY, A. 2007. Global 
proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass 
spectrometry. Proc Natl Acad Sci U S A, 104, 2199-204. 
 
MOORE, R. C. & CYR, R. J. 2000. Association between elongation factor-1alpha and 
microtubules in vivo is domain dependent and conditional. Cell Motil Cytoskeleton, 45, 279-92. 
 
MOORE, R. C., DURSO, N. A. & CYR, R. J. 1998. Elongation factor-1alpha stabilizes 
microtubules in a calcium/calmodulin-dependent manner. Cell Motil Cytoskeleton, 41, 168-80. 
 
MUNSHI, R., KANDL, K. A., CARR-SCHMID, A., WHITACRE, J. L., ADAMS, A. E. & KINZY, T. 
G. 2001. Overexpression of translation elongation factor 1A affects the organization and function 
of the actin cytoskeleton in yeast. Genetics, 157, 1425-36. 
 
MURTHI, A., SHAHEEN, H. H., HUANG, H. Y., PRESTON, M. A., LAI, T. P., PHIZICKY, E. M. & 
HOPPER, A. K. 2010. Regulation of tRNA bidirectional nuclear-cytoplasmic trafficking in 
Saccharomyces cerevisiae. Mol Biol Cell, 21, 639-49. 
 
NATHAN, C. O., FRANKLIN, S., ABREO, F. W., NASSAR, R., DE BENEDETTI, A., WILLIAMS, 
J. & STUCKER, F. J. 1999. Expression of eIF4E during head and neck tumorigenesis: possible 
role in angiogenesis. Laryngoscope, 109, 1253-8. 
 
NEWBERY, H. J., GILLINGWATER, T. H., DHARMASAROJA, P., PETERS, J., WHARTON, S. 
B., THOMSON, D., RIBCHESTER, R. R. & ABBOTT, C. M. 2005. Progressive loss of motor 
neuron function in wasted mice: effects of a spontaneous null mutation in the gene for the                
eEF1 A2 translation factor. J Neuropathol Exp Neurol, 64, 295-303. 
 
NEWBERY, H. J., LOH, D. H., O'DONOGHUE, J. E., TOMLINSON, V. A., CHAU, Y. Y., BOYD, 
J. A., BERGMANN, J. H., BROWNSTEIN, D. & ABBOTT, C. M. 2007. Translation elongation 
factor eEF1A2 is essential for post-weaning survival in mice. J Biol Chem, 282, 28951-9. 
 
NOCITO, A., KONONEN, J., KALLIONIEMI, O. P. & SAUTER, G. 2001. Tissue microarrays 
(TMAS) for high-throughput molecular pathology research. Int J Cancer, 94, 1-5.  
   
OHTA, K., TORIYAMA, M., MIYAZAKI, M., MUROFUSHI, H., HOSODA, S., ENDO, S. & SAKAI, 
H. 1990. The mitotic apparatus-associated 51-kDa protein from sea urchin eggs is a GTP-
binding protein and is immunologically related to yeast polypeptide elongation factor 1 alpha.                 
J Biol Chem, 265, 3240-7. 




ONG, S. E., BLAGOEV, B., KRATCHMAROVA, I., KRISTENSEN, D. B., STEEN, H., PANDEY, 
A. & MANN, M. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple 
and accurate approach to expression proteomics. Mol Cell Proteomics, 1, 376-86. 
 
OWEN, C. H., DEROSIER, D. J. & CONDEELIS, J. 1992. Actin crosslinking protein EF-1a of 
Dictyostelium discoideum has a unique bonding rule that allows square-packed bundles.                        
J Struct Biol, 109, 248-54.  
 
ØROM, U. A., NIELSEN, F. C. & LUND, A. H. 2008. MicroRNA-10a binds the 5'UTR of 
ribosomal protein mRNAs and enhances their translation. Mol Cell, 30, 460-71. 
 
PALMIERI, G., CAPONE, M., ASCIERTO, M. L., GENTILCORE, G., STRONCEK, D. F., 
CASULA, M., SINI, M. C., PALLA, M., MOZZILLO, N. & ASCIERTO, P. A. 2009. Main roads to 
melanoma. J Transl Med, 7, 86.  
 
PAN, J., HU, H., ZHOU, Z., SUN, L., PENG, L., YU, L., SUN, L., LIU, J., YANG, Z. & RAN, Y. 
2010. Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human 
gastric cancer cells. Oncol Rep, 24, 105-12. 
 
PAN, J., RUEST, L. B., XU, S. & WANG, E. 2004. Immuno-characterization of the switch of 
peptide elongation factors eEF1A-1/EF-1alpha and eEF1A-2/S1 in the central nervous system 
during mouse development. Brain Res Dev Brain Res, 149, 1-8. 
 
PANASYUK, G., NEMAZANYY, I., FILONENKO, V., NEGRUTSKII, B. & EL'SKAYA, A. V. 2008. 
A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation 
and ability to interact with different signalling molecules. Int J Biochem Cell Biol, 40, 63-71. 
 
PARKIN, D. M., BRAY, F., FERLAY, J. & PISANI, P. 2005. Global cancer statistics, 2002. CA 
Cancer J Clin, 55, 74-108. 
 
PASTAN, I. & WILLINGHAM, M. 1978. Cellular transformation and the 'morphologic phenotype' 
of transformed cells. Nature, 274, 645-50. 
 
PECORARI, L., MARIN, O., SILVESTRI, C., CANDINI, O., ROSSI, E., GUERZONI, C., 
CATTELANI, S., MARIANI, S. A., CORRADINI, F., FERRARI-AMOROTTI, G., CORTESI, L., 
BUSSOLARI, R., RASCHELLA, G., FEDERICO, M. R. & CALABRETTA, B. 2009. Elongation 
Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, 
survival and motility. Mol Cancer, 8, 58. 
 
PENDARIES, C., TRONCHERE, H., PLANTAVID, M. & PAYRASTRE, B. 2003. 
Phosphoinositide signaling disorders in human diseases. FEBS Lett, 546, 25-31. 
 
PERUCHO, M., GOLDFARB, M., SHIMIZU, K., LAMA, C., FOGH, J. & WIGLER, M. 1981. 
Human-tumor-derived cell lines contain common and different transforming genes. Cell, 27, 467-
76. 
 
PICKERING, B. M. & WILLIS, A. E. 2005. The implications of structured 5' untranslated regions 
on translation and disease. Semin Cell Dev Biol, 16, 39-47. 
 
PINKE, D. E., KALLOGER, S. E., FRANCETIC, T., HUNTSMAN, D. G. & LEE, J. M. 2008. The 
prognostic significance of elongation factor eEF1A2 in ovarian cancer.                                           
Gynecol Oncol, 108, 561-8. 
 
                                                                                                                            
227 
 
PINO, M. S. & CHUNG, D. C. 2010. The chromosomal instability pathway in colon cancer. 
Gastroenterology, 138, 2059-72. 
 
QUALTROUGH, D., SINGH, K., BANU, N., PARASKEVA, C. & PIGNATELLI, M. 2009.                    
The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility 
in adenoma cells in vitro. Br J Cancer, 101, 1124-9. 
 
RASHEED, S., NELSON-REES, W. A., TOTH, E. M., ARNSTEIN, P. & GARDNER, M. B. 1974. 
Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer, 33, 1027-33. 
 
REHMSMEIER, M., STEFFEN, P., HOCHSMANN, M. & GIEGERICH, R. 2004. Fast and 
effective prediction of microRNA/target duplexes. Rna, 10, 1507-17. 
 
RODNINA, M. V. & WINTERMEYER, W. 2009. Recent mechanistic insights into eukaryotic 
ribosomes. Curr Opin Cell Biol, 21, 435-43. 
 
ROSENBERRY, T. L., KRALL, J. A., DEVER, T. E., HAAS, R., LOUVARD, D. & MERRICK, W. 
C. 1989. Biosynthetic incorporation of [3H]ethanolamine into protein synthesis elongation factor 
1 alpha reveals a new post-translational protein modification. J Biol Chem, 264, 7096-9. 
 
ROSENWALD, I. B., CHEN, J. J., WANG, S., SAVAS, L., LONDON, I. M. & PULLMAN, J. 1999. 
Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon 
carcinogenesis. Oncogene, 18, 2507-17. 
 
ROSENWALD, I. B., HUTZLER, M. J., WANG, S., SAVAS, L. & FRAIRE, A. E. 2001. Expression 
of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in 
bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer, 92, 2164-71. 
 
ROZEN, S. & SKALETSKY, H. 2000. Primer3 on the WWW for general users and for biologist 
programmers. Methods Mol Biol, 132, 365-86. 
 
RUEST, L. B., MARCOTTE, R. & WANG, E. 2002. Peptide elongation factor eEF1A-2/S1 
expression in cultured differentiated myotubes and its protective effect against caspase-3-
mediated apoptosis. J Biol Chem, 277, 5418-25. 
 
RUGGERO, D. & PANDOLFI, P. P. 2003. Does the ribosome translate cancer? Nat Rev Cancer, 
3, 179-92. 
 
SAHAI, E. 2005. Mechanisms of cancer cell invasion. Curr Opin Genet Dev, 15, 87-96. 
 
SCHIRMAIER, F. & PHILIPPSEN, P. 1984. Identification of two genes coding for the translation 
elongation factor EF-1 alpha of S. cerevisiae. EMBO J, 3, 3311-5. 
 
SCHLAEGER, C., LONGERICH, T., SCHILLER, C., BEWERUNGE, P., MEHRABI, A., TOEDT, 
G., KLEEFF, J., EHEMANN, V., EILS, R., LICHTER, P., SCHIRMACHER, P. & RADLWIMMER, 
B. 2008. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. 
Hepatology, 47, 511-20. 
 
SCHMIDT, E. K., CLAVARINO, G., CEPPI, M. & PIERRE, P. 2009. SUnSET, a nonradioactive 
method to monitor protein synthesis. Nat Methods, 6, 275-7. 
 
SCHWARTZ, D. R., KARDIA, S. L., SHEDDEN, K. A., KUICK, R., MICHAILIDIS, G., TAYLOR, 
J. M., MISEK, D. E., WU, R., ZHAI, Y., DARRAH, D. M., REED, H., ELLENSON, L. H., 
GIORDANO, T. J., FEARON, E. R., HANASH, S. M. & CHO, K. R. 2002. Gene expression in 
                                                                                                                            
228 
 
ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from 
other poor-prognosis ovarian carcinomas. Cancer Res, 62, 4722-9. 
 
SCRIDELI, C. A., CARLOTTI, C. G., JR., OKAMOTO, O. K., ANDRADE, V. S., CORTEZ, M. A., 
MOTTA, F. J., LUCIO-ETEROVIC, A. K., NEDER, L., ROSEMBERG, S., OBA-SHINJO, S. M., 
MARIE, S. K. & TONE, L. G. 2008. Gene expression profile analysis of primary glioblastomas 
and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide 
microarray and real-time quantitative PCR. J Neurooncol, 88, 281-91. 
 
SELGA, E., OLEAGA, C., RAMIREZ, S., DE ALMAGRO, M. C., NOE, V. & CIUDAD, C. J. 2009. 
Networking of differentially expressed genes in human cancer cells resistant to methotrexate. 
Genome Med, 1, 83. 
 
SHAMOVSKY, I., IVANNIKOV, M., KANDEL, E. S., GERSHON, D. & NUDLER, E. 2006.                    
RNA-mediated response to heat shock in mammalian cells. Nature, 440, 556-60. 
 
SHAMOVSKY, I. & NUDLER, E. 2008. New insights into the mechanism of heat shock response 
activation. Cell Mol Life Sci, 65, 855-61. 
 
SHIBUI-NIHEI, A., OHMORI, Y., YOSHIDA, K., IMAI, J., OOSUGA, I., IIDAKA, M., SUZUKI, Y., 
MIZUSHIMA-SUGANO, J., YOSHITOMO-NAKAGAWA, K. & SUGANO, S. 2003. The 5' terminal 
oligopyrimidine tract of human elongation factor 1A-1 gene functions as a transcriptional initiator 
and produces a variable number of Us at the transcriptional level. Gene, 311, 137-45. 
 
SHIINA, N., GOTOH, Y., KUBOMURA, N., IWAMATSU, A. & NISHIDA, E. 1994. Microtubule 
severing by elongation factor 1 alpha. Science, 266, 282-5. 
 
SHIN, S. I., FREEDMAN, V. H., RISSER, R. & POLLACK, R. 1975. Tumorigenicity of virus-
transformed cells in nude mice is correlated specifically with anchorage independent growth in 
vitro. Proc Natl Acad Sci U S A, 72, 4435-9. 
 
SHLOMIT, R., AYALA, A. G., MICHAL, D., NINETT, A., FRIDA, S., BOLESLAW, G., GAD, B., 
GIDEON, R. & SHLOMI, C. 2000. Gains and losses of DNA sequences in childhood brain 
tumors analyzed by comparative genomic hybridization. Cancer Genet Cytogenet, 121, 67-72. 
 
SHULTZ, L. D., SWEET, H. O., DAVISSON, M. T. & COMAN, D. R. 1982. 'Wasted', a new 
mutant of the mouse with abnormalities characteristic to ataxia telangiectasia.                                    
Nature, 297, 402-4. 
 
SILVERA, D., FORMENTI, S. C. & SCHNEIDER, R. J. 2010. Translational control in cancer.             
Nat Rev Cancer, 10, 254-66. 
 
SLAUGHTER, D. P., SOUTHWICK, H. W. & SMEJKAL, W. 1953. Field cancerization in oral 
stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 6, 963-8. 
 
SLOBIN, L. I. 1980. The role of eucaryotic factor Tu in protein synthesis. The measurement of 
the elongation factor Tu content of rabbit reticulocytes and other mammalian cells by a sensitive 
radioimmunoassay. Eur J Biochem, 110, 555-63. 
 
SLOBIN, L. I. & RAO, M. N. 1993. Translational repression of EF-1 alpha mRNA in vitro.                      
Eur J Biochem, 213, 919-26. 
 
                                                                                                                            
229 
 
SOARES, D. C., BARLOW, P. N., NEWBERY, H. J., PORTEOUS, D. J. & ABBOTT, C. M. 2009. 
Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of 
sequence variation and potential differences in phosphorylation. PLoS One, 4, e6315. 
 
SONG, J. M., PICOLOGLOU, S., GRANT, C. M., FIROOZAN, M., TUITE, M. F. & LIEBMAN, S. 
1989. Elongation factor EF-1 alpha gene dosage alters translational fidelity in Saccharomyces 
cerevisiae. Mol Cell Biol, 9, 4571-5. 
 
STAPULIONIS, R., KOLLI, S. & DEUTSCHER, M. P. 1997. Efficient mammalian protein 
synthesis requires an intact F-actin system. J Biol Chem, 272, 24980-6. 
 
SUDA, M., FUKUI, M., SOGABE, Y., SATO, K., MORIMATSU, A., ARAI, R., MOTEGI, F., 
MIYAKAWA, T., MABUCHI, I. & HIRATA, D. 1999. Overproduction of elongation factor 1alpha, 
an essential translational component, causes aberrant cell morphology by affecting the control of 
growth polarity in fission yeast. Genes Cells, 4, 517-27. 
 
SUEHIRO, Y., SAKAMOTO, M., UMAYAHARA, K., IWABUCHI, H., SAKAMOTO, H., TANAKA, 
N., TAKESHIMA, N., YAMAUCHI, K., HASUMI, K., AKIYA, T., SAKUNAGA, H., MUROYA, T., 
NUMA, F., KATO, H., TENJIN, Y. & SUGISHITA, T. 2000. Genetic aberrations detected by 
comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology, 59, 50-6. 
 
SUNDSTROM, P., SMITH, D. & SYPHERD, P. S. 1990. Sequence analysis and expression of 
the two genes for elongation factor 1 alpha from the dimorphic yeast Candida albicans. J 
Bacteriol, 172, 2036-45. 
 
TANAKA, K., ARAO, T., MAEGAWA, M., MATSUMOTO, K., KANEDA, H., KUDO, K., FUJITA, 
Y., YOKOTE, H., YANAGIHARA, K., YAMADA, Y., OKAMOTO, I., NAKAGAWA, K. & NISHIO, 
K. 2009. SRPX2 is overexpressed in gastric cancer and promotes cellular migration and 
adhesion. Int J Cancer, 124, 1072-80. 
 
TANNER, M. M., GRENMAN, S., KOUL, A., JOHANNSSON, O., MELTZER, P., PEJOVIC, T., 
BORG, A. & ISOLA, J. J. 2000. Frequent amplification of chromosomal region 20q12-q13 in 
ovarian cancer. Clin Cancer Res, 6, 1833-9. 
 
TANNER, M. M., TIRKKONEN, M., KALLIONIEMI, A., COLLINS, C., STOKKE, T., KARHU, R., 
KOWBEL, D., SHADRAVAN, F., HINTZ, M., KUO, W. L. & ET AL. 1994. Increased copy number 
at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes.                          
Cancer Res, 54, 4257-60. 
 
TATSUKA, M., MITSUI, H., WADA, M., NAGATA, A., NOJIMA, H. & OKAYAMA, H. 1992. 
Elongation factor-1 alpha gene determines susceptibility to transformation. Nature, 359, 333-6. 
 
TEJADA, S., LOBO, M. V., GARCIA-VILLANUEVA, M., SACRISTAN, S., PEREZ-MORGADO, 
M. I., SALINAS, M. & MARTIN, M. E. 2009. Eukaryotic initiation factors (eIF) 2alpha and 4E 
expression, localization, and phosphorylation in brain tumors.                                                                  
J Histochem Cytochem, 57, 503-12. 
 
TERRANOVA, V. P., HUJANEN, E. S., LOEB, D. M., MARTIN, G. R., THORNBURG, L. & 
GLUSHKO, V. 1986. Use of a reconstituted basement membrane to measure cell invasiveness 
and select for highly invasive tumor cells. Proc Natl Acad Sci U S A, 83, 465-9. 
 
THOMAS, G. & THOMAS, G. 1986. Translational control of mRNA expression during the early 
mitogenic response in Swiss mouse 3T3 cells: identification of specific proteins.                              
J Cell Biol, 103, 2137-44. 




THOMPSON, J. D., HIGGINS, D. G. & GIBSON, T. J. 1994. CLUSTAL W: improving                        
the sensitivity of progressive multiple sequence alignment through sequence weighting,            
position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22, 4673-80. 
 
THORGEIRSSON, S. S. & GRISHAM, J. W. 2002. Molecular pathogenesis of human 
hepatocellular carcinoma. Nat Genet, 31, 339-46. 
 
THORNTON, S., ANAND, N., PURCELL, D. & LEE, J. 2003. Not just for housekeeping: protein 
initiation and elongation factors in cell growth and tumorigenesis. J Mol Med, 81, 536-48. 
 
TILI, E., MICHAILLE, J. J., ALDER, H., VOLINIA, S., DELMAS, D., LATRUFFE, N. & CROCE, 
C. M. 2010. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-
suppressors and effectors of TGFβ signalling pathway in SW480 cells.                                         
Biochem Pharmacol, Epub ahead of print. 
 
TOMLINSON, V. A., NEWBERY, H. J., BERGMANN, J. H., BOYD, J., SCOTT, D., WRAY, N. R., 
SELLAR, G. C., GABRA, H., GRAHAM, A., WILLIAMS, A. R. & ABBOTT, C. M. 2007. 
Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: 
overexpression of the gene is not dependent on modifications at the EEF1A2 locus.                              
Br J Cancer, 96, 1613-20. 
 
TOMLINSON, V. A., NEWBERY, H. J., WRAY, N. R., JACKSON, J., LARIONOV, A., MILLER, 
W. R., DIXON, J. M. & ABBOTT, C. M. 2005. Translation elongation factor eEF1A2 is a potential 
oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer, 5, 113. 
 
TSAI, W. L. & CHUNG, R. T. 2010. Viral hepatocarcinogenesis. Oncogene, 29, 2309-24. 
 
UETSUKI, T., NAITO, A., NAGATA, S. & KAZIRO, Y. 1989. Isolation and characterization of the 
human chromosomal gene for polypeptide chain elongation factor-1 alpha. J Biol Chem, 264, 
5791-8. 
 
UONG, A. & ZON, L. I. 2010. Melanocytes in development and cancer. J Cell Physiol, 222,                 
38-41. 
 
VAN ROOIJ, E., LIU, N. & OLSON, E. N. 2008. MicroRNAs flex their muscles. Trends Genet, 
24, 159-66. 
 
VERHAGEN, P. C., HERMANS, K. G., BROK, M. O., VAN WEERDEN, W. M., TILANUS, M. G., 
DE WEGER, R. A., BOON, T. A. & TRAPMAN, J. 2002. Deletion of chromosomal region               
6q14-16 in prostate cancer. Int J Cancer, 102, 142-7. 
 
VIVANCO, I. & SAWYERS, C. L. 2002. The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. Nat Rev Cancer, 2, 489-501. 
 
VOORMA, H. O., THOMAS, A. A. & VAN HEUGTEN, H. A. 1994. Initiation of protein synthesis 
in eukaryotes. Mol Biol Rep, 19, 139-45. 
 
VOYTIK-HARBIN, S. L., BRIGHTMAN, A. O., WAISNER, B., LAMAR, C. H. & BADYLAK, S. F. 
1998. Application and evaluation of the alamarBlue assay for cell growth and survival of 
fibroblasts. In Vitro Cell Dev Biol Anim, 34, 239-46. 
 
                                                                                                                            
231 
 
WELSH, G. I. & PROUD, C. G. 1992. Regulation of protein synthesis in Swiss 3T3 fibroblasts. 
Rapid activation of the guanine-nucleotide-exchange factor by insulin and growth factors. 
Biochem J, 284 ( Pt 1), 19-23. 
 
WENDEL, H. G., SILVA, R. L., MALINA, A., MILLS, J. R., ZHU, H., UEDA, T., WATANABE-
FUKUNAGA, R., FUKUNAGA, R., TERUYA-FELDSTEIN, J., PELLETIER, J. & LOWE, S. W. 
2007. Dissecting eIF4E action in tumorigenesis. Genes Dev, 21, 3232-7. 
 
WHITTAKER, S., MARAIS, R. & ZHU, A. X. 2010. The role of signaling pathways in the 
development and treatment of hepatocellular carcinoma. Oncogene, 29, 4989-5005. 
 
WILKIE, G. S., DICKSON, K. S. & GRAY, N. K. 2003. Regulation of mRNA translation by 5'- and 
3'-UTR-binding factors. Trends Biochem Sci, 28, 182-8. 
 
WONG, C. M. & NG, I. O. 2008. Molecular pathogenesis of hepatocellular carcinoma.                         
Liver Int, 28, 160-74. 
 
WU, J. & BAG, J. 1998. Negative control of the poly(A)-binding protein mRNA translation is 
mediated by the adenine-rich region of its 5'-untranslated region. J Biol Chem, 273, 34535-42. 
 
XU, W. L., WANG, X. L., WANG, H. & LI, X. B. 2007. Molecular characterization and expression 
analysis of nine cotton GhEF1A genes encoding translation elongation factor 1A. Gene, 389,       
27-35. 
 
YAMAGUCHI, H., WYCKOFF, J. & CONDEELIS, J. 2005. Cell migration in tumors.                                
Curr Opin Cell Biol, 17, 559-64. 
 
YANG, F., DEMMA, M., WARREN, V., DHARMAWARDHANE, S. & CONDEELIS, J. 1990. 
Identification of an actin-binding protein from Dictyostelium as elongation factor 1a.                         
Nature, 347, 494-6. 
 
YANG, W. & BOSS, W. F. 1994. Regulation of phosphatidylinositol 4-kinase by the protein 
activator PIK-A49. Activation requires phosphorylation of PIK-A49. J Biol Chem, 269, 3852-7. 
 
YANG, W., BURKHART, W., CAVALLIUS, J., MERRICK, W. C. & BOSS, W. F. 1993. 
Purification and characterization of a phosphatidylinositol 4-kinase activator in carrot cells.                     
J Biol Chem, 268, 392-8. 
 
YOSHIHAMA, M., UECHI, T., ASAKAWA, S., KAWASAKI, K., KATO, S., HIGA, S., MAEDA, N., 
MINOSHIMA, S., TANAKA, T., SHIMIZU, N. & KENMOCHI, N. 2002. The human ribosomal 
protein genes: sequencing and comparative analysis of 73 genes. Genome Res, 12, 379-90. 
 
ZABIEROWSKI, S. E. & HERLYN, M. 2010. Embryonic stem cells as a model for studying 
melanocyte development. Methods Mol Biol, 584, 301-16. 
 
ZENDER, L., VILLANUEVA, A., TOVAR, V., SIA, D., CHIANG, D. Y. & LLOVET, J. M. 2010. 
Cancer gene discovery in hepatocellular carcinoma. J Hepatol, 52, 921-9. 
 
ZHANG, J., GUO, H., MI, Z., GAO, C., BHATTACHARYA, S., LI, J. & KUO, P. C. 2009.                           
EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in 
HepG2 and Hep3B cells. Exp Cell Res, 315, 304-12. 
 
                                                                                                                            
232 
 
ZHANG, L., PAN, X. & HERSHEY, J. W. 2007. Individual overexpression of five subunits of 
human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast 
cells. J Biol Chem, 282, 5790-800. 
 
ZHANG, L., SMIT-MCBRIDE, Z., PAN, X., RHEINHARDT, J. & HERSHEY, J. W. 2008.                        
An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3.                     
J Biol Chem, 283, 24047-60. 
 
ZHONG, D., ZHANG, J., YANG, S., SOH, U. J., BUSCHDORF, J. P., ZHOU, Y. T., YANG, D. & 
LOW, B. C. 2009. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell 
migration. J Cell Sci, 122, 414-24. 
 
ZHOU, X., TEMAM, S., OH, M., PUNGPRAVAT, N., HUANG, B. L., MAO, L. & WONG, D. T. 
2006. Global expression-based classification of lymph node metastasis and extracapsular 
spread of oral tongue squamous cell carcinoma. Neoplasia, 8, 925-32. 
 
ZHU, H., LAM, D. C., HAN, K. C., TIN, V. P., SUEN, W. S., WANG, E., LAM, W. K., CAI, W. W., 
CHUNG, L. P. & WONG, M. P. 2007. High resolution analysis of genomic aberrations by 
metaphase and array comparative genomic hybridization identifies candidate tumour genes in 
lung cancer cell lines. Cancer Lett, 245, 303-14. 
 
ZHU, J., SPENCER, E. D. & KASPAR, R. L. 2003. Differential translation of TOP mRNAs                              
in rapamycin-treated human B lymphocytes. Biochim Biophys Acta, 1628, 50-5.
              
                                                                                    
 
